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Despite high prevalence and mortality, and an excellent knowledge of the aetiologic
genetic changes of sporadic colorectal cancer, the causes of this disease are not well
defined. DNA mismatch repair and Wnt signalling (via (3-catenin) are classic genetic
pathways altered during colorectal carcinogenesis, currently there is little evidence to
suggest how gene-environment interactions could influence these pathways. Recent
studies have found that adherent Escherichia coli are associated with colonic
adenocarcinomas, leading to speculation that in similarity to gastric cancer, bacterial
infection has a central role in colonic tumourigenesis. The attaching and effacing
(AE) bacterium enteropathogenic E. coli (EPEC) intimately attaches to the intestinal
epithelium and is found in 2.5-10% of healthy children and adults in developed
countries. When attaching to host cells, EPEC secretes effector proteins that have
wide ranging effects on host molecular biology. The aim of this study was to test the
hypothesis that EPEC infection causes molecular changes in host epithelial cells that
predispose to neoplastic transformation. Model systems for EPEC infection were
successfully established using in vitro co-culture with human colorectal cancer cell
lines and co-culture with ex vivo human colonic mucosa; human adenocarcinomas
were also probed for the presence of AE E. coli. Immunofluorescence identified
mucosa associated AE E. coli in 5/20 (25%) adenocarcinomas. When co-cultured
with normal human colonic mucosa, EPEC entered 10.6% of crypts, and closely
associated with cells in the proliferative progenitor compartment. Mass spectrometry
and microarray analysis validated the in vitro model and revealed a range of
proteomic and transcriptomic effects in EPEC infected cells. Western blots and
quantitative immunofluorescence demonstrated that EPEC downregulated the
expression of key DNA mismatch repair proteins MSH2 and MLH1 and the Wnt
signalling / adhesion protein (3-catenin in vitro. Disruption ofDNA mismatch repair is
a causative factor in the development of many hereditary and sporadic colorectal
cancers, and disruption of cell-cell adhesion has the potential to subvert normal
colonic crypt homeostasis. These novel findings therefore suggest that chronic EPEC
infection can predispose to cancer development by increasing the susceptibility of
colonic epithelial cells to mutation by dietary or other carcinogens, and by altering
expression of cytoskeletal and cell attachment proteins.
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Cancer is a worldwide disease, estimated to be responsible for over 6.2 million
deaths per year (Parkin et. al., 2001). Clinically, cancer is characterised by the
growth of tumours - large masses of cells that have no physiological function.
Tumours which do not affect surrounding tissues are classed as benign and do not
cause an immediate risk to health. Tumours that invade surrounding tissues or spread
to secondary sites around the body are classed as malignant. Malignant tumours
subvert the normal function of the tissues and organs that they invade, eventually
causing organ failure and death. Over the last 60 years, the development of
molecular biology has confirmed that genetic abnormalities are responsible for the
changes that transform a normal cell into a cell capable of forming a tumour. Studies
on genetics and the molecular biology of cancer cells have demonstrated that a wide
range of genetic changes (mutations) can contribute to cellular transformation.
The term "oncogene" was introduced in 1969 to describe genes that when expressed,
promote the transformation of normal cells into those capable of forming tumours
(Huebner & Todaro, 1969). Oncogenes such as ras and c-myc encode proteins that
promote cell cycle progression and therefore cell division. In cancer, mutations that
cause over expression of oncogenes such as H-ras and c-myc lead to over stimulation
of cell growth and proliferation, therefore promoting tumourigenesis (Sinn et. al.,
1987). Activation of oncogenes therefore provides a simple explanation for the
initiation of cancer. However, experimental activation of these genes in normal cells
does not lead to proliferation, as mechanisms exist to prevent excessive cell division
(Alberts et. al., 2002). Hence the action of no oncogene or combination of oncogenes
can cause tumourigenesis unless the pathways that suppress oncogenic activity are
also inactivated (Harris, 2005).
Studies in which a tumourigenic and normal cell were fused together revealed that
genes expressed in the normal cell had the ability to suppress tumourigenicity (Harris
et. al., 1969). Genes with this property are termed "tumour-suppressor" genes, and
their continual expression is thought to be required in healthy cells to prevent
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uncontrolled growth. The first tumour suppressor gene to be characterised was RB,
(Friend et. al., 1986), retinoblastoma protein (Rb), the product of RB regulates the
cell cycle, acting as a brake on proliferation. In retinoblastoma (an inherited form of
eye cancer), RB mutation results in loss of Rb function and increased cell division
(Alberts et. al., 2002). Another well-known tumour suppressor gene is TP53 (Finlay
et. al., 1989), which is mutated in many forms of cancer. The protein product of
TP53 (p53) has been extensively studied and is involved in the cell cycle, DNA
repair and programmed cell death (apoptosis). Via these pathways, p53 inhibits cell
proliferation and promotes cell death in response to stress. In cancer, mutation of
TP53 prevents normal p53 expression and therefore increases cell division, while
also decreasing apoptosis, hence facilitating tumour growth (Knudson, 2001).
The identification of tumour suppressor genes and oncogenes and the functional
pathways that they influence has furthered the understanding of cancer development.
Mutations of genes that control cell cycle and apoptosis leading to uncontrolled cell
division are therefore capable of promoting tumour growth. However, the question of
whether genetic aberrations in these pathways are either the critical factor in tumour
initiation or transition from a benign to malignant state remains unclear. It has been
argued that chromosomal abnormalities initiate tumour formation, and that the factor
limiting tumour growth is the blood supply a tumour can obtain (by angiogenesis).
Recently it has been argued that none of these pathways provides an adequate
explanation for the origination of malignant tumours, and that cancer should be seen
as a disease of cell differentiation rather than cell division (Harris, 2004). This model
for tumourigenesis is explained by the contention that exponential multiplication
rather that rest is the normal state for cells, and therefore the key step in determining
normal cell behaviour is differentiation. By this argument, the initiating event in the
formation of a malignant tumour could be a mutation that inactivates a specific gene
involved in the process of normal differentiation (Harris, 2005).
The process by which cancerous gene mutations are acquired and how these
mutations affect gene function (i.e. protein expression) are also key features in
cancer development. The traditional "two-hit" model proposed by Alfred Knudson
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was based on epidemiological studies of retinoblastoma (Knudson et. ah, 1971). This
study determined that both (maternal and paternal) alleles of the RB gene must be
mutated in order for cancer to develop. The author noted that the first mutation was
often inherited; but that inheritance of a mutated gene did not necessarily mean the
carrier would develop cancer, thus confirming the recessive nature of the mutation.
Therefore, in order for cancer to develop in an individual with an inherited mutation,
another (second) mutation must occur during childhood. Hence, the model dictates
that children who develop retinoblastoma in the absence of an inherited a mutation in
RB, must have sustained two mutations during their lifetime.
This model also illustrates that mutations may be inherited within the genetic
information from parents (germline mutations) or generated during the life of the
organism (somatic mutations). Somatic mutations may arise spontaneously (e.g. due
to errors in DNA replication), or be caused by exogenous environmental factors that
damage DNA (e.g. ultraviolet light).
Though it has been suggested that oncogene mutations could be genetically
dominant, it is now accepted that they are generally recessive in nature (Cavanee et.
ah, 1989), supporting the need for multiple mutations. Despite providing a
convenient model for retinoblastoma development, the two-hit model cannot account
for the development of most cancers. It is now accepted that cancer occurs as a
consequence of several somatic mutations (Knudson, 2001). For example, colon
cancer development is a multi-stage process, which occurs over a number of years.
In this case a genetic "five-hit" hypothesis (including one to two mutations in APC,
RAS and TP53) has been proposed, whereby each mutation confers clonal growth
advantage (Fearon & Vogelstein, 1990). Mutation of genes other that those classed
as oncogenes and tumour suppressor genes can also promote tumourigenesis. Genes
that have a function in mechanisms that maintain overall genomic stability (such as
DNA repair) are also affected in cancer.
Aside from gene mutations there are a number of other mechanisms that contribute
to cancer development at a genetic level. Chromosomal abnormalities (e.g. abnormal
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number and structure) are very often found in cancers (Knudson, 2001). Whether
aneuploidy is a primary or secondary event in cancer development has received
much debate (Harris, 2005). An accepted consequence of chromosomal changes is
the loss of genetic material, which is the most frequently observed genetic
abnormality in solid tumours (Kufe et. al., 2003). Gene deletion often results in the
loss of either the maternal or paternal allele of a gene. This loss of heterozygosity
(LOH) occurs frequently, with tumour suppressor genes such as APC and TP53 often
affected (Fearon & Vogelstein, 1990). Once LOH has occurred, a single mutation in
the remaining allele can lead to loss of function.
Epigenetic phenomena, such as chromatin remodelling do not affect the primary
DNA sequence, but can regulate the expression of oncogenes and tumour suppressor
genes. Chromatin alterations can be caused by changes in DNA methylation and by
altered patterns of histone modifications (reviewed by Baylin & Ohm, 2006).
Methylation of CpG islands within gene regulatory regions occurs throughout the
genome. Widespread hypomethylation has been observed in colon adenomas and
adenocarcinomas, and is thought to cause increased chromosomal instability
(Rodriguez et. al., 2006). Hypermethylation of CpG islands reduces the expression
of the genes that the island precedes and can result in the silencing of tumour
suppressor genes. In colon cancer, hypermethylation of the MLH1 promoter
correlates with a lack of MLH1 expression in sporadic tumours and in repair
defective tumour cell lines (Kane et. al., 1997).
In summary, cancer at cellular level is a genetic disease promoted by gene mutations,
the key consequences of which are changes in the function or expression of proteins.
Mutations may be inherited or somatic, with exogenous factors having the potential
to cause somatic mutations. The development of malignancy depends on
accumulation of several mutations over time, and is therefore a feature of the
influence of environment on the genome.
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1.2. Colorectal Cancer
1.2.1. Epidemiology and clinical background
Each year over 940,000 new cases of colorectal cancer are diagnosed worldwide, and
colorectal cancer is responsible for nearly half a million deaths. Though relatively
rare in developing countries, colorectal cancer is the second most common form of
cancer in terms of incidence and mortality in affluent societies (IARC, 2003). Hence
it was estimated that in 2006 there were 412,900 cases and 207,400 deaths
attributable to colorectal cancer in Europe (Ferlay et. al., 2007). This represents an
increase in the number of deaths caused by colorectal cancer of 1.8% since estimates
only 2 years earlier. With the increasing age of the European population and an
expected reduction in lung cancer cases (due to a reduction in smoking) colorectal
cancer may soon become the most prevalent form of cancer in Europe. Furthermore,
the link between colorectal cancer and affluence suggests that economic growth in
developing countries is likely to increase the rates of colorectal cancer worldwide.
Cases of colorectal cancer can be crudely classified as being either familial or
sporadic. Patients with familial disease have inherited germline mutations that
predispose to colorectal cancer, in sporadic colorectal cancer genetic mutations are
caused by exogenous factors. The genes involved in the overall development of both
sporadic and familial colorectal cancer are often the same, thus it may be difficult to
assess whether a cancer is purely sporadic or whether inherited genetic factors are
involved. A review of genetic predisposition to colorectal cancer suggests that the
"textbook" estimate for the proportion of familial disease is 20-25%, however, the
author points out that this varies according to the definition of "familial" (de la
Chapelle, 2004). The World Health Organisation states that colorectal cancer is
inherited in only 5% of cases (IARC, 2003). Whether defined as familial or
sporadic, the long-term development of most colorectal cancers is likely to depend
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The clinical development of colorectal cancer has long been known to involve the
transformation of normal mucosa into adenomatous polyps, of which one or more
eventually progresses to carcinoma (Muto et. al., 1975). This "adenoma to
carcinoma" sequence is a multi-stage process that occurs over several years (Figure
1.1). Hence the possibility to apply medical (generally surgical) interventions to slow
or halt the progression to carcinoma is good; therefore colorectal cancer is
theoretically a preventable disease. Unfortunately, the vast majority of patients with
early forms of colorectal cancer are asymptomatic; the eventual presentation of
symptoms (such as bleeding) usually indicating advanced disease. This lack of
symptoms severely impairs the diagnosis of colorectal cancer when it is at a stage
early enough for medical intervention to be efficacious. A potential solution to the
problem of diagnosis is screening. However, screening via endoscopy is costly
(although it may prove cost effective long term) and often inaccurate (Lieberman et.
al., 2001; Winawer et. al., 2000). At present procedural screening for colorectal
cancer is only performed on higher risk individuals i.e. those over the age of 50 or
younger individuals who have familial predisposition. Development of improved
diagnostic techniques using less invasive tests (e.g. biochemical markers) therefore
has the potential to greatly enhance the diagnosis and treatment of colorectal cancer.
1.2.2. Genetics
The orderly pathological progression of colorectal cancer has facilitated research into
the genetic events underlying colorectal tumourigenesis and the discovery of
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mutations in a number of genes (Figure 1.2). The existence of familial colorectal
cancer syndromes has also promoted the understanding of cancer genetics. Familial
Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) are well-defined inherited syndromes that confer direct genetic
predisposition to colorectal cancer. Accounting for approximately 20% of familial
colorectal cancer, these syndromes have been extensively studied, providing a vital
insight into distinct molecular pathways involved in colorectal cancer.
FAP is dominantly inherited and carries a 100% risk for the development of
colorectal cancer if untreated (Fearnhead et. al., 2002). The main clinical feature of
FAP is the appearance of hundreds to thousands of adenomatous polyps in the colon
and rectum. The key genetic characteristic of FAP is a germline mutation of the
adenomatous polyposis coli (APC) gene. LOH or somatic mutation of the
homologous APC allele triggers colorectal cancer development and is followed by
activation of oncogenes such as K-ras and c-myc (Jessup et. al., 1992). This
sequence of events creates a state of chromosomal instability, promoting the
occurrence of further LOH, particularly in the tumour suppressor gene p53 and the
deleted in colorectal cancer (DCC) gene (Vogelstein et. al., 1988). This mechanism
of colorectal cancer development is classically termed the suppressor or
chromosomal instability (CIN) pathway (Lengauer et. al., 1998).
HNPCC is also dominantly inherited, carriers having an 80% lifetime risk of
developing colorectal cancer (Lynch & de la Chapelle, 2003). The key genetic
changes underlying HNPCC were first identified by Ionov and co-workers (1993).
This group reported thousands of somatic mutations in simple repeated sequences in
colorectal cancer cells, terming them ubiquitous somatic mutations. These findings
supported the earlier hypothesis of Loeb (1991) who postulated that a mutator
phenotype (created by genomic instability) was implicated in colorectal
tumourigenesis. Thibodeau and colleagues (1993) observed a similar pattern of
mutations in colon tumours (noting that LOH was not present) and introduced the




















Figure 1.2. Temporal outline of colorectal cancer development and progression.
A schematic diagram including common genetic mutations (sporadic / familial), the
corresponding functional pathways affected by these mutations and the likely clinical stage.
Adapted from Fearnhead et. at., 2002 and Jessup et. at., 2002.
As germline mutations of the APC gene are the catalyst for chromosomal instability
in FAP, so germline mutations of DNA mismatch repair (MMR) genes are chiefly
responsible for the mutator phenotype and hence MSI in HNPCC. The human MMR
genes produce two sets of proteins, the MutS (MSH2, MSH3 and MSH6) and MutL
(MLHl, PMS1, PMS2 and MLH3) homologues (Jiricny, 2006). The MMR genes can
be described as indirect tumour suppressor genes. Their role is to correct DNA base
pair mismatches acquired from replication, recombination and chemical damage
(Figure 1.3). Failure of this DNA repair system confers significant genomic
instability, enabling a cell to rapidly accumulate mutations most easily identified as
MSI. Progression of HNPCC tumours is thought to involve mutation ofAPC and the
tumour-suppressor gene TGF/3RII, activation ofK-ras and mutation ofp53 (Jessup et.
al., 1992). In addition to its presence in the majority of HNPCC cases, MSI is also
found in 12-15% of sporadic cases of colorectal cancer (Liu et. al., 1995).
APC mutations are present in up to 70-75% of all colorectal carcinomas (Kinzler &
Vogelstein, 1996). Mutation of the APC gene is one of the earliest genetic changes
observed in colorectal cancer and is potentially the critical step in the initiation of
neoplastic transformation in colorectal epithelial cells (Powell et. al., 1992). Wild-
type APC protein is a key component of the Wingless/Wnt signal transduction
pathway. In the absence ofWnt stimulation, APC protein forms a functional complex
with axin and glycogen synthase kinase-3|3 (GSK-3|3) that phosphorylates
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cytoplasmic (3-catenin. Phosphorylation of (3-catenin is rapidly followed by
ubiquitinylation and proteosomal degradation.
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PCNA binds upstream of the
mismatch. As the clamp slides
away from the mismatch it meets
replication factor C (RCF), which
it displaces, recruiting
exonuclease-1 (EX01).
Activated EX01 degrades the
DNA single strand in 5' - 3'
direction.
Replication protein A (RPA)
stabilises the single stranded
gap.
DNA polymerase 8 (Pol 6) binds
adjacent to PCNA and this
complex catalyses the formation
of single stranded DNA to fill the
gap in 5' - 3' direction.
DNA ligase I seals the remaining
nick to complete the repair
process.
Figure 1.3. Schematic diagram representing human DNA MMR system. The MutS-MutL
sliding clamp may slide up or downstream of the base-pair mismatch, here it is shown
moving upstream. Adapted from Jiricny, 2006.
However, when Wnt binds to cell surface 'frizzled' receptors, GSK-3|3 is inactivated
and p-catenin escapes phosphorylation and subsequent degradation. When this
occurs, |3-catenin molecules accumulate within the cytoplasm and translocate to the
nucleus where they bind to TCF/LEF (T-cell factor/lymphoid enhancer factor). This
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complex then activates the transcription ofWnt target genes including the oncogenes
c-myc and cyclin Dl, extracellular proteases such as MMP-7, and nuclear receptor
factors such as the peroxisome proliferator-activator receptor 5 (PPAR8). The protein
products of these genes are thought to promote cell growth, proliferation and/or
inhibition of apoptosis. In colorectal cancer, and particularly FAP, mutations of the
APC gene promote neoplastic transformation by preventing formation of functional
APC protein-axin-GSK-3(3 complexes, leading to elevated cytoplasmic (3-catenin
levels and activation ofWnt target genes.
In addition to its function as a signal transduction protein in the Wnt pathway,
(3-catenin has an important role in cell-cell adhesion (Figure 1.4). The majority of
cellular (3-catenin is bound to cadherins (transmembrane adhesion molecules) at
adherens junctions. Here, [3-catenin helps anchor E-cadherin to the actin cytoskeleton
(Alberts et. al., 2002), facilitating strong cell-cell adhesion. Disruption of the
catenin-cadherin-cytoskeleton complex is often found in cancer and confers an
invasive phenotype (Mareel et. al., 1997).
Epigenetic gene silencing via DNA methylation is an additional mechanism involved
in colorectal cancer development (reviewed by Baylin & Ohm, 2006).
Hypermethylation of the MLH1 gene promoter (Herman et. al., 1998; Wheeler et. al.,
1999) and of the promoter region of the tumour suppressor gene encoding pi 6 (Burri
et. al., 2001) have been reported in colorectal cancer. Presently, silencing ofMLH1
by hypermethylation is the most prevalent genetic aberration found in cases of
sporadic colorectal cancer, and MLH1 silencing is thought to be an early event in
carcinogenesis (Giovannucci & Ogino, 2005).
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Figure 1.4. Schematic diagram illustrating the role of |3-catenin in the Wnt signalling
pathway. At the cell periphery, |3-catenin helps anchor cell-cell adherens junctions to the
actin cytoskeleton by binding to E-cadherin and a-catenin. In the absence of Wnt, unbound
cytoplasmic |3-catenin is phosphorylated by the APC / GSK-3[3 / Axin complex, leading to
ubiquitination and proteosomal degradation. Binding of Wnt to cell surface Frizzled receptors
leads to inhibition of the APC / GSK-3|3 / Axin complex via Dishevelled. Subsequently,
cytoplasmic (3-catenin is not degraded and translocates to the nucleus, here |3-catenin
interacts with TCF/LEF (T-cell factor/lymphoid enhancer factor), promoting the transcription
ofWnt target genes. Adapted from Nathke, 2006.
1.2.3. Aetiology and risk factors
Currently, the main exogenous factors thought to be responsible for causing sporadic
colorectal cancer are so called "lifestyle factors" such as diet, obesity, exercise,
smoking and alcohol intake. In an ongoing prospective study of 478,040 men and
women across 10 European countries, it was found that colorectal cancer risk was
positively associated with high consumption of red and processed meat, and
inversely associated with fish intake (Norat el. ah, 2005). Within this trial (the
European Prospective Investigation into Cancer and Nutrition) body size was also
studied as a risk factor. Indicators of abdominal obesity (such as waist-height-ratio
and waist circumference) were strongly associated with colorectal cancer risk in men
and women (Pischon et. al., 2006). Somewhat inevitably, a diet rich in calories and
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animal fat, but low in vegetables and fibre is associated with increased colorectal
cancer risk (IARC, 2003).
There is evidence to support the role of alcohol as a causative factor in number of
forms of cancer, with alcohol metabolites such as acetaldehyde thought to be the
cancer causing agents (reviewed by Seitz & Stickel, 2007). A recent study (using
pooled data equating to over 480,000 participants) on the link between alcohol
consumption and colorectal cancer found that high levels of alcohol intake correlated
with a modest relative elevation in cancer rate (Cho et. al., 2004). Smoking tobacco,
the main risk factor for lung cancer, has also been strongly linked to colorectal
cancer development. It has been reported that smoking over a pack of cigarettes per
day can cause an increase in colon cancer risk of up to 50% (Slattery et. al., 1997).
Factors thought to reduce colorectal cancer risk include physical exercise and
increased vitamin D and calcium intake (IARC, 2003). Folic acid, originally thought
to reduce colorectal cancer risk (Song et. al., 2000), may in fact increase risk (Cole
et. al., 2007). Chronic use of non-steroidal anti-inflammatory drugs (NSAIDS) such
as aspirin was first identified as a protective factor for colorectal cancer development
nearly 20 years ago (Kune et. al., 1988). Currently, NSAIDS are accepted as
effective chemopreventive agents against colorectal cancer. However, this effect
seems only to occur in a genetically defined subset of the population, suggesting it is
a pharmacogenetic effect (reviewed by Ulrich et. al., 2006). Another
pharmacological intervention that may reduce colorectal cancer risk (in women) is
hormone replacement therapy (HRT) (Pischon et. al., 2006).
Ulcerative colitis, an inflammatory disease of the bowel is a strong pre-disposing
factor to colorectal cancer development. Colitis associated cancers are clinically and
genetically distinct from other forms of colorectal cancer (Figure 1.1), evolving from
microscopic dysplasia rather than from adenomas (Hardy et. al., 2000). Bacteria
have a major influence on the environment of the colon and potentially on colonic
diseases such as ulcerative colitis; their role in colorectal cancer development is
discussed below.
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Overall there is a lack of convincing evidence as to how these risk factors can
promote tumourigenesis at a molecular level. It is highly likely that carcinogens are
contained within the diet (especially in developed countries) and it is probable that
risk factors work in combination to increase susceptibility to mutation. However, cell
turnover in the colonic epithelium is high and cells that acquire mutations should, in
theory be shed before they have the chance to cause cancer. The following statement
succinctly summarises current understanding of the causes of colorectal cancer:
"Gene-gene and gene-environment interactions have a significant influence on the
susceptibility to colorectal cancer. Our current understanding of these interactions
is limited, and concerted research efforts in this area will be importantfor a full
understanding ofpredisposition to this cancer. "
Albert de la Chapelle, Nature Reviews Cancer: Vol 4; 770. 2004.
1.2.4. Bacteria as a risk factor for cancer and colorectal cancer
It has been estimated that in 1990 15.6% of all cancers worldwide were attributable
to some form of infection, including viruses, bacteria, schistosomes and liver flukes
(Pisani et. ah, 1997). The bacteria Salmonella typhi is associated with gallbladder
cancer and Chlamydia pneumoniae with lung cancer (reviewed by Mager, 2006). A
precedent for tumourigenesis in the gastro-intestinal tract due to bacterial infection is
provided by Helicobacter pylori (H. pylori) within the stomach. It was concluded by
The International Agency for Research on Cancer in 1994 that there is a causal
relationship between H. pylori infection and gastric cancer (IARC, 1994).
Subsequent analysis of data from epidemiological studies supports this conclusion
(Huang et. al., 1998), and Graham (2000) claims that H. pylori infection is the
primary cause of gastric cancer. Despite a wealth of research into the interaction
between H. pylori and the gastric mucosa, the underlying mechanisms responsible
for cancer development remain unclear. Oxidative DNA damage-induced gastric
inflammation has been identified as a potential contributing factor (Hahm et. al.,
1997; Farinati et. al., 1998). H. pylori infection has also been shown to impair DNA
mismatch repair via reduction in MSH2 and MLH1 protein levels in gastric epithelial
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cells (Kim et. ah, 2002; Park et. ah, 2005). It has also been found that patients with
MSI-positive tumours were more likely to have active H. pylori infection than
patients with MSI-negative tumours (Leung et. al., 2000).
Within the colon, a number of bacteria have been linked to increased susceptibility to
cancer, including streptococcus sanguis (Siegert & Overbosch, 1995), group G
streptococcus (Kim et. al., 2002), and particularly Streptococcus bovis (Gold et. ah,
2004). The presentation of frequent colon neoplasia in patients with Streptococcus
bovis associated endocarditis has lead to further investigation of this bacterium.
Potential mechanisms of S. bovis carcinogenesis include chemokine and
prostaglandin release corresponding to cyclooxygenase-2 (COX-2) over-expression,
activation of mitogen activated protein kinases, increased inflammation, reduced
apoptosis and increased proliferation (reviewed by Mager, 2006).
In light of multiple studies focussed on H. pylori infection (relating to gastric
cancer), Swidsinski et. ah (1998) set out to study mucosa-associated bacteria in
colorectal cancer patients. Of control individuals (without adenomas or carcinomas)
bacteria were identified in biopsies from 1/31 (3%) asymptomatic patients and 10/34
(31%) patients with GI symptoms. However, high levels of bacteria (1,000-10,000
CFU/pl) were identified in 27/29 (93%) adenoma patients, and 28/31 (90%)
carcinoma patients. E. coli were the predominant bacteria species identified in 62%
and 77% of adenoma and carcinoma patients respectively compared to 3% and 12%
of asymptomatic and symptomatic controls respectively (Swidsinski et. ah, 1998).
A recent study analysing the presence of bacteria in tissue removed from colon
cancer patients revealed that over 70% of patients had mucosa-associated bacteria.
A significant proportion of the bacterial isolates were Escherichia coli strains that
demonstrated in vitro adhesion to embryonic intestinal (1407) and colon
adenocarcinoma (HT29) cells (Martin et. ah, 2004). Isolated E. coli also caused
release of interleukin-8 (IL-8) from 1407 cells. The authors suggest that mucosa-
associated bacteria might express adhesins with binding specificity for the
"oncofetal" carbohydrate antigens that are over-expressed by mucosal
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glycoconjugates on adenocarcinoma cells. Furthermore, the authors contend that
colon cancer might be primarily a bacterial disease, proposing a central role for
mucosally adherent bacteria in the pathogenesis of colon cancer. This thesis will
further explore the role of mucosally adherent E. coli in colon cancer development.
1.3. Enteropathogenic Escherichia coli (EPEC)
1.3.1. Diarrheagenic E. coli', characterisation of EPEC
Escherichia coli are gram negative, anaerobic bacteria found in abundance within the
human intestine. Most E. coli strains are non-pathogenic, only causing illness in
susceptible individuals or when infection escapes from the intestine. However,
several highly adapted pathogenic E. coli strains are able to cause disease in healthy
individuals, included in this category are the diarrheagenic E. coli strains. These
strains share an enhanced ability to adhere to and colonise the intestinal epithelium,
but derive pathogenicity by specific mechanisms that differ between pathotypes. The
virulence factors that confer these adaptations (e.g. toxin secretion, intimate
adherence, aggregation, invasion) are encoded on virulence related plasmids and in
chromosomal pathogenicity islands that are absent in non-pathogenic E. coli (Nataro
& Kaper, 1998). Hence each pathotype has distinct pathogenic mechanisms,
resulting in varying clinical symptoms (Table 1.1).
The term 'enteropathogenic E. coif was initially used to describe all E. coli causing
pathological intestinal infection (Neter, 1965). Subsequently, the strains releasing
toxins (ETEC, EHEC) or with invasive ability (EIEC) were characterised and
separately categorised. At this point the pathogenicity of bacteria remaining within
the EPEC group was poorly understood. The ability of EPEC strains to intimately
attach to epithelial cells (in the ileum and colon of pigs and rabbits), causing
effacement of microvilli, led to the characterisation of EPEC as "attaching and
effacing" (AE) E. coli (Moon et. al., 1983). The authors also noted "considerable
animal-animal variation in response to the same strain of EPEC", and drew attention
to the ability of other bacteria to cause AE lesions i.e. Citrobacter freundii in mice.
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Currently, the only bacteria known to induce AE lesions in man are EPEC, EHEC,
and some Hafnia alvei strains (Nataro & Kaper, 1998).
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encoded F1845 fimbriae Watery diarrhoea
Table. 1.1. Summary of diarrheagenic E. coli pathotypes. Other symptoms associated
with diarrheagenic E. coli infection include fever and vomiting. Compiled from Nataro &
Kaper, 1998.
Since the initial characterisation of the AE phenotype, considerable research has
been undertaken into how intimate attachment is achieved and how this process
relates to EPEC's pathogenicity. The ability to identify EPEC based on pathogenic
characteristics has also facilitated the identification of EPEC as an important
category of diarrheagenic E. coli, responsible for human diarrhoeal infections
worldwide.
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1.3.2. EPEC Clinical background and epidemiology
Transmission of EPEC is generally faecal-oral, via contamination of hands and food.
Acute EPEC infection is characterised by severe, profuse watery diarrhoea, which
may be accompanied by vomiting and fever, symptoms are usually acute, but may
last for weeks. Infants are far more susceptible to EPEC infection than adults. The
major danger to the health of a patient is dehydration, which is compounded by
malabsorption of nutrients due to effacement of absorptive enterocytes. Parenteral
rehydration and nutrition may therefore be required (especially in infants), without
which death often results (Nataro & Kaper, 1998). In developing countries the lack
of rapid, appropriate medical care for EPEC induced diarrhoea often results in death.
For example, in a recent study of children under 5 years old admitted to hospital with
acute diarrhoea in Brazil, over 30% of patients had EPEC, and of the 17 patients who
died, over halfwere infected with EPEC (Fagundes-Neto & Andrade, 1999).
With improved treatment of acute diarrhoea and hospital hygiene, the incidence of
EPEC induced diarrhoeal infections in developed countries has considerably
decreased since the mid 1900's. Consequently, EPEC is not viewed as a major
pathogen in the developed world, and routine screening is no longer performed in
hospitals (Nataro & Kaper, 1998). However, outbreaks of EPEC induced diarrhoea
(affecting children and adults) still occur in developed countries (Wight et. al., 1997;
Viljanen et. al., 1990). Furthermore, epidemiological studies continue to reveal the
presence of EPEC in symptomatic and asymptomatic children in Europe, the United
States and Australia (Table 1.2).
The reservoir of EPEC infection is thought to be asymptomatic and symptomatic
children, and asymptomatic adult carriers; the inability to identify certain strains of
EPEC in animals supports the conclusion that man is a natural reservoir for EPEC
(Levine & Edelman, 1984). It is difficult to estimate the carriage of EPEC amongst
healthy adults in the developed world; this is due to the lack of routine screening and
the fact that epidemiological studies focus on children. It is certainly possible for
healthy adults (and children) to carry EPEC without displaying any symptoms.
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Overall there is strong evidence that a significant proportion of the healthy






































































Jensen et. al., 2007
Table 1.2. Summary of recent EPEC studies in developed countries. In this study the
number of individuals from which bacterial strains were obtained is not stated, only the total
number of strains that were analysed.
1.3.3. Genetic basis of the EPEC AE phenotype
The defining characteristic of EPEC is its ability to form AE lesions on host
intestinal epithelial cells. AE lesion formation is characterised by the effacement of
microvilli and formation of cup-like pedestal structures on which EPEC sits in
intimate contact with the apical membrane of the host cell (Moon et. al., 1983). The
virulence factors on which this process depends are encoded by the EPEC Attaching
and Effacing (EAF) plasmid, and the 35.6b kb chromosomal pathogenicity island
entitled the Locus of Enterocyte Effacement (LEE). The genes encoded by LEE and
the EAF have specific roles and work in combination to achieve AE lesion formation
and intimate attachment.
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1.3.3.1. Locus of enterocyte effacement (LEE)
The first chromosomal gene necessary for AE lesion formation to be identified was
eae (E. coli attaching and effacing) in 1990 (Jerse et. al., 1990). The LEE
pathogenicity island (containing eae) was identified five years later (McDaniel el.
al., 1995) and eventually cloned (McDaniel & Kaper, 1997). The genes encoded by
LEE were initially separated into three groups; the first containing esc genes,
encoding structural proteins that form the type III secretion system (TTSS); the
second group containing eae and tir, encoding intimin and the translocated intimin
receptor respectively; and the third group including the esp genes, which encode the
EPEC secreted proteins (EspA, B, D, F) (Elliot et. al., 1998; reviewed by Frankel et.
al., 1998). Further investigation has revealed the function of other LEE encoded
genes, summarised in Table 1.3.
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Secreted effector proteins










Effector protein acting on
mitochondria and tight junctions
- ler, grIA, R Regulate LEE gene expression
Table 1.3. Genes encoded by the EPEC (E2348/69) Locus of Enterocyte Effacement
(LEE) and protein functions. Compiled from Garmendia et. at., 2005.
The EPEC TTSS shares homology with other bacteria, including Yersinia, Shigella
and Salmonella. Assembly of this multi-component organelle opens a physical
channel between bacteria and host cell allowing rapid, one-step translocation of
bacterial proteins (Garmendia et. al., 2005). The Esc proteins form the basal body of
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the TTSS, penetrating the inner and outer bacterial membranes; at the bacterial outer
membrane polymerised EspA proteins form a hollow filament, at the end of which
are EspD/B proteins, which form a pore in the host plasma membrane (Garmendia et.






























Figure 1.5. Schematic representation of EPEC type III secretion system (TTSS).
Diagram shows structural assembly of Esc & Esp proteins required for a functional TTSS
and examples of secreted effector proteins (EspF, Map, SepD) including Tir, which localises
to the host apical plasma membrane in readiness to bind the bacterial adhesin intimin (Int.).
Adapted from Garmedia et. al., 2005.
1.3.3.2. EPEC adherence factor plasmid (EAF/pMAR2)
Prior to identification of the LEE chromosomal pathogenicity island, it had been
deduced that EPEC adhesion and pathogenicity could be mediated by plasmid
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encoded virulence factors (Baldini et. al., 1983; Nataro et. al., 1985). EPEC
adherence factor (EAF) was suggested as a name for the putative plasmid encoded
factor necessary for adhesion and virulence in humans (Levine et. al., 1985). A
subsequent study revealed that EPEC strains cured of the EAF plasmid were unable
to grow as adherent colonies due to the absence of surface filaments, which the
authors termed bundle forming pili (Bfp) (Giron et. al., 1991). Bfp provide a means
for bacteria-bacteria adherence by forming an intertwined mesh in which bacteria
become embedded. This mechanism is responsible for the "localised adherence"
pattern of EPEC on epithelial cells whereby bacteria adhere in clusters
(microcolonies). The bfp gene cluster contains 14 genes required for bfp biogenesis
(Stone et. al., 1996).
The role of bfp in bacteria-cell interaction is contentious, particularly whether bfp
mediate the initial attachement of bacteria to host cells. The use of EPEC strains with
mutations in bfp genes has revealed that that loss of bfpA drastically reduces EPEC
adhesion to cultured epithelial cells and prevents LA, but does not preclude adhesion,
or prevent AE formation if intimin is expressed (Zhang & Donnenberg, 1996). Loss
of intimin however, does prevent AE lesion formation but does not prevent localised
adhesion to cultured cells (Donnenberg & Kaper 1991). Experiments co-culturing
EPEC mutants with isolated human tissue reveal that loss of bfp does not prevent
adherence, but that loss of intimin does, suggesting that bfp are not involved in initial
adherence in vivo (Hicks et. al., 1998). However, co-culturing bfp mutant EPEC and
C. rodentium with mouse and human intestinal epithelial cells support a role for bfp
in the initial adherence of AE bacteria and their species specificity (Tobe &
Sasakawa, 2001 & 2002).
Though the EAF plasmid is not essential for AE lesion formation, its presence does
enhance the efficiency of the AE process, possibly by increased expression of LEE
genes due to regulatory (per) genes in the EAF plasmid (Nataro & Kaper, 1998).
Alternative mediators of initial bacterial adherence have been suggested and include
rod-like fimbriae and fimbrillae, a second adhesin molecule (in addition to intimin)
and flagella (reviewed by Clarke et. al., 2003).
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The matter of bfp mediated adherence is particularly relevant to naturally occurring
EPEC strains which do not contain the EAF plasmid. These so called "atypical
EPEC" are often found in developed countries (Beutin et. al., 2003; Robins-Browne
et. al., 2004). The pathogenicity of atypical EPEC has not been fully established and
their clinical significance remains unresolved. In a recent study, atypical EPEC were
found to be slightly more prevalent in patients with diarrhoea than controls (not
statistically significant), however, a significant association was observed with
diarrhoea lasting for 14 days or more, a finding that may indicate a role of atypical
EPEC in prolonged disease (Afset et. al., 2004).
1.3.4. The process of EPEC pathogenesis
The sequence of events by which EPEC induces the formation of AE lesions on host
cell is complex, relying on initial attachment, the assembly of various multi-molecule
complexes, secretion of effector proteins and significant changes within the host cell.
Presently a four-stage model is proposed to describe this process and is outlined in
figure 1.6 (Clarke et. al., 2003).
1.3.5. Consequences of EPEC attachment
EPEC induced pedestals are composed of: Filamentous actin (F-actin), actin
regulatory proteins [such as Arp2/3, neuronal Wiskott-Aldrich syndrome protein (N-
WASP), calpactin, cofilin, cortactin, ezrin, gelsolin, lipoma preferred partner (LLP),
pl30cas, tropomyosin, vasodilator-stimulated phosphoprotein (VASP), and zyxin],
adaptor proteins [including Nek, Crkll, Grb2 and She], focal adhesion associated
proteins [e.g. a-actinin, talin and vinculin], lipid rafts [e.g. annexin 2 and CD44] and
intermediate filaments (reviewed by Caron et. al., 2006).
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-A Bundle forming pili li Intimin Actin
| Type III secretion system Translocated intimin receptor • Secreted effector proteins
Figure 1.6. Schematic representation of four stage EPEC pathogenesis.
1. Bacterial expression of Bfp, intimin and EspA filaments (environment dependent)
2. Initial adherence via Bfp and EspA filaments, injection of Tir and effector molecules via
TTSS, resulting in actin de-polymerisation and loss of microvilli, phosphorylation and
insertion of Tir into apical membrane
3. Loss of EspA filaments, intimin binds to Tir, intimate attachment, accumulation of actin
and other cytoskeletal proteins at site of adhesion
4. Massive accumulation of cytoskeletal elements, formation of pedestal structure, microvilli
elongation, adhesion of other EPEC via Bfp to initiate microcolonies (localised
adherence), translocated effector molecules precipitate a wide range of cellular events
Adapted from Clarke et. at., 2003.
The process of intimate attachment, AE lesion formation and insertion of bacterial
effector proteins has significant and wide-ranging effects on the host cell and
surrounding tissue. The exact changes that occur, and the mechanisms that cause
them are not fully understood, but they are interlinked and undoubtedly complex.
EPEC induced changes will be crudely divided and discussed as follows:
(i) Cytoskeletal remodelling
(ii) Disruption of epithelial barrier
(iii) Mitochondrial damage
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(iv) Cell cycle disruption
(v) Pro-apoptotic and anti-apoptotic responses
(vi) Inflammatory cell transmigration and activation
(vii) Diarrhoea
(viii) Signal transduction
(i) Cytoskeletal remodelling. EPEC attachment modulates all three host cell
cytoskeletal networks - actin microfilaments, intermediate filaments and cytoskeletal
microtubules (Caron et. al., 2006). Clustering of Tir molecules within the host apical
membrane initiates the downstream signalling events that lead to actin
polymerisation and pedestal formation. After Tir is phosphorylated by host tyrosine
kinases, it recruits the host adaptor protein Nek to initiate N-WASP-Arp2/3-mediated
actin polymerisation (Schuller et. al., 2007). In order for progression from this stage
to full intimate attachment and pedestal formation, Tir must bind to intimin in the
bacterial outer membrane, failure to do so results in the formation of immature AE
lesions (Taylor et. al., 1999). This is likely to be achieved by intimin dependent
tyrosine kinase activation, as loss of intimin or addition of tyrosine kinase inhibitors
prevents EPEC induced pedestal formation (Kenny & Finlay, 1997). Pedestal
formation is a highly specialised strategy, which combined with microvilli
elongation is likely to aid in the avoidance of immune cells by partially 'hiding' the
adherent bacteria. Furthermore, the ability of EPEC to induce TTSS dependent
cytoskeletal rearrangements protects it from phagocytosis by macrophages (Goosney
et. al., 1999).
(ii) Disruption of epithelial barrier. A result of EPEC attachment is a reduction in
transepithelial electrical resistance (TER), indicating compromised epithelial barrier
function (Simonovic et. al., 2001). Epithelial membrane integrity depends on cell-
cell adhesion junctions (e.g. adherens junctions and tight junctions) and cell-matrix
adhesion junctions (e.g. focal adhesions and hemidesmosomes). These structures also
help maintain cell polarity, by anchoring the base of the cell to the basal lamina
membrane (Alberts et. al., 2002). The benefit to EPEC of reduced barrier function
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could be access to nutrients within the lamina propria (Shifrin et. al., 2002), and also
access to adhesion molecules that form the junctions (Muza-Moons et. al., 2003).
Intercellular tight junctions provide a dynamic, regulated barrier to the movement of
water, ions and immune cells across the intestinal epithelium, and control cell
polarity by limiting diffusion of proteins between the basolateral and apical
membranes (Shen & Turner, 2006). EPEC infection has been shown to disrupt tight
junctions, causing redistribution of occludin (McNamara et. al., 2001). EPEC
induced phosphorylation of ezrin (a protein that links the plasma membrane to the
cytoskeleton) causes this protein to become associated with the cytoskeleton,
resulting in disruption of tight junction function (Simonovic et. al., 2001). It has been
suggested that Rho kinase may regulate phosphorylation of ezrin and mediate other
EPEC induced protein changes that effect epithelial barrier function (Simonovic et.
al., 2001). EPEC induced tight junction disruption has also been related to
phosphorylation of myosin light chain protein (Yuhan et. al., 1997). EPEC infection
also causes disruption of adherens junctions via PKC mediated effects on catenin
redistribution (Malladi et. al. 2004).
In vitro experiments demonstrate that EPEC infection causes epithelial cells to
detach from the substratum. This effect has been attributed to modification of focal
adhesions via EPEC induced dephosphorylation of focal adhesion kinase (FAK)
(Shifrin et. al., 2002). EPEC infection has also been shown to disrupt epithelial cell
polarity, enabling basolateral proteins (such as ff-integrin), to migrate to the host
apical membrane, potentially providing additional biding sites for intimin (Muza-
Moons et. al., 2003). EPEC induced migration of basolateral adhesion proteins, such
as integrins from focal adhesions or hemidesmosomes would also reduce host cell
adhesion to the basal lamina.
EPEC induced changes in both tight junctions and focal adhesions were dependent
on a fully functioning TTSS system (Shifrin et. al., 2002; Muza-Moons et. al., 2003).
This suggests that secreted effector molecules mediate these processes and
translocated EspF has indeed been found to fulfil this function (McNamara et. al.,
26
2001). The secreted protein Map is also important in tight barrier disruption
(Garmendia et. al., 2005). A recent study has found that EspG dependent RhoA
activation is related to increased paracellular permeability of epithelial cells
consequent to EPEC infection (Matsuzawa et. al., 2005).
(iii) Mitochondrial damage. In addition to functions in epithelial barrier disruption,
Map and EspF are both targeted to host cell mitochondria via N-terminal targeting
sequences (reviewed by Garmendia et. al., 2005). Map interferes with mitochondrial
membrane potential, leading to mitochondrial swelling and damage (Kenny &
Jepson, 2000). EspF induces mitochondrial membrane permeabilisation, the release
of the toxic protein cytochrome c from mitochondria and with caspase-3 cleavage,
indicating a role in initiation of the mitochondrial death pathway (Nougayrede &
Donnenberg, 2004) this will be discussed further under pro- and anti-apoptotic
responses (v).
(iv) Cell cycle. Bacterial effectors that modulate the eukaryotic cell cycle are known
as cyclomodulins. A recently discovered EPEC secreted effector known as Cif (cycle
inhibiting factor) has been shown to block the cell cycle at G2/M transition, causing
cell cycle arrest, characterised by inactive phosphorylated Cdkl (Marches et. al.,
2003). Cif also has a role in promotion of actin cytoskeleton rearrangement, and is
the first EPEC effector molecule to be encoded by a pro-phage rather than in the
LEE (Marches et. al., 2003). The pro-phage is only found in some EPEC strains and
is not present in the classic wild-type strain (E2348/69) or in C. rodentium
(Garmendia et. al., 2005).
(v) Pro-apoptotic and anti-apoptotic effects. The literature surrounding the effects
of EPEC on cell death, and in particular apoptosis is somewhat tentative. For
bacterial pathogens such as Salmonella, Yersinia and Shigella, apoptosis is a
favourable mechanism of pathogenesis, advantageously stimulated by cytotoxic
bacterial effector molecules (reviewed by Melo et. al., 2005). Unlike these bacteria,
EPEC does not invade cells; hence it depends on the host cell to provide a
specialised binding site and commits considerable resources into influencing host
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cell biology. Therefore it seems unlikely (certainly in the short term) that induction
of cell death would profit an AE pathogen such as EPEC. Despite this logic it seems
that most studies seek to study the induction of pro- rather than anti-apoptotic
pathways in response to EPEC.
In a study on EPEC induced cell death it was found that EPEC induced comparably
less cell death that Salmonella, Yersinia and Shigella (Crane et. al., 1999). The
authors also found that addition of a tyrosine kinase inhibitor to cells co-cultured
with EPEC greatly increased apoptosis (suggesting that EPEC signalling suppresses
apoptosis). Furthermore, this study potentially overestimated apoptosis by using dye
permeability and lactate dehydrogenase (LDE1) release assays. These are
inappropriate choices considering EPEC carry a TTSS capable of creating pores
(large enough for dye uptake or LDH release) in the host plasma membrane. The
authors note that EPEC adherence has been shown to strongly activate anti-apoptotic
pathways, such as (intimin dependent) protein kinase C activation (Crane & OH,
1997). Their own results support tyrosine kinase activation as one such pathway.
Despite interesting speculation by the authors that EPEC has developed strategies to
slow rather than stimulate apoptosis, the title of the paper only draws attention to the
fact that 'Host cell death due to enteropathogenic E. coli infection has features of
apoptosis.'
Another study intent on investigating 'induction of epithelial cell death including
apoptosis by Enteropathogenic E. coif establishes that Bfp expression is a key
mediator of host cell apoptosis and necrosis (Abul-Milh et. al., 2001). The link
between Bfp and cell death is undoubtedly a valid one, however, careful analysis of
the data, combined with consideration of the more recently described affects of
EPEC reveals a potentially more interesting result. Using microscopic analysis of
host cell nuclei as a measure of apoptosis and necrosis, this study finds that loss of
Bfp expression attenuates EPEC induced cell death to non-pathogenic E. coli levels.
Also, introduction of Bfp (but not intimin) into the non-pathogenic E. coli strain
more than doubled its apoptotic response. Interestingly, in one cell line the non¬
pathogenic Bfp+/intimin" strain induced more cell death than wild-type EPEC
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(Bfp+/intimin+). This suggests that wild-type EPEC do promote anti-apoptotic
pathways in the host cell, and that intimate attachment mediated by intimin is
responsible.
A pathway by which intimin expression could promote an anti-apoptotic response is
via tyrosine kinase activation. Intimin signalling (during intimate attachment)
induces host cell tyrosine kinase activation (Kenny & Finlay, 1997) and the results of
Crane et. al. (1999) show that attachment-dependent tyrosine kinase activation
mediates an anti-apoptotic host response. Thus, mutant EPEC cured of eae
(Bfp+/intimin~) would be expected to induce more apoptosis that wild-type EPEC
(Bfp+/intimin+). However, EPEC lacking intimin induced less cell death than either
wild-type EPEC (Bfp+/intimin+) or natural non-pathogenic E. coli (Bfp+/intimin").
This counter intuitive observation can be explained when the method of cell death
detection is considered. In this assay, indicative changes in nuclear morphology were
used to judge cell death (Abul-Milh et. al., 2001). It is now known that EPEC
secreted cyclomodulins (e.g. Cif) are able to induce cell cycle arrest, causing changes
in nuclear morphology that do not necessarily indicate cell death (Marches et. al.,
2003). Following EPEC induced G2/M arrest, the cytoskeleton attaches to the host
cell membrane, a process that causes the inhibition of mitosis while DNA replication
occurs unimpeded. Hence cellular and nuclear enlargement occurs with excess DNA
within the nucleus (Marches et. al., 2003). This could easily be mistaken for signs of
cell death, hence cells infected with wild-type EPEC could be counted as apoptotic /
necrotic when they were not.
Therefore it is possible that intimin signalling does mediate a specific anti-apoptotic
response that opposes and balances the pro-apoptotic response to Bfp. Indeed when
using an alternative (annexin labelling) method Abul-Milh et. al. (2001) found that
infection with EPEC cured of eae (Bfp+/intimin~) induced higher levels of apoptosis
than the wild-type EPEC (Bfp+/intimin+).
The initiation of the mitochondrial death pathway by EPEC via Map and EspF has
already been introduced (iii). Nougayrede & Donnenberg (2004) demonstrated that
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EPEC infection induced cytochrome c release and cleavage of caspase-3 and
caspase-9 via EspF. It should be noted that cells were only infected with EPEC
strains for 1 hour, giving little time for induction of anti-apoptotic pathways. Also,
cleavage of caspase-9 was only identified in EPEC strains with transactivated EspF,
which showed far higher EspF protein expression than wild-type EPEC. Plence the
authors concede that over-expression of EspF may overwhelm EPEC induced anti-
apoptotic signals in these experiments.
Other studies on EPEC induced apoptosis revolve around signalling by NF-kB, a
nuclear factor that is activated by EPEC infection (Savkovic et. al., 1997). NF-kB
has pro- and anti-apoptotic effects in different cell types, but has been shown to
promote cell survival in intestinal epithelial cells (Chen et. al., 2000). EPEC induced
NF-kB activation is however only a transient effect (Savkovic et. al., 1997; Melo et.
al., 2005). Furthermore, a recent study has found that a compound suppressing NF-
kB did not promote apoptosis on its own or influence EPEC induced apoptosis (Melo
et. al., 2005). The authors conclude that although Bfp expression was essential for
EPEC apoptosis signalling, NF-kB signalling was not.
It is important to consider that in vitro studies of apoptosis do not necessarily well
represent the in vivo situation. In a rare paper that declares in its title that EPEC is
responsible for 'decreased apoptosis' an in vivo model (rabbit) was used. Heczko et.
al. (2001) found that severe EPEC infection (with a rabbit specific strain) caused a
significant decrease in apoptosis in Peyer's patches (using TUNEL assay), the tips of
ileal absorptive villi (H&E staining morphology) and in whole ileal cell lysates
(caspase-3 assay). Overall there is overwhelming evidence that in addition to pro-
apoptotic mechanisms (probably induced non-specifically by Bfp), EPEC has
evolved the ability to specifically induce anti-apoptotic pathways. Intimin dependent
tyrosine kinase and protein kinase activation surely contribute to these anti-apoptotic
pathways, providing a balance between pro- and anti-apoptotic mechanisms
beneficial to the adherent bacteria.
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(vi) Immune response. The initial immune response to pathogenic infection
involves recruitment of acute inflammatory cells; EPEC has been shown to induce
the recruitment of polymorphonuclear leukocytes (PMN) into the infected intestinal
lumen (Moon et. al., 1983). The pro-inflammatory cytokine interleukin-8 (IL-8)
mediates PMN recruitment in intestinal epithelial cells and IL-8 transcription is
governed by NF-kB. Early studies of EPEC induced PMN transepithelial migration
found the process to be dependent on EPEC attachment (via intact TTSS) and cite
EPEC induced NF-kB nuclear translocation as the mechanism (Savkovic et. al., 1996
& 1997). However, a subsequent study found that although EPEC initially increased
nuclear NF-kB, in the longer term (>1 hour) it was reduced. Furthermore, this study
found that pre-infection of cells with EPEC prevented TNFa induced NF-kB nuclear
accumulation (Hauf & Chakraborty, 2003). This study demonstrates that although
there is an initial pro-inflammatory response, EPEC is eventually able to initiate an
anti-inflammatory effect. This time frame suggests that insertion of secreted effector
proteins into the host cell is responsible for the anti-inflammatory response.
A recent study has found that incubation of epithelial cells with sterile supernatant
from EPEC culture caused higher IL-8 secretion than did EPEC itself; an effect
dependent on an intact TTSS (Sharma et. al., 2006). This and another study have
found that EPEC flagella are potent stimulators of IL-8 secretion (Zhou et. al., 2003).
Hence it can be concluded that EPEC induced NF-kB activation is an initial non¬
specific effect initiated by contact of epithelial cell with EPEC flagella, and that once
secreted effector proteins enter the host cell, NF-kB signalling is suppressed. It is
notable that the studies that found NF-kB activation to be EPEC attachment specific
effect used a growth medium (DMEM) that has been shown to both inhibit EPEC
flagella expression and to reduce EPEC flagella induced IL-8 secretion (Zhou et. al.,
2003). Hence it may be concluded that the net effect of EPEC infection on epithelial
cells is a balance between pro- and anti-inflammatory mediators (Sharma et. al.,
2006) based on active strategies to evade the host immune response, and is therefore
analogous to apoptosis.
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(vii) Diarrhoea. The exact mechanism(s) leading to EPEC induced diarrhoea are still
unclear, disruption of the epithelial barrier and malabsorption (caused by microvilli
effacement) are thought to contribute. Disrupted electrolyte transport is also thought
to contribute to EPEC induced diarrhoea, support for this mechanism is provided by
a study that demonstrated upregulation of galanin-1 receptors in response to EPEC
(Hecht et. al., 1999). Intestinal epithelial cells express galanin-1 receptors, which
secret CI" on activation, leading to net loss of water from cells into the lumen. EPEC
infection was shown to upregulate galanin-1 receptors via NF-kB mediated
transcriptional activation (Hecht et. al., 1999). Intimin dependent tyrosine
phosphorylation of phospholipase C-yl (Kenny & Finlay, 1997) is thought to
promote diarrhoea via inositol phosphate, calcium ion and diacylglycerol signalling
resulting in activation of protein kinase C and 'brisk secretion of ions and fluids'
(reviewed by Garmendia et. al., 2005).
(viii) Signalling pathways. The ability of EPEC to induce signal transduction
mechanisms is clear. The cellular consequences of EPEC infection previously
discussed are a combination of; (a) signalling pathway effects (TTSS and intimin
mediated intimate attachment dependent); (b) specific effects of secreted effector
proteins (requiring TTSS but not necessarily intimin); (c) non-specific (generally
toxic) effects of extracellular factors such as flagella and Bfp. However, many more
EPEC induced effects on host cell biology are likely to be discovered as a result of
these, and other pathways. A recent study in which the proteome of EPEC infected
cells was analysed (Hardwidge et. al., 2004) has revealed that changes in the
expression of proteins within the following categories occurred: Actin binding,
carbohydrate metabolism, cell cycle, cytochrome, cytoskeletal, DNA repair, DNA
replication, extracellular matrix, general metabolism, G-protein signalling, immunity,
ion transport, lipid metabolism, protein degradation, signal transduction,
transcription and translation, as well as proteins with currently unclassified functions.
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1.3.6. EPEC - a potential risk factor for colorectal cancer?
The finding that adherent E. coli are present on colonic adenocarcinomas has raised
the possibility of a link between AE E. coli and carcinogenesis (Swidsinski et. ah,
1998; Martin et. al., 2004). Perhaps surprisingly, all bacteria isolates found by
Martin et. al. (2004) were negative for virulence factors of the classic E. coli
pathotypes (aside from a gene encoding a cytotoxin), including eae (intimin), the
EAF plasmid, bfp and espB. However, it is apparent that these studies do suggest a
link between attaching E. coli strains and cancer. Whether this relationship is a cause
of cancer or an effect of cancer remains to be seen.
In mice, evidence of a link between AE bacteria and carcinogenesis has been
provided by Citrobacter rodentium (Citrobacter freundii biotype 4280).
C. rodentium is the causative agent in Transmissible Murine Colonic Hyperplasia, a
gross thickening of the colon in laboratory mice (Schauer et. al., 1995). In mice
C. rodentium infection has been shown to reduce the latent period in appearance of
chemically induced tumours (Barthold & Jonas, 1977), and cause a three-fold
increase in colonic adenomas in ApcMml+ animals (Newman et. al., 2001). A recent
literature review draws parallels between El. pylori and C. rodentium pathogenicity
mechanisms, concluding that signals delivered to the colonic epithelium from
infecting bacteria "might exacerbate defects in developmental or oncogenic
pathways in the tissue" (Vogelmann & Amieva, 2007).
EPEC has effects on pathways such as cell cycle control (Marches et. al., 2003),
DNA repair (Hardwidge et. al., 2004), apoptosis (Heczko et. al., 2001) and cell
adhesion (Simonovic et. al., 2001) that are disrupted in the pathogenesis of cancer.
Many of these properties are shared by the carcinogenic bacterium H. pylori, which
also associates closely with gastric epithelial cells. H. pylori has been shown to
efface microvilli and cause the formation of cup / pedestal structures containing
polymerised actin while intimately attaching to epithelial cells (Smoot et. al., 1993;
Segal et. al., 1996). Like EPEC, H. pylori have a secretion system (type IV secretion
system) and translocate the effector protein CagA (Odenbreit et. al., 2000), which is
33
tyrosine phosphorylated within host cells (Asahi et. al., 2000). Also in similarity to
EPEC, H. pylori induce disruption of host adherens junctions (via CagA) causing
loss of epithelial cell adhesion (Suzuki et. al., 2005), and interfere with host cell
DNA repair protein expression (Kim et. al., 2002).
1.4. Summary
• Colorectal cancer is a disease of high prevalence and mortality, caused by well
defined genetic changes, including activating mutations of oncogenes and
inactivating mutations of tumour suppressor genes.
• The genetic aberrations that contribute to colorectal tumourigenesis occur in a
multiple-hit fashion and accumulate over decades. Concurrent with these genetic
changes, the pathology of colorectal cancer follows a characteristic multi-stage
adenoma-carcinoma sequence.
• Although it is accepted that gene-environment interactions play a crucial role in
the generation of somatic mutations in sporadic colorectal cancer, there is a
paucity of understanding in the nature and mechanism of these interactions.
Hence the risk factors so far identified for colorectal cancer do not adequately
explain the aetiology of this disease.
• Bacteria are a known cause of (gastric) cancer in man, and are abundant in the
colon, furthermore adherent E. coli are very often associated with colonic
adenocarcinomas.
• Enteropathogenic E. coli are carried by a significant percentage of healthy
individuals and attach intimately to the colonic mucosa.
• EPEC shares many properties with the carcinogenic bacterium H. pylori, and
influences apoptosis, cell cycle, cell-cell adhesion and DNA repair in host cells,
pathways frequently disrupted in colorectal cancer.
• In mice AE bacteria are strongly linked to tumourigenesis.
• In combination these findings support the investigation of EPEC infection as a
possible risk factor for colorectal cancer development.
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1.5. Hypothesis
It is the study hypothesis that infection of colonic epithelial cells by enteropathogenic
E. coli can increase the susceptibility of these cells to neoplastic transformation in
man.
1.6. Aims & Objectives
This study aimed to establish the effects of EPEC infection on molecular genetic
pathways involved in colorectal cancer development via the following objectives:
• Establish and validate in vitro, in vivo and ex vivo models for EPEC infection.
• Analyse the ability of AE E. coli to colonise the normal human colonic
mucosa and colonic adenocarcinoma tissue.
• Analyse the effect of infection on DNA MMR repair, Wnt signalling ((3-





Unless otherwise stated, reagents were obtained from Sigma, Poole, UK.
2.1. In vitro co-culture model
2.1.1. General cell culture
The human colorectal cancer cell lines SW480, HT29, LS513 and the mouse colorectal
cancer cell line CMT93 were obtained from the European Collection of Animal Cell
Cultures (ECACC; Porton Down, Wiltshire, UK). Stocks of HT29, SW480 and LS513
were grown in Roswell Park Memorial Institute 1640 (RPMI) media containing
L-glutamine (300g/L 2.05mM) (Gibco/Invitrogen, Paisley, UK) supplemented with 5%
(v/v) foetal calf serum (Labtech/Biosera, Sussex, UK), referred to as R5. CMT93 cells
were grown in Dulbecco's modified Eagle's Medium (DMEM) (Gibco/Invitrogen,
Paisley, UK) supplemented with 10% foetal calf serum, referred to as D10. Cells were
grown as adherent monolayers in T25 and T75 (25 cm2 & 75cm2) cell culture flask
(Costar/Corning, High Wycombe, UK) and incubated at 37°C in a humidified
atmosphere of 5% CO2 in air.
Stock cells were grown to 90-95% confluency before passage. After removal of growth
media, cells were washed with PBS and treated with warmed trypsin solution
(Gibco/Invitrogen, Paisley, UK) and incubated at 37°C for 4-6 minutes. Trypsin was
inactivated by the addition of RPMI / DMEM supplemented with foetal calf serum.
New flasks were seeded from a 1 in 10 dilution of the trypsinised cell suspension.
Frozen cell stocks were maintained in RPMI or DMEM supplemented with 5-10%
foetal calf serum and Dimethyl sulphoxide (DMSO) 10% and stored in a liquid nitrogen
freezer.
2.1.2. Bacterial strains
Wild-type (wt) EPEC, strain E2348/69 and mutant (mut) EPEC strain UMD864
(E2348/69 A48-759 espBl\ Taylor et. al., 1999) were kindly donated by Professor
Michael Donnenberg, University of Maryland. Wild-type Citrobacter rodentium strain
DBS 100 and mutant Citrobacter rodentium strain DBS255 (DBS 100 Aeae) were kindly
donated by Professor David Schauer, Massachusetts Institute of Technology.
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2.1.3. Bacterial Glycerol Stocks
EPEC glycerol stocks were made by adding glycerol (final concentration 20%) to
overnight bacterial cultures grown in Luria Bertani (LB) broth (Table 2.1) + Nalidixic
acid 0.005% (50mg/L) at 37°C in an orbital shaker. 1ml aliquots of glycerol stock were
stored at -70°C. Citrobacter rodentium glycerol stocks were made by adding 20%
glycerol to overnight bacterial cultures grown in LB broth + Nalidixic acid 0.005% at
37°C in an orbital shaker. 1ml aliquots of glycerol stock were stored at -70°C.
2.1.4. Working bacterial cultures
Working stocks of bacteria were grown on nutrient agar. EPEC strains were grown on
selective MacConkey agar and Citrobacter rodentium strains were grown on LB agar.
Agar plates were set up by inoculating lOOul of sterile LB broth with an aliquot (~10-
20ul) of glycerol stock obtained by a stab with a sterile pipette tip. The suspension was
mixed, pipetted on to the agar and spread with a sterile spreading tool. Plates were
incubated overnight at 37°C then stored at 4°C. Fresh plates were set up every eight
weeks. Bacterial cultures used for co-culture experiments were grown from single
colonies picked from agar plates. Colonies were transferred to 4ml sterile LB broth
using a sterile pipette tip and incubated overnight at 37°C in an orbital shaker set to 180
revolutions per minute.
Working stocks of EPEC were maintained on MacConkey agar supplemented with
crystal violet, sodium chloride, 0.15% bile and 0.005% Nalidixic acid (Table 2.2).
Overnight cultures were grown from single colonies inoculated into LB broth and
incubated at 37°C in an orbital shaker. Citrobacter rodentium working stocks were
maintained on LB nutrient agar (Table 2.3), overnight cultures were grown from single
colonies inoculated into LB broth and incubated at 37°C in an orbital shaker.
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Component Concentration
Tryptone (SLS, Nottingham, UK) 1.0%
Yeast extract (SLS, Nottingham, UK) 0.5%
NaCI (Fisher, Loughborough, UK) 0.5%
Dissolved in ddH20, pH adjusted to 7.2
Table 2.1. LB Broth composition
Component Concentration




Bile salts (ICN Biomedicals, Ohio, USA) 0.15%
NaCI (Fisher, Loughborough, UK) 0.5%
Neutral red 0.005%
Grams Crystal Violet Solution




Table 2.2. MacConkey Agar composition
Components Concentration
Bacto Agar (BD Biosciences, Oxford, UK) 1.2%
Dissolved in LB broth
Table 2.3. Nutrient agar composition
2.1.5. Twelve-hour co-culture protocol with three-hourly washes, providing protein
for western blot analysis.
HT29 cells were grown to 90-100% confluency in T75 cell culture flasks. At the start
of the co-culture period medium was aspirated from all flasks, four flasks received 15ml
media plus 150ul E2348/69 (wt) overnight bacterial culture, and four flasks received
15ml media plus 150ul UMD864 (mut) overnight bacterial culture (MOI -10:1). Two
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flasks were uninfected; one was washed by the same protocol as the infected flasks and
one was not washed (Table 2.3). All flasks were incubated at 37°C in a humidified
atmosphere of 5% CO2 in air. At intervals of three hours, flasks were removed from the
incubator and washed by the following method: Medium was aspirated and
approximately 10ml of fresh R5 media was added to each flask. Flasks were then
gently tilted side-to-side by hand to ensure the media washed over the cells 4-6 times,
medium was aspirated and the process repeated a further two times.
Once the cells had been washed three times they received 15ml of fresh R5 media.
150ul of overnight culture of UMD864 was re-added to the mutant-infected cells to
replace the non-adherent bacteria that had been washed away. After washing, cells
were returned to the incubator. When cells reached the designated time-point for protein
isolation they were liberated from the flask by treatment with warmed trypsin and










1 HT29 cells No wash 12h
2 HT29 cells 3, 6, 9, 12h 12h
3 HT29 cells & EPEC (wt) 3h 3h
4 HT29 cells & EPEC (wt) 3, 6h 6h
5 HT29 cells & EPEC (wt) 3, 6, 9h 9h
6 HT29 cells & EPEC (wt) 3, 6, 9, 12h 12h
7 HT29 cells & EPEC (mut) 3h 3h
8 HT29 cells & EPEC (mut) 3, 6h 6h
9 HT29 cells & EPEC (mut) 3, 6, 9h 9h
10 HT29 cells & EPEC (mut) 3,6, 9, 12h 12h
Table 2.4. In vitro co-culture conditions for isolating protein at 3 hour time-points, where
bacteria were first added to cells at 0 hours.
2.1.6. Nine- and twelve-hour co-culture time-course, with three-hourly wash,
providing protein for western blot analysis and fixed cells for immunofluorescence.
Once it had been established that changes in protein expression in HT29 cells generally
occurred after 9-12 hours of co-culture it was decided to further analyse these changes
in situ by use of immunofluorescence. By growing cells in dishes containing cover-slips
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it was possible to obtain cells for immunofluorescence and isolate protein from the
same population of cells. A bacterial pre-culture step was also included to activate the
bacteria prior to infection (Rosenshine et. al., 1996).
Ten sterile 13mm glass cover-slips were placed into round 10cm diameter cell culture
dishes and spaced out so that no overlapping occurred. Cells (HT29/SW480/LS513)
were added to the dishes and grown to 90-100% confluency, whereby the cell
monolayer covered both the cover-slips and the exposed surface of the dish. E2348/69
and UMD864 EPEC were prepared by diluting overnight cultures 1:50 in warmed
(37°C) R5 media. This infected media was then incubated for 1 hour at 37°C (without
shaking) in order to "activate" the bacteria (Rosenshine et. al, 1996).
At the start of the co-culture period media was aspirated from all dishes, two dishes
received 10ml media infected with wild-type EPEC and two dishes received 10ml
media infected with mutant EPEC (MOI ~ 50:1). Two dishes were uninfected; one was
washed by the same protocol as the infected flasks and one was not washed (Table 2.4).
All dishes were incubated at 37°C in a humidified atmosphere of 5% CO2 in air. At
intervals of three hours dishes were removed from the incubator and washed as
previously described (section 2.2.1). Once the cells had been washed three times they
received 10ml of fresh R5. lOOul of overnight culture of mutant UMD864 EPEC was
re-added to the mutant infected cells to replace the non-adherent bacteria that had been
washed away. After washing, cells were returned to the incubator.
At the relevant time-points cover-slips were removed from the dish and placed into new
10cm cell culture dish where they were fixed for immunofluorescence (section 2.3.5.1).
Cells that remained adherent to the original dish were washed with PBS, removed by
treatment with trypsin and centrifuged to form cell pellets. Protein was immediately
isolated from the cell pellets by the standard method (section 2.3.1).
2.1.7. Recovery from infection
HT29 cells were initially co-cultured with E2348/69 for 9 and 12 hours (as described in
section 2.2.2) then washed three times with RPMI media and treated with R5 media
supplemented with penicillin 200,000 u/L, streptomycin 200mg/L and gentamicin
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1 OOmg/L (all from Gibco/Invitrogen, Paisley, UK). Media was changed approximately
every 12 hours. After 36 - 39 hours (12 hour and 9 hour prior infection respectively)








1 HT29 cells No wash 12h
2 HT29 cells 3, 6, 9, 12h 12h
3 HT29 cells & EPEC (mut) 3, 6, 9h 9h
4 HT29 cells & EPEC (wt) 3, 6, 9h 9h
5 HT29 cells & EPEC (mut) 3, 6, 9, 12h 12h
6 HT29 cells & EPEC (wt) 3, 6, 9, 12h 12h




Cell pellets were re-suspended in RIPA buffer (NP-40, 1%; Sodium deoxycholate,
0.5%; SDS, 0.1%; in PBS, pH 8.8) containing Complete Protease Inhibitor (Roche
Diagnostics GmbH, Mannheim, Germany). The suspension was mixed using a vortex
mixer at high speed for approximately 10 seconds then repeatedly drawn through a 25G
(0.5mm diameter) needle attached to a sterile plastic 1ml syringe. The resultant lysate
was centrifuged at 13,000 rpm for 15 minutes at 4°C to remove cell debris. The
supernatant (comprising whole-cell protein extract) was removed and homogenised,
aliquots were stored at -70°C.
2.2.2. Polyacrylamide gel electrophoresis
Whole cell protein extracts were resolved through pre-cast 4-12% gradient NuPAGE®
gels (Invitrogen, Paisley, UK) using MOPS running buffer (Invitrogen, Paisley, UK).
Gels were removed from their plastic cast, trimmed and washed three times with ddH20.
Protein bands were identified by staining overnight with Simplyblue Safestain®
(Invitrogen, Paisley, UK). Gels were then destained with two 1-hour washes with
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dd^O. Gels were either dried using the DryEase™ Mini-Gel Drying system
(Invitrogen, Paisley, UK) or bands were cut out for mass spectrometry. Gels used for
mass spectrometry were manipulated inside class II safety cabinets and stained,
destained and stored in fresh, sterile plastic-ware.
2.2.3. Mass spectrometry
Whole cell protein extracts were resolved through pre-cast 4-12% gradient NuPAGE®
Novex gels (Invitrogen, Paisley, UK). Gels were stained overnight with SimplyBlue®
Safestain (Invitrogen, Paisley, UK) and destained in ddHhO to reveal protein bands.
Bands were cut from gels, washed with actonitrile 50%, dried and reduced with
dithiothreitol (DTT) lOmM and EDTA 0.2% in ammonium bicarbonate lOOmM, then
alkylated with iodoacetamide 20mM in ammonium bicarbonate lOOmM. After washing,
proteins were digested with sequencing grade modified trypsin (Promega, Southampton,
UK). Spectra were measured on a Voyager DE-STR Maldi-Tof Mass Spectrometer
(Applied Biosystems, Foster City, CA). Protein matches were identified via the MS-Fit
SwissProt. database:
http://prospector.ucsf.edU/prospector/4.0.8/html/msfit.htm.
2.2.4. Western blot analysis
Whole cell protein extracts were resolved through pre-cast (4-12% gradient / 10%)
NuPAGE Novex gels (Invitrogen, Paisley, UK) or 10% sodium dodecyl sulphate /
polyacrylamide (SDS-PAGE) gels (Table 2.6) and transferred to polyvinylidene
difluoride (PVDF) membranes (Hybond P, GE Healthcare Biosciences,
Buckinghamshire, UK). Protein levels could not be equalised via conventional
densitometry due to the presence of bacterial protein in some samples. Therefore, levels
were equalised via successive western blots with reference to beta-actin and
proliferating cell nuclear antigen (PCNA) band intensities, coumassie blue staining was
also used to aid equal protein loading.
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Name Composition / Product
10% SDS-PAGE stacking gel
Tris pH 6.8, 0.125M





10% SDS-PAGE resolving gel
Tris base pH 8.8, 0.375M














SDS-PAGE protein loading buffer
Tris base pH 6.8, 0.0625M






BenckMark prestained protein ladder
(Invitrogen, Paisley, UK)
NuPAGE running buffer
NuPAGE MOPS SDS running buffer (20X)
(Invitrogen, Paisley, UK)
NuPAGE transfer buffer
NuPAGE transfer buffer (20X)
(Invitrogen, Paisley, UK)
NuPAGE protein loading buffer






TBS (Tris buffered saline)
TBST (TBS with 0.1% Tween-20)
Blocking buffer
TBST with 5% Marvel powdered milk
(Premier Int. Foods, Lincolnshire, UK)
Coumassie stain SimplyBlue SafeStain
(Invitrogen, Paisley, UK)
Table 2.6. Electrophoresis and Western blot solutions
Primary antibodies were used at a concentration of 1 in 250 to 1 in 5000, incubation
time varied from 45 minutes at room temperature to 16-hours (overnight) at 4°C (Table
2.7). Peroxidase conjugated secondary antibodies were applied for 30 minutes - 2 hours
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at room temperature (Table 2.8). Proteins were detected using ECL Plus
chemiluminescence detection system and exposed to Hyperfilm MP (both from GE
Healthcare Bio-Sciences, Buckinghamshire, UK), which was developed in a
Hyperprocessor (Amersham Biosciences, Buckinghamshire, UK).















































































1 in 500 Overnight
(4°C)
Table 2.7. List of primary antibodies used for probing Western blots.














































1 - 2 hours
RT
Table 2.8. List of secondary antibodies used for probing Western blots.
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2.2.5. Immunofluorescent staining of proteins and phalloidin staining of F-actin
2.2.5.1. Fixing cells
Cover-slips holding cell monolayers were placed into fresh sterile 10cm cell culture
dishes and washed twice with 10ml sterile PBS. Cells were then fixed with 10ml
paraformaldehyde in PBS (Table 2.14) for 5 minutes. The paraformaldehyde solution
was aspirated and cells were washed three times with PBS. Finally, 15ml of PBS
supplemented with 0.02% sodium azide was added, dishes were sealed with paraffin
film and stored at 4°C.
2.2.5.2. Immunocytochemistry
• Cover-slips were placed cell-side up in individual wells in 12-well plastic plates
(Costar/Corning, High Wycombe, UK) and washed in PBS for 5 minutes on an
orbital shaker
• A solution of 0.1% v/v Triton-XlOO in PBS was added (to enhance cell membrane
permeability) and plates were placed on an orbital shaker for 30 minutes
• The Triton solution was aspirated and cells were washed in PBS for 5 minutes on
an orbital shaker
• Blocking buffer (Bovine serum albumin, 0.3%; Tween-20, 0.2% in PBS) was
added and plates were placed on an orbital shaker for 1 hour
• Blocking buffer was aspirated and cells were washed in PBS for 5 minutes on an
orbital shaker
• Primary antibodies (Table 2.9) were diluted in PBST (Tween-20, 0.2% in PBS)
and added to cells, plates were placed on the bench (stationary) for 1 hour
• Antibody solution was aspirated and cells were washed with PBST (three 5
minute washes) on an orbital shaker
• Secondary antibodies (Table 2.10) were diluted in PBST and added to cells, plates
were covered in metal foil and placed on the bench (stationary) for 30 minutes
• Antibody solution was aspirated and cells were washed with PBST (three 5
minute washes) on an orbital shaker
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• Cover-slips were removed from wells, blotted on tissue paper to remove excess
PBST and mounted (cell-side down) onto glass microscope slides with
Vectashield Mounting Medium with DAPI (Vector Labs, Burlingame, CA).
• Excess mounting medium was blotted away with tissue paper
• Slides were placed in slide holders, covered with metal foil and stored at 4°C.
































1 in 500 1 hour
















































1 in 500 1 hour
2.9. Table of primary antibodies used for Immunofluorescence immunocytochemistry







Goat 1 in 2000 1 hour
Texas red conjugated
Alexa-fluor 594











Goat 1 in 2000 1 hour
2.10. Table of secondary antibodies used for immunofluorescent immunocytochemistry
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2.2.5.3. In situ cell death detection
Cells undergoing late stage apoptosis / necrosis were identified based on labelling of
DNA strand breaks (TUNEL technology) using an In Situ Cell Death Detection Kit
(Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturers
instructions, and visualised via fluorescence microscopy. Percentages of TUNEL
positive cells were calculated by counting at least 400 cells from each experimental
condition (n = 3). Positive control cells were treated with DNAse (Qiagen, Crawley,
UK).
2.2.5.4. Early apoptosis detection
Early stage apoptosis was detected in cells by immunofluorescence staining of
cytochrome c (Castedo et. al., 2002), either in conjunction with the mitochondrial
marker MTC02 or MLH1 using the antibodies listed in Table 2.9. Positive control cells
were treated with etoposide lpM for 2 hours, followed by 6 hours in normal media,
then fixed as described above.
2.2.6. Immunofluorescence image capture and quantitative image analysis
Fluorescent images were captured using either a Zeiss Axioskop 20 fluorescence
microscope (Zeiss, Luton, UK) using Smartcapture software (Digital Scientific,
Cambridge, UK) or a Zeiss Axioplan II fluorescence microscope using IPLab software
(Scanalytics Corp., Fairfax, VA). Image analysis was performed using in-house scripts
written for IPLab Spectrum (Scanalytics Corp., Fairfax, VA). Software calculated the
nuclear staining intensities for the proteins of interest. With reference to images of
uninfected controls, cells were categorized as having either negative / very low (-),
intermediate (+) or very strong (++) nuclear staining. The numerical staining intensity
boundaries between these three cell populations were calculated for control cells and
applied to the intensity data generated from each of the experimental conditions. The
individual intensity values for over 300 cells were counted for each experimental
condition (see appendix for example).
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2.3. Mutation frequency analysis by inter-Alu PCR
2.3.1. Co-culture and DNA isolation
To demonstrate method reproducibility, uninfected, untreated SW480 cells were used.
To analyse the effect of EPEC on mutation frequency, SW480 cells grown in T75 flasks
were either uninfected or infected with mutant or wild-type EPEC. After 12 hours, cells
were treated with antibiotics and allowed to recover from infection as previously
described. Once cells reached 100% confluency, flasks were split into 10 new T25
flasks and grown to 100% confluency (this took longer for cells infected with wild-type
EPEC). Cells were removed from flasks by treatment with trypsin and centrifuged to
form cell pellets. After removal of the media supernatant, cell samples were incubated
with lysis buffer (Table 2.11) for 2 hours at 37°C while rotating. DNA was isolated
from the resulting homogenate by phenol / chloroform extraction (Phenol : Chloroform





Ethylenediaminetetraacetic acid disodium (EDTA), 0.1%
In ddH20, pH 8.3
Lysis buffer
Tris base pH 8, 10mM
Sodium chloride, 400mM
EDTA, 3mM
Sodium dodecyl sulphate, 1%
Proteinase K, 0.4mg/ml
Agarose gel for PCR
Biotechnology grade agarose (Amresco, Solon, OH), 3%







In Severn Super Sequencer; 6.5% Acrylamide, Urea,
TBE solution (Severn Biotech, Worcestershire, UK)
Table 2.11. Gels and solutions for PCR
2.3.2. Inter-Alu PCR
The Alu-specific primer R12A/267 (AGCGAGACTCCG) spans 12 nucleotides at the 3'
end of the Alu consensus sequence, downstream from position 267 (Zietkiewicz et. al.,
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1992). Reactions were performed using R12A/267 in the presence of redivue
deoxyadenosine 5'-[alpha-33P] triphosphate (triethylammonium salt, 9.25 MBq, 250
uCi, GE Healthcare Biosciences, Buckinghamshire, UK). PCR products were resolved
through denaturing 6.5% polyacrylamide gels (Table 2.11) and visualised by overnight
exposure of dried gels to Kodac X-OMAT AR autoradiographic film (VWR
International, Leicestershire, UK).
2.4. Microarray gene expression analysis
2.4.1. Co-culture and RNA isolation
HT29 cells were either uninfected or co-cultured with wild-type or mutant EPEC for 9
and 12 hours as described above (section 2.2.2). A total of three repeat co-culture
experiments were performed on separate days. Cells were removed from dishes with
trypsin and centrifuged to form cell pellets. Supernatant media was removed and pellets
were stored at -70°C overnight. RNA was isolated from cell pellets using Qiagen Mini
Prep kits with the addition of DNAse (Qiagen, Crawley, UK) according to the
manufacturer's instructions. The concentration and stability (RIN number) of RNA
samples was analysed on an Agilent Bioanalyser (Agilent Technologies, Berkshire,
UK). RNA isolated from cells co-cultured with EPEC (especially wild-type EPEC)
generally had lower RIN number and concentration. RNA concentrations were
equalised prior to amplification.
2.4.2. RNA amplification and biotin tagging
RNA was amplified and biotin tagged using Illumina Total Prep RNA Amplification
Kits (Ambion, Cambridge, UK) according to the manufacturer's instructions.
Subsequent to amplification, the concentration and purity of samples was checked on an
Agilent Bioanalyser (Agilent Technologies, Berkshire, UK) and sample concentrations
were equalised before microarray analysis.
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2.4.3. Microarray analysis
The microarray hybridisation procedure was carried out by staff at the Wellcome Trust
Clinical Research Facility (Western General Hospital) in accordance with
manufacturers instructions. Sentrix Human-6 v2 Beadchips were used in conjunction
with the Illumina microarray platform (Illumina Inc., Cambridge, UK).
2.4.4. Microarray data output and analysis
A total of three Beadchips, each holding six individual arrays were used, hence each
repeat experiment was performed on one Beadchip (Table 2.12). Each Human-6 v2
Beadchip generated expression data for over 46,000 gene probes, corresponding to
approximately 26,000 characterised genes and 20,000 uncharacterised genes.
Experiment Infection Time-course Abbreviation Replicate Array Beadchip
1
- 0 h -Oh A 1
1
- 12 h -12h B 2
mut EPEC 9 h +mut 9h C 3
mut EPEC 12 h +mut 12h D 4
wt EPEC 9 h +wt 9h E 5
wt EPEC 12 h +wt 12h F 6
2
- 0 h -Oh A 7
2
- 12 h -12h B 8
mut EPEC 9 h +mut 9h C 9
mut EPEC 12 h +mut 12h D 10
wt EPEC 9 h +wt 9h E 11
wt EPEC 12 h +wt 12h F 12
3
- 0 h -Oh A 13
3
- 12 h -12h B 14
mut EPEC 9 h +mut 9h C 15
mut EPEC 12 h +mut 12h D 16
wt EPEC 9 h +wt 9h E 17
wt EPEC 12 h +wt 12h F 18
Table 2.12. Microarray sample list showing co-culture conditions and experimental
replicates.
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Raw gene expression data was collated by the proprietary Illumina Beadstudio software
(Illumina Inc., Cambridge, UK). Raw data was uploaded to the IlluminaGUI software
package (downloaded from http://illuminagui.dnsalias.org), running from the 'R'
statistical computing programme (v-2.5.1 www.r-project.org/index.html) IlluminaGUI
is a recently introduced graphical user interface for analysing gene expression data
generated from the Illumina Beadchip platform (Schultze & Eggle, 2007). Analysis of
the functional pathways to which differentially expressed genes belonged was
performed using the DAVID (Database for Annotation, Visualisation and Integrated
Discovery) 2007 bioinformatics database (http://david.abcc.ncifcrf.gov; Dennis et. al.,
2003).
Outline of data analysis workflow:
• Upload raw data to IlluminaGUI
• Output control probe data (validation of array performance, see appendix)
• Normalise data
• Validate normalisation method by comparing normalised and non-normalised (i.e.
raw) data via box & whisker plots, MA plots and scatter plots
• Group replicate data
• Perform differential expression analysis, based on fold change and statistical
significance
• Record number of differentially expressed genes and plot as 'volcano' scatter plots
• Examine gene ontology by clustering based on functional annotation and pathway
enrichment (via DAVID Bioinformatics database)
• Examine expression of individual genes of interest
The IlluminaGUI data analysis package was chosen as it was designed specifically for
Illumina Beadchip data and allows use of the powerful R statistical platform with a
straightforward user interface. Normalisation techniques used were quantile/quantiles
normalisation (Bolstad et. al., 2003) and variance stabilisation normalisation (VSN)
(Huber et. al., 2002). The statistical tests used were conventional T-test and significance
analysis ofmicroarrays (SAM) test (Tusher et. al., 2001).
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2.5. In vivo mouse model of EPEC infection
2.5.1. Animal husbandry
All animal work was approved by the University of Edinburgh, under Home Office
personal and project licences. C57B1/6 mice and C3H/HeN mice were obtained from
Charles River (Kent, UK). Mice were caged and housed in negative pressure isolators
with a normal 12 hour light / dark cycle. Mice were fed standard solid diet and allowed
drinking water ad libitum.
2.5.2. In vivo infection of C57B1/6 mice with Citrobacter rodentium
Mature, male C57B1/6 mice received lOOul (~1 x 108) of Citrobacter rodentium
DBS 100 (n = 3) or DBS255 (n = 3) bacterial suspension (grown overnight in LB broth)
by gavage using a rigid gavage needle, negative controls (n = 3) were untreated.
After 14 days all animals were killed by cervical dislocation. The abdomen was opened
and the entire colon (from just below the cecum to the rectum) was excised. The colon
was cut longitudinally and opened, then thoroughly washed in sterile PBS to remove all
faecal matter. The tissue was placed lumen side up onto a dry sterile Petri dish lid and
forceps were used to fully unfold the tissue. The resulting strip of tissue was rolled
around a small metal rod (3mm diameter) to form a compact roll. The roll was carefully
removed from the rod with forceps and pierced with a metal sewing pin to hold it
together. Tissue was fixed in 4% buffered formalin for 48 hours then embedded in
paraffin (Histopathology Labs, QMRC, Little France, Edinburgh).
2.5.3. In vivo infection of C57B1/6 mice with EPEC
This mouse model for EPEC infection is derived from that published by Savkovic et. al.
(2005).
2.5.3.1. Inoculation of mice
EPEC E2348/69 were grown overnight in 4ml LB broth. The bacterial suspension was
centrifuged (3500g for 10 minutes) and the LB broth was aspirated. The bacterial pellet
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was re-suspended in 4ml PBS. Nine male 6-8 week old C57B1/6 mice received 200ul of
the EPEC E2348/69 bacterial suspension (~2 x 108 bacteria) by gavage using a rigid
gavage needle and returned to their cages.
2.5.3.2. Infection time-course
At intervals of 24, 48 and 72 hours from the time of infection, animals (n = 3) were
removed from the group and killed by cervical dislocation. The abdomen was opened
and the gastrointestinal tract (ileum to rectum) was excised and placed into sterile PBS.
The tissue was cut into ileum, cecum, proximal colon and distal colon sections. Each
section was cut longitudinally, and thoroughly washed in a universal container
containing sterile PBS (10ml for ileum, and colon sections, 20ml for cecum). The PBS-
lumen contents suspensions were retained. The tissue was then washed a further three
times in sterile PBS, placed in a universal container containing 5ml sterile PBS and
transported to the laboratory.
2.5.3.3. Mechanical homogenisation of tissue
All tissues were weighed within their containers (the weight of each container + the
relevant volume of PBS had previously been recorded). Tissues were removed from
their containers and placed onto a sterile, dry, plastic Petri dish lid. Tissues were cut
repeatedly with curved scissors (John Weiss, Buckinghamshire, UK) until all pieces
were no bigger than lmnT. Tissue was then transferred back into its original container
(containing 5ml PBS) and repeatedly drawn (6-8 times) through a 21G (0.8mm x
40mm) needle attached to a sterile 10ml plastic syringe.
2.5.3.4. Bacteria counts
The number of EPEC adherent to gastrointestinal tissue sections was calculated by
inoculating selective MacConkey agar plates with lOOul of the PBS-tissue homogenate.
The number of non-adherent EPEC present in the lumen of the gut sections was
calculated by inoculating selective MacConkey agar plates with lOOul of the PBS-
lumen contents suspension. Three agar plates - each inoculated with lOOul - were
grown from each tissue / lumen suspension. The agar plates were covered and placed
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upside down in a 37°C incubator for 24 hours. EPEC colony forming units (CFEl's)
were identified as round pink colonies and counted manually. Average numbers of
CFU's were calculated and the total number of adherent / non-adherent EPEC were
calculated based on the dilution in PBS and size of the inoculum.
2.5.3.5. Longer-term infection
EPEC E2348/69 and UMD864 were grown overnight in 4ml LB broth. The bacterial
suspensions were centrifuged (3500g for 10 minutes) and the LB broth was aspirated.
The bacterial pellets were re-suspended in 4ml PBS. Male 6-8 week old C57B1/6 mice
received 200ul of either EPEC E2348/69 (n = 3) or UMD864 (n = 3) bacterial
o
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suspension (~2 x 10 bacteria) by gavage using a rigid gavage needle and returned to
their cages. After 14 days animals were killed and tissue was prepared as described
above (section 2.6.2.1).
2.5.4. In vivo infection of C3H/HeN mice with EPEC
The aim of this protocol was to improve on the C57B1/6 mouse model for EPEC
infection, i.e. to produce a mouse model that was colonized by higher numbers of EPEC
for a greater period of time. C3H/HeN mice were used because of their increased
susceptibility to infection by attaching and effacing bacteria (Citrobacter rodentium)
(Vallance et. al., 2003). Also, bacteria preparation was modified in order to activate
bacteria (Rosenshine et. al., 1996) before gavage.
2.5.4.1. Inoculation of mice
EPEC E2348/69 were grown overnight in 4ml LB broth. 1ml of the bacterial
suspension was added to 20ml of LB broth and incubated until optical density was 0.5
at 600nm. This bacterial suspension was centrifuged (3500g for 10 minutes) and the
LB broth was aspirated. The bacterial pellet was re-suspended in 3.5ml of sterile PBS.
Fifteen male 6-8 week old C3H/HeN mice received 200ul of the EPEC E2348/69
bacterial suspension (~1 x 109 bacteria) by gavage using a rigid gavage needle and
returned to their cages.
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2.5.4.2. Infection time-course, homogenisation of tissue and bacteria counts
Infected mice (n = 9) were used for bacteria counts using the same protocol as
previously described.
2.5.4.3. Longer-term infection
The remaining animals (n = 6) were kept under normal conditions for over 5 weeks post
infection. Over this time their behaviour was observed to be normal, with no signs of
diarrhoea. Three of these animals were killed 38 days post infection; numbers of
adherent and non-adherent EPEC in the cecum and proximal colon were counted as
previously described.
2.5.4.4. Fixed cecum and proximal colon tissue for H&E staining
A second group of C3H/HeN mice (n = 3) were infected with EPEC by the same
method. All animals were killed 48 hours from the time of infection. The cecum and
proximal colon were excised, lumen contents were collected, tissues were washed three
times, rolled and fixed in 4% buffered formalin. Within 48 hours, fixed tissues were
taken to the Histopathology Laboratories at Queens Medical Research Centre where
they were embedded in paraffin, cut into 4um sections and placed onto glass
microscope slides for immunohistochemistry. Cecum and proximal colon tissues from
C3H/HeN mice not infected with EPEC were used as controls and prepared for staining
in the same way.
2.6. Human tissue ex vivo
2.6.1. Ethics
Ethical approval for the use of human tissue was provided by the NHS Lothian
Research Ethics Committee, under the title: Edinburgh Cancer Research Centre tissue




Tissue was removed from patients undergoing surgical resection of the large intestine at
the Western General Hospital, Edinburgh. Only normal, 'healthy' tissue (removed from
sites distant from any disease) was used in co-culture (Table 2.13).
Reference
number Age Sex Disease Tissue sample
OMSA241238 69 F Metastatic endometrial cancer Transverse colon
OMSA290942 65 M Rectal cancer Transverse colon
OMSA040143 64 M Rectal cancer Transverse colon
Table 2.13. Patient details for colon mucosa tissue donors
2.6.3. Bacteria preparation
EPEC E2348/69 and UMD864 were prepared by diluting overnight cultures 1:50 in
warmed (37°C) R5 media. This infected media was then incubated for 1-2 hours at
37°C (without shaking) in order to "activate" the bacteria (Rosenshine et. al., 1996).
2.6.4. Co-culture
In vitro organ co-culture of ex vivo tissue with EPEC was based on the published in
vitro organ culture (IVOC) protocols of Browning & Trier (1969), Knutton et. al.
(1987) and Cleary et. al. (2004).
Full thickness sections of colon tissue were removed from surgical patients and washed
thoroughly with sterile saline. The mucosal layer was separated from the muscularis,
leaving strips of colonic mucosa with surface area of approximately 3.5 - 4.5cm2.
Mucosa strips were placed into universal containers containing R5 media (room
temperature) supplemented with Nalidixic acid 0.005% and transferred to the laboratory
in 10-20 minutes. Tissues were washed twice in warmed (37°C) sterile PBS then
trimmed with scissors to produce roughly equally sized pieces of mucosa with surface
area approximately 2 - 3cm . Each piece ofmucosa was placed onto a flat rectangle of
stainless steel mesh (United Wire, Edinburgh, UK) measuring approximately 4cm2 and
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manipulated with tweezers so that it was completely unfolded with the luminal side
facing upward. The gauze was placed into a 6cm central well culture dish containing
2.5ml R5 media and Nalidixic acid 0.005%, warmed to 37°C. More media was added
to the central well until the surface of the mucosa was covered to a depth of 1 - 2 mm.
Figure 2.1. In vitro organ culture of ex vivo human colon mucosa.
Mucosa sections that were to be infected with EPEC were inoculated with 200ul of
infected media directly onto the surface of the mucosa. Dishes were covered and placed
into a modular incubator chamber (Billups-Rothenberg, CA) that was closed, gassed
with 5% CO2 in O2 (BOC Medical Supplies, Guildford, UK) sealed and placed into a
bench top oven set to 37°C. At three hour intervals tissues were removed from their
dishes (by grasping metal gauze with forceps), washed twice in sterile PBS and
transferred to a fresh 6cm central well culture dish containing 2.5ml R5 media
supplemented with Nalidixic acid 0.005%, warmed to 37°C. More media was added to
the central well until the surface of the tissue was covered to a depth of 1 - 2 mm.
2.6.5. Fixing and embedding tissue
At the relevant time-points the mucosa sections were removed from their culture dishes,
washed twice in sterile PBS and submerged (whilst still attached to the metal gauze) in
4% buffered formalin (Table 2.14). Tissue was allowed to fix for 14-16 hours then
separated from the gauze and transferred to 70% ethanol in ddPEO. Within 48 hours,
fixed tissues were taken to the Histopathology Laboratories at Queens Medical
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Research Centre where they were embedded in paraffin, cut into 3pm sections and
placed onto glass microscope slides for immunohistochemistry.
2.7. Identifying AE E. coli in human adenocarcinoma and normal colon
2.7.1. Tissue
Formalin fixed, paraffin embedded tissue sections were provided by the Histopathology
Department, University of Edinburgh, New Royal Infirmary of Edinburgh. Sections of
normal and adenocarcinoma tissue from 20 colorectal cancer patients were used.
Sections were cut to 3 pm for immunofluorescence staining and 20pm for PCR.
2.7.2. DNA isolation and PCR for eae
Paraffin embedded tissue sections were subjected to proteinase K digestion in lysis
buffer (Table 2.11) for 48 hours at 55°C, then phenol chloroform extraction of DNA
(Phenol: Chloroform: Isoamyl alcohol, Ambion, Cambridge, UK) followed by ethanol
precipitation in the presence of yeast transfer RNA. Primers for eae were: forward 5'
GTG ACG ATG GGG ATC GAT and reverse 5' GGC TCA ATT TGC TGA GAC
CAC GGT T (product llObp) or 5' ACG GCT GCC TGA TAA TGT T (150bp
product). PCR cycle conditions: 94°C 2min, (94°C 30 sec, 58°C 30sec) x 30 cycles.
PCR primers designed by Scott Bader.
PCR products were resolved through 3% agarose gels with ethidium bromide (Table
2.11). Products were visualised under UV light in a Bio-Rad Gel Doc (Bio-Rad
Laboratories, Elercules, CA) in conjunction with Quantity One software version 4.6
(Bio-Rad Laboratories).
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2.8. Immunofluorescence staining protocol
• Paraffin was removed and tissue was hydrated by washing slides sequentially in
xylene (two 5 minute washes), 100% ethanol (two 5 minute washes), 70% ethanol
(one 5 minute wash) and tap water (one 5 minute wash)
• Antigen retrieval was carried out by submerging slides in citrate buffer (Table
2.14), heating at full power in a 950 Watt microwave-oven for 25 minutes (buffer
was topped up every 6-8 minutes) and allowing slides to cool for one hour at
room temperature
• Slides were then rinsed in deionised water and placed onto plastic Sequenza clips
(Shandon, Cheshire, UK) and slotted into a Sequenza immunostaining rack
(Shandon, Cheshire, UK)
• A solution of 1% Triton-XlOO was added (to enhance tissue permeability) for 20
minutes
• Slides were washed with PBS (two 5 minute washes)
• PBA blocking buffer was added for 1 hour
• Slides were washed with PBS (two 5 minute washes)
• Primary antibodies (Table 2.15) were diluted in PBS and added for the relevant
time-course
• Slides were washed with PBS (three 5 minute washes)
• Secondary antibodies (Table 2.15) were diluted in PBS and added for 30 minutes
(after addition of the secondary antibody slides were protected from prolonged
exposure to light using metal foil)
• Slides were washed with PBS (three 5 minute washes)
• Slides were removed from the plastic clips, excess PBS was wiped away
• Cover-slips were mounted onto slides using Vectashield® Mounting Medium with
DAPI (Vector Laboratories, Burlingame, CA)
• Slides were placed into holders, covered in metal foil and stored at 4°C.
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Solution Composition
Paraformaldehyde (PFA) Paraformaldehyde (Sigma-Aldrich, Steinheim,Germany) 4% in PBS.
Buffered formalin Formaldehyde solution, for molecular biology, 36.5%
(Sigma, Poole, UK) diluted in PBS to 4%.
Citrate buffer
Citric acid, trisodium salt dihydrate, 99% (Arcos
Organics, Geel, Belgium) 0.3% in ddH20, pH adjusted
to 6.4.
Table 2.14. Immunocytochemistry and immunohistochemistry solutions
Antibody Clone Manufacturer Raised in Cone. Time


































Goat 1 in 2000 1 hour
Table 2.15. Primary and secondary antibodies used for immunofluorescence staining of
human tissue
2.9. Haematoxylin and eosin (H&E) staining
• Paraffin was removed and tissue was hydrated by washing slides sequentially in
xylene (two 5 minute washes), 100% ethanol (two 5 minute washes), 70% ethanol
(two 5 minute washes) and tap water (one 5 minute wash)
• Slides were placed in Harris Haematoxylin for 5 minutes, then washed in water
for 30 seconds
• Slides were then placed in acid alcohol solution (0.5% v/v HC1 in 70% v/v
ethanol) for 30 seconds, then washed in water for 30 seconds
• Next, slides were placed in Lithium carbonate solution (Li2C03 0.5% in ddH20)
for 30 seconds, then washed in water for 30 seconds
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• Slides were then stained with eosin aqueous solution 1% (BDH Laboratory
Supplies, Poole, UK) for 20 seconds, then washed in water for 30 seconds
• Finally, slides were dehydrated by reversing the alcohol gradient listed above and
cover-slips were mounted onto slides with Pertex mounting solution (CellPath,
Newtown, UK)
2.10. Bright-field image capture
Images ofH&E stained tissue were captured using an Olympus BX51TF microscope
(Olympus Optical, Japan) in conjunction with Olympus DP-Soft Software.
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Chapter 3.
Development and validation of an extended time-
in vitro model for EPEC infection.
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3.1. Introduction
3.1.1. In vitro EPEC co-culture models
An in vitro co-culture model provides a convenient means to study the molecular
consequences of EPEC infection on human epithelial cells. Review of the literature
describing in vitro co-culture of EPEC with human cells reveals two notable trends;
firstly, the majority of reports use 3-4 hour co-culture protocols; and secondly, the
effects of EPEC infection change with time and cell type. Good examples are studies
analysing the effect of EPEC on NF-kB. Savkovic et. al. (1997) report on EPEC
induced activation of NF-kB, showing a large increase in nuclear accumulation in
T84 cells after 1 hour, however, after only 3 hours, nuclear NF-kB was significantly
diminished. Melo et. al. (2005) co-cultured EPEC with EleLa cells for 1-4 hours and
found that nuclear NF-kB signal was maximal after 2-3 hours, decreasing thereafter.
The hypothesis that EPEC infection has the ability to increase susceptibility of
colonic epithelial cells to neoplastic transformation is based on the assumption of
chronic, asymptomatic intestinal colonisation. Hence the initial aim of this study was
to establish an extended time-course in vitro co-culture model using a biologically
relevant cell line.
The time-course of any experiment that co-cultures bacteria with mammalian cells is
fundamentally limited by the non-specific toxicity eventually generated by bacterial
overgrowth. Specific bacterial effects may also shorten the co-culture period before
adherent mammalian cells undergo apoptosis / necrosis or other changes which result
in loss of adhesion. EPEC infection has the potential to induce both specific and non¬
specific host cell alterations that would potentially limit the co-culture period. These
include loss of adhesion due to focal adhesion / tight junction / adherens junction
disruption (Shifrin et. al., 2002; McNamara et. al., 2001; Malladi et. al., 2004) or
possible induction of cell death (Abul-Milh et. al., 2001; Melo et. al., 2005).
Therefore a key aspect of developing an extended time-course model was
minimising non-specific toxicity.
64
Reference Topic Time-course MOI Cell type
Hardwidge et. al., 2004 Cell death 4 h 50:1 Caco-2
Abul-Milh et. al., 2001 Cell death 5 h 100:1 Caco-2, HEp-2,HeLa
Melo et. al., 2005 Cell death 4 h - HeLa





1-3 h 100:1 Caco-2
Crane et. al., 2004 PKC activation 30 - 60 min. 100-200:1 T84, HeLa
Kenny & Finlay 1997 PLC activation 2.5-3 h 100:1 HeLa
Cleary et. al., 2004 Bfp effects 3-6 h* - HEp-2, Caco-2
Table 3.1. Representative sample of published protocols for co-culture of EPEC with
adherent cell monolayers. Caco-2 & T84 derived from colon cancers, HeLa derived from
cervical cancer and HEp-2 from laryngeal cancer. * In this study cells co-cultured with EPEC
for 6 hours were washed after 3 hours. Where stated, the initial multiplicity of infection (MOI)
(i.e. approximate number of bacteria per human cell) is included.
3.1.2. Cell lines
The literature demonstrates that EPEC can intimately attach to cells derived from the
epithelia of different organs (Table 3.1). In order to achieve a biologically relevant
model, cell lines derived from the human colon were used in this study. HT29 cells
represent a good model as they are derived from human colonic (adenocarcinoma)
cells and form adherent monolayers displaying tight junctions and a brush border
(Chantret et. al., 1988). In genetic terms HT29 cells also represent a good model as
they express the proteins we hope to analyse i.e. DNA MMR repair (Wheeler et. al.,
1999), |3-catenin and cell adhesion proteins (Efstathiou et. al., 1998). However, like
many colon cancer cell lines (and especially those that have wild-type MMR genes)
HT29 cells carry mutations in APC (Rowan et. al., 2000) that may effect the
regulation of the proteins of interest (e.g. (3-catenin). Repeat co-culture experiments
were performed with SW480 (and in one instance LS513) cells to help confirm the
effects of EPEC. SW480 cells were derived from a human colonic adenocarcinoma
(Chantret et. al., 1988) and LS513 cells were derived from a human mucin-secreting
cecal tumour (Suardet et. al., 1992). HT29, SW480 and LS513 cells are all classed as
microsatellite stable, i.e. they have no mismatch repair defects and have no MSI
(Gayet et. al., 2001).
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3.1.3. Bacterial strains
EPEC E2348/69 is a wild-type strain isolated from an outbreak of diarrhoea in
Taunton in 1969 (Gross et. al., 1976). It is the classic wild-type EPEC strain, and is
commonly used experimentally. E2348/69 carries complete copies of both the EAF
plasmid, encoding bundle forming pili, and the LEE pathogenicity island, encoding
the TTSS, EPEC secreted effector proteins and eae (Cleary et. al., 2004). EPEC
UMD864 is an experimentally generated isogenic mutant of E2348/69, which does
not express the LEE encoded EPEC secreted protein EspB (Taylor et. al., 1998).
UMD864 is therefore unable to form a functional TTSS, hence it cannot translocate
effector proteins into host cells so is unable to achieve intimate attachment. UMD864
was used as a negative control, to help identify whether the effects of wild-type
EPEC were specific (i.e. dependent on secreted effector molecules and / or intimin
signalling) or non-specific (i.e. induced by alteration to cell environment / contact
with Bfp, bacterial filaments or other factors).
3.1.4. FAS test
Initial validation of the in vitro model included evaluation of cell detachment and the
ability of cells to survive post-infection. It was also important to ensure that EPEC
strains were displaying their relative phenotypes in vitro. A convenient test for AE
lesion formation by wild-type EPEC is the fluorescent actin-staining (FAS) test
(Knutton et. al., 1989). This test utilises the phallotoxin phalloidin, which binds with
high affinity and specificity to filamentous actin in vitro. Hence fluorescein
isothiocyanate (fitc) labelled phalloidin binds to the AE lesions, displaying intense
spots of fluorescence indicating site-specific concentration of cytoskeletal actin
below adherent bacterium. This is a highly sensitive diagnostic test for AE bacteria.
3.1.5. Mass spectrometry
Co-culture of wild-type EPEC with human colonic cells has a wide range of effects
on the host cell proteome after 4 hours, causing the up-regulation and down-
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regulation of hundreds of proteins (Hardwidge et. al., 2004). As a further validation
of our in vitro model, and to gain an insight into the molecular effects of EPEC, host
cell protein expression was analysed subsequent to infection. Protein separation by
electrophoresis followed by mass spectrometry represents a crude but rapid means of
proteomic analysis. In the proteomic context, mass spectrometry was initially used to
analyse protein structure and to detect errors in translation or post-translation
changes in known proteins. This is achieved by measuring the mass of peptides
cleaved from the protein by proteases, changes in peptide masses reflect protein
structural or sequence changes. This approach has generated a database of accurate
molecular weight 'fingerprints' for many proteins. Comparison of the molecular
weight fingerprints of unknown sample proteins to this database has subsequently
enabled the identification of proteins via mass spectrometry (Pappin et. al., 1993).
Matrix-assisted laser desorption time of flight (Maldi-tof) mass spectrometry is
appropriate for analysing peptides as it utilises a 'soft' ionisation technique suitable
for thermo-labile high molecular weight compounds.
3.1.6. Gene expression microarray
Further validation of our model, and insight into the effects of EPEC infection was
gained by studying gene expression in host cells. Gene expression may be analysed
by reference to cellular mRNA levels (indicating the level of gene transcription),
microarray analysis is a recently developed technique that utilises this approach.
Microarray analysis is achieved by exposing a fixed array of probe DNA nucleotides
(corresponding to regions of all human genes) to tagged, amplified cDNA
transcribed from mRNA isolated from the sample. Hybridisation of transcribed
cDNA nucleotides to the array probes identifies the genes being expressed and the
amount of corresponding mRNA. Comparison ofmRNA levels between control and




3.2.1. HT29 cells were co-cultured with wild-type EPEC for 12 hours and
survived post infection
The initial objective was to control bacterial growth in order to extend the co-culture
period and hence analyse the longer-term molecular effects of EPEC infection on
host cells. By washing cells three times every 3 hours to remove non-adherent
bacteria, and adding fresh media it was possible to maintain co-culture conditions for
12 hours. Detachment of HT29 cells was observed, particularly after 12 hours co-
culture and subsequent washing with PBS, however, a significant proportion of cells
remained attached (Figure 3.1a). Post-infection antibiotic treatment ofHT29 cells co-
cultured with wild-type EPEC for 12 hours allowed them to recover and survive long
term (Figure 3.1b).
It was notable that during the recovery period, cells temporarily continued to lose
adherence from the culture flask. Hence, although most cells were still adherent
after 12 hours infection, only -50% of cells were still adherent after 84 hours
treatment with antibiotics. It was also evident that subsequent to infection, cell
division was inhibited, with cells not dividing until 60 hours post antibiotic
treatment. Due to this effect, nine days of recovery were needed before cells
returned to pre-infection confluency (-95%). These observations are likely to reflect
the time taken to remove all of the bacteria from culture and for any inhibitory
cellular changes within host cells to be reversed.
3.2.2. Co-culture with EPEC induced actin rearrangement in HT29 cells
Fluorescein isothiocyanate (fitc) labelled phalloidin was used to perform the
fluorescent actin staining (FAS) test (Knutton et. al., 1989) on HT29 cells co-
cultured with wild-type EPEC (Figure 3.2). Images show the change in actin
distribution brought about by intimate attachment of EPEC to the host cells. That is,
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Figure 3.2. Fluorescent actin staining (FAS) test. HT29 cells were either uninfected (-) or
co-cultured with wild-type EPEC for 12 hours (+ wt EPEC). Cells were stained with fitc
conjugated phalloidin for F-actin (green) and immunostained for E. coli (red), nuclei were
counter stained with DAPI (blue). Focal plane in infected cells moves from basal to apical
planes (a). Different focal planes (i) & (ii) are required to observe actin and EPEC co-
localisation (b). Original Magnification x 100.
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3.2.3. Co-culture with EPEC for 12 hours caused up and down-regulation of
HT29 cell proteins
Whole cell protein extracts of HT29 cells that were uninfected or co-cultured with
wild-type EPEC for 12 hours were subjected to ID gel electrophoresis followed by
coumassie staining. A number of crude changes in protein band pattern after 12
hours co-culture were observed (Figure 3.3a). Changes included the apparent up-
and downregulation of protein bands, in addition to bands showing relatively
constant expression. The protein content of selected bands was analysed via mass
spectrometry (Figure 3.3b).
Proteins belonging to a wide range of functional categories, including actin-binding,
cytoskeletal, metabolic, cell-cell adhesion, DNA repair, signal transduction and
protein synthesis were identified. A number of proteins that were identified in
uninfected E1T29 cells were not detected in matched bands from cells co-cultured
with EPEC, suggesting that EPEC infection caused their downregulation (Table 3.2).
Conversely, a range of proteins that were not detected in uninfected cells, were
identified in matched bands from EPEC infected cells. Elence the expression of these
proteins was potentially upregulated by EPEC infection (Table 3.3). Several proteins
were also identified in matched bands taken from infected and uninfected cells,
suggesting that the expression of these proteins remained relatively constant during
infection (Table 3.4). Proteins identified from a number of bands that showed high
expression in EPEC infected cells contained E. coli proteins (Table 3.5).
These results suggest that after 12 hours, EPEC continues to have differential effects
on expression of host cell proteins with a wide range of functions. These results also
demonstrate that the proteomic consequences of EPEC infection are complex, with
proteins belonging to the same functional category (e.g. actin binding) showing
upregulated, downregulated or unchanged expression simultaneously.
71
Figure 3.3. Effect of EPEC on protein expression in HT29 cells. Cells were either
uninfected (-) or co-cultured with wild-type (E2348/69) EPEC for 12 h. Whole cell protein
extracts were obtained by lysis with RIPA buffer and resolved through pre-cast 4-12%
gradient Novex NuPAGE gels. Protein was stained non-specifically with coumassie blue
stain (a,b). Bands enclosed with boxes (b) were subjected to mass spectrometry (see
Tables 3.2 - 3.5). Protein bands were cut from gels, digested with trypsin and subjected to
MALDI-TOF mass spectrometry. Protein matches were identified via the MS-Fit SwissProt.
database (http://prospector.ucsf.edU/prospector/4.0.8/html/msfit.htm). Information on protein










Protein function / processes
F
Heat shock protein HSP 90-
beta (& alpha)
P08238 2.33e+16 26%





P46940 6.15e+15 23% Regulation of cell morphology & motility
A Spectrin alpha chain, brain (&
beta chain, brainl)
Q13813 5.54e+10 22%
Actin cross-linking molecular scaffold
protein
E Mitogen-activated protein
kinase kinase kinase 4
Q9Y6R4 1.03e+6 11% Environmental stress response
E NEDD4-binding protein 2 /
BCL-3 binding protein
Q86UW6 9.70e+5 9%
Possible role in transcription coupled DNA








P23381 3.87e+5 7% Catalyses aminoacetylation of tRNA,
negative regulation of proliferation
H Calnexin precursor P27824 3.60e+5 8%






Binds to BRCA1 aiding its tumour
suppression properties
Table 3.2. Proteins potentially downregulated by EPEC infection. Proteins identified by
mass spectrometry in protein bands from uninfected HT29 cells, but not in matched protein
bands from HT29 cells infected with wild-type EPEC. Accession number refers to Entrez
Gene database (http://www.ncbi.nlm.nih.qov/sites/entrez?db=qene). Molecular weight
search (MOWSE) score gives an indication of the validity of the protein match, the higher the
score, the greater the probability of a correct match. The percentage of 'masses matched'
represents the number of peptide masses in a sample that match peptide masses for a








Protein function / processes
I Heat shock 70kDa protein 5 P11021 4.67e+9 13% Folding and assembly of proteins, proteintransport monitoring
C
Zinc finger protein 106
homolog
Q9H2Y7 7.04e+6 11% Metal ion and nucleic acid binding
C Myosin IIIA Q8NEV4 2.69e+6 11%




containing family G member 1















domain & WD repeat
containing protein 1
Q96BP3 3.12e+5 10%











protein / p53-induced protein
10
014682 1.02e+5 8%
A p53 induced protein (PIG), binds protein &
actin
Table 3.3. Proteins potentially upregulated by EPEC infection. Proteins identified by mass
spectrometry in protein bands from HT29 cells infected with wild-type EPEC, but not in matched
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Table 3.4. Proteins whose expression is potentially unchanged by EPEC infection.
Proteins identified by mass spectrometry in both protein bands from HT29 cells infected with
wild-type EPEC, and in matched protein bands from uninfected HT29 cells (top row MOWSE








Protein function / processes
N Elongation factor Tu P0A6N1 2.86e+9 13% Translation, response to osmotic stress
N Enolase P0A6P9 1.76e+8 10%
Anaerobic respiration; gluconeogenesis,
glycolysis
G E. coli elongation factor P0A6M8 2.11e+13 22%
Translation, ribosomal structure &
biogenesis
0 GAPDH-A P0A9B2 1.02e+5 10% Pyridoxine biosynthetic process,
gluconeogenesis, glycolysis
Table 3.5. E. coli proteins identified in protein bands from HT29 ceils co-cultured with
EPEC. Proteins identified by mass spectrometry in protein bands from HT29 cells infected
with wild-type EPEC, but not in matched protein bands from uninfected HT29 cells.
74
3.2.4. EPEC strains show different adherence patterns on HT29 cells
Immunofluorescent staining of EPEC revealed the crude pattern of wild-type and
mutant EPEC adherence after 9 and 12 hours co-culture with HT29 cells (Figure
3.4). Wild-type EPEC shows widespread distribution after 9 hours co-culture, co-
localising with virtually all cells. By 12 hours, wild-type EPEC had extensively
colonised the surface of the HT29 cell monolayer. In contrast, after 9 hours, the
mutant EPEC is distributed in small, discrete colonies. After 12 hours the colonies
of mutant EPEC show increased size, however their distribution remains limited to
discrete patches, covering no more than 1-4 cells.
These observations demonstrate the inability of the mutant EPEC to attach and
colonise the host cells in the same way as the wild-type bacteria. This difference in
adhesion is due to the absence of espB, the gene encoding EPEC secreted protein B
(EspB), essential for the formation of the TTSS. These results indicate that without
the TTSS this strain is only able to adhere to HT29 cells in a "localised adherence"
pattern only. EspB expression and hence a functional TTSS allows widespread
colonisation over a cell monolayer. For this reason UMD864 represents a good
negative biological control for wild-type EPEC infection. Hence, differences in
biological effects caused by mutant and wild-type EPEC infection represent changes
brought about consequent to the insertion of EPEC secreted proteins and intimin
signalling pathways.
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3.2.5. Co-culture with EPEC caused changes in gene expression in HT29 cells
Microarray analysis was performed on total mRNA extracts from HT29 cells that
were either: uninfected and untreated (-Oh), uninfected but washed in the same way
as infected cells (-12h), infected with mutant EPEC for 9 hours (+mut 9h) or 12
hours (+mut 12h), or infected with wild-type EPEC for 9 hours (+wt 9h) or 12 hours
(+wt 12h). Gene expression profiles from each condition were compared to the
baseline condition (-12h) also; mutant and wild-type infected cells were compared
directly (+mut 9h / +wt 9h and +mutl2h / +wt 12h).
Internal microarray quality control measures validated the microarray analysis
procedure (appendix). Differentially expressed genes were identified by comparing
gene expression using conventional T-test and significance analysis of microarray
(SAM) statistical tests (Figure 3.5). Tests were performed on raw data and on data
that been normalised by quantiles normalisation or variance stabilisation
normalisation (VSN). Choice of normalisation technique had a marked effect on the
number of genes that were reported as up or downregulated after EPEC infection.
VSN normalised data more closely resembled the raw data, where approximately 4-5
times as many genes were downregulated compared to those upregulated after wild-
type EPEC infection. Quantiles normalised data showed that approximately equal
numbers of genes were up and downregulated after wild-type EPEC infection. In
either case, it is clear that these results support the ability of EPEC infection to have
differential effects on gene expression after 9-12 hours infection. That is, while the
expression of the vast majority of genes was not significantly changed by infection,
many genes were upregulated or downregulated.
The effects of wild-type EPEC on gene expression were clearly greater (both in
terms of up- and downregulated genes) than for mutant EPEC. This supports the role
of EPEC secreted effector molecules and intimin signalling in influencing host cells
gene expression and therefore host signalling pathways.
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■ > +2 fold-change Q >-2 fold-change
Figure 3.5. Quantification of differentia! gene expression in HT29 cells co-cultured
with EPEC, using different statistical tests and normalisation methods Data was either
compared via a conventional T-test (P<0.05, >2 fold change, difference in expression >100)
or significance analysis of microarray (SAM) test (false discovery rate = 0.1, > 2 fold
change). Raw data was normalised using Quantiles normalisation or VSN (Variance
stabilisation normalisation) methods. Data includes characterised and uncharacterised
genes.
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Figure 3.6. 'Volcano' scatter plots of gene expression in HT29 cells co-cultured with
EPEC, using Quantiles normalisation and T-test. Genes above the horizontal red line
have -Log10 P-value of > 1.3 (i.e. P-value < 0.05), genes to the left and right of
corresponding vertical red lines have Log2 Fold-change (ratio) values > + 1 respectively (i.e.
fold-change > +2). Data includes characterised genes only, i.e. 25,503 gene probes. P-
values below 0.0005 were rounded to 0.0005.
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Figure 3.7. 'Volcano' scatter plots of gene expression in HT29 cells after co-culture
with EPEC, using VSN normalisation and T-test. Genes above the horizontal red line
have -Log10 P-value of > 1.3 (i.e. P-value < 0.05), genes to the left and right of
corresponding vertical red lines have Log2 Fold-change (ratio) values > +1 respectively (i.e.
fold-change > +2 ). Data includes characterised genes only, i.e. 25,503 gene probes.
P-values below 0.0005 were rounded to 0.0005.
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Volcano plots give an indication of the effect of EPEC infection on global gene
expression in HT29 cells (Figures 3.6 and 3.7). Although it is clear that the
expression of hundreds of genes is potentially altered subsequent to EPEC infection,
it is also clear from these plots that expression of the overwhelming majority of
genes was not significantly changed. It can be seen that the expression of a small
number of genes was altered by the washing procedure (-Oh / -12h), supporting the
use of the uninfected, washed cells (- 12h) as the baseline for differential expression
analysis. It is also notable that when the mutant and wild-type EPEC infected cells
are compared directly (e.g. +mut 12h / +wt 12h) there are differences in gene
expression, demonstrating that effects of EPEC on the host cell can be intimate
attachment specific.
Further analysis of the lists of differentially expressed genes was achieved by using
bioinformatics database searches, based on enrichment of gene ontology terms. The
results of these searches reveal a vast array of host pathways affected by both wild-
type and mutant EPEC infection (Tables 3.6 and 3.7). Many pathways identified in
the literature as being targets for EPEC induced effects (e.g. cell cycle, apoptosis,
NF-kB, inflammation) were identified. Pathways involving proteins identified by
mass spectrometry (section 3.2.3) in this study (e.g. MAP kinase, Ras, BRCA1) also
showed altered gene expression. More detailed functional annotation clustering
searches (see appendix) show more specific pathways influenced by EPEC infection.
These include pro-and anti-apoptotic pathways and DNA metabolism, processing
and repair.
Analysis of the effect of EPEC infection on individual mismatch repair genes (mutS
and mutL homologues) identified specific changes due to EPEC infection (Tables 3.8
& 3.9). It was noticeable that wild-type EPEC consistently caused a 2-3.9 fold
reduction in MSH2, MLH1 and MSH6 (the three MMR genes most commonly
implicated in colorectal cancer development) gene expression. Although mutant
EPEC also caused a general downregulation in the expression of these genes, the
changes were lower and were not reported at all by the SAM test. Conversely, the
expression of MSH3, MSH4, MSFI5 and MLH3 was not significantly altered by
81
EPEC infection. The expression of the genes encoding the Wnt signalling and cell-
cell adhesion proteins (3- and y-catenin show a similar pattern to MSH2, MLH1 and
MSH6 (Tables 3.10 and 3.11). That is, wild-type EPEC infection induced a 2-3 fold
reduction in the expression of these genes. Whereas, the genes encoding the
functionally related molecules E-cadherin, a-catenin and ezrin remained relatively
constant despite EPEC infection.
-Oh / -12h
Database Pathway Count % P value
BIOCARTA -
KEGG ARGININE AND PROLINE METABOLISM 3 5.3 2.70E-02
+mut 9h / -12h
Database Pathway Count % P value
BIOCARTA CD40L Signaling Pathway 3 1.4 2.70E-02
BIOCARTA TNFR2 Signaling Pathway 3 1.4 3.80E-02
BIOCARTA p53 Signaling Pathway 3 1.4 3.80E-02
BIOCARTA Influence of Ras and Rho proteins on G1 to S Transition 3 1.4 7.40E-02
BIOCARTA NFkB activation by Nontypeable Hemophilus influenzae 3 1.4 7.40E-02
KEGG CELL CYCLE 11 5 2.30E-05
KEGG LIMONENE AND PINENE DEGRADATION 4 1.8 1.80E-02
KEGG ETHYLBENZENE DEGRADATION 3 1.4 3.90E-02
KEGG HISTIDINE METABOLISM 4 1.8 6.30E-02
KEGG BUTANOATE METABOLISM 4 1.8 7.20E-02
KEGG 1- AND 2-METHYLNAPHTHALENE DEGRADATION 3 1.4 7.60E-02
KEGG VALINE, LEUCINE AND ISOLEUCINE DEGRADATION 4 1.8 7.90E-02
KEGG TYROSINE METABOLISM 4 1.8 8.90E-02
KEGG GLYCOLYSIS / GLUCONEOGENESIS 4 1.8 9.90E-02
+mut 12h / -12h
Database Pathway Count % P value
BIOCARTA Cadmium induces DNA synthesis and proliferation in macrophages 3 0.8 7.70E-02
BIOCARTA p53 Signaling Pathway 3 0.8 8.60E-02
BIOCARTA METS affect on Macrophage Differentiation 3 0.8 8.60E-02
BIOCARTA Hypoxia-Inducible Factor in the Cardiovascular System 3 0.8 9.40E-02
KEGG GLYCOLYSIS / GLUCONEOGENESIS 6 1.7 2.30E-02
KEGG CELL CYCLE 8 2.2 2.70E-02
KEGG B CELL RECEPTOR SIGNALING PATHWAY 6 1.7 3.30E-02
KEGG CYTOKINE-CYTOKINE RECEPTOR INTERACTION 13 3.7 3.30E-02
KEGG ADIPOCYTOKINE SIGNALING PATHWAY 6 1.7 3.70E-02
KEGG LIMONENE AND PINENE DEGRADATION 4 1.1 5.00E-02
KEGG DITERPENOID BIOSYNTHESIS 2 0.6 7.60E-02
KEGG ETHYLBENZENE DEGRADATION 3 0.8 7.90E-02
+wt9h/-12h
Database Pathway Count % P value
BIOCARTA CDK Regulation of DNA Replication 4 0.4 3.80E-03
BIOCARTA Cell Cycle 5 0.5 4.30E-02
BIOCARTA ATM Signaling Pathway 4 0.4 5.40E-02
BIOCARTA Oxidative Stress Induced Gene Expression Via Nrf2 4 0.4 6.80E-02
KEGG CELL CYCLE 25 2.5 1.50E-08
KEGG PYRIMIDINE METABOLISM 19 1.9 8.00E-06
KEGG GLYCOLYSIS / GLUCONEOGENESIS 11 1.1 3.00E-03
KEGG HISTIDINE METABOLISM 9 0.9 9.40E-03
KEGG RNA POLYMERASE 6 0.6 2.10E-02
KEGG PURINE METABOLISM 17 1.7 2.30E-02
KEGG ARGININE AND PROLINE METABOLISM 8 0.8 4.50E-02
KEGG FRUCTOSE AND MANNOSE METABOLISM 7 0.7 4.80E-02
KEGG SELENOAMINO ACID METABOLISM 6 0.6 4.90E-02
KEGG NITROBENZENE DEGRADATION 4 0.4 6.20E-02





Pathway Count % P value
BIOCARTA Cyclins and Cell Cycle Regulation 9 0.5 1.50E-03
BIOCARTA Cell Cycle 9 0.5 6.50E-03
BIOCARTA Oxidative Stress Induced Gene Expression Via Nrf2 7 0.4 1.40E-02
BIOCARTA Hypoxia and p53 in the Cardiovascular system 7 0.4 3.10E-02
BIOCARTA Regulation of p27 Phosphorylation during Cell Cycle Progression 5 0.3 3.70E-02
BIOCARTA Spliceosomal Assembly 5 0.3 5.80E-02
BIOCARTA Role of Mitochondria in Apoptotic Signaling 6 0.3 6.00E-02
BIOCARTA BTG family proteins and cell cycle regulation 4 0.2 6.10E-02
BIOCARTA AKAP95 role in mitosis and chromosome dynamics 4 0.2 6.10E-02
BIOCARTA Apoptotic Signaling in Response to DNA Damage 6 0.3 7.00E-02
BIOCARTA Cell Cycle 6 0.3 7.00E-02
BIOCARTA Activation of Src by Protein-tyrosine phosphatase alpha 4 0.2 7.90E-02
BIOCARTA p53 Signaling Pathway 5 0.3 8.40E-02
KEGG CELL CYCLE 40 2 6.50E-12
KEGG PYRIMIDINE METABOLISM 27 1.4 6.30E-06
KEGG GLYCOLYSIS / GLUCONEOGENESIS 19 1 6.90E-05
KEGG FRUCTOSE AND MANNOSE METABOLISM 13 0.7 2.70E-03
KEGG SELENOAMINO ACID METABOLISM 11 0.6 2.90E-03
KEGG PURINE METABOLISM 30 1.5 3.30E-03
KEGG NITROBENZENE DEGRADATION 7 0.4 4.70E-03
KEGG AMINOPHOSPHONATE METABOLISM 8 0.4 4.80E-03
KEGG RNA POLYMERASE 9 0.5 7.50E-03
KEGG HISTIDINE METABOLISM 13 0.7 7.70E-03
KEGG PYRUVATE METABOLISM 11 0.6 1.60E-02
KEGG ONE CARBON POOL BY FOLATE 6 0.3 2.30E-02
KEGG GLYCOSYLPHOSPHATIDYLINOSITOL(GPI)-ANCHOR BIOSYNTHESIS 7 0.4 2.50E-02
KEGG OXIDATIVE PHOSPHORYLATION 24 1.2 2.60E-02
KEGG GLYCEROPHOSPHOLIPID METABOLISM 14 0.7 7.70E-02
KEGG ARGININE AND PROLINE METABOLISM 11 0.6 8.00E-02




+wt 9h / +mut 9h
Count % P value
IL 17 Signaling Pathway
NITROBENZENE DEGRADATION
■
+wt 12h / +mut 12h
database Pathway
BIOCARTA Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)
BIOCARTA Role of Mitochondria in Apoptotic Signaling
BIOCARTA Hypoxia and p53 in the Cardiovascular system
BIOCARTA p53 Signaling Pathway
BIOCARTA Chaperones modulate interferon Signaling Pathway
BIOCARTA Cell Cycle
BIOCARTA Regulation of BAD phosphorylation
BIOCARTA ATM Signaling Pathway




KEGG GLYCOLYSIS / GLUCONEOGENESIS
KEGG APOPTOSIS
KEGG GLYCOSPHINGOLIPID METABOLISM
KEGG AMYOTROPHIC LATERAL SCLEROSIS (ALS)







































(Table 3.6 part 2)
Table 3.6. Gene ontology: Pathways with altered gene expression in HT29 cells co-
cultured with EPEC, using VSN normalisation and T-test. Genes with fold-change > +2
(with P<0.05) subjected to functional annotation pathway enrichment search via DAVID
functional annotation tool (http://david.abcc.ncifcrf.gov/tools.isp). Results of both BIOCARTA
and KEGG functional pathway databases included. 'Count' signifies the number of
differentially expressed genes found in the pathway, and as a percentage (%) of the total
number of differentially expressed genes. P_value = modified Fisher Exact P-value for gene








Database Pathway Count % P value
BIOCARTA Adhesion and Diapedesis of Granulocytes 3 5.2 4.60E-03
BIOCARTA Cells and Molecules involved in local acute inflammatory response 3 5.2 4.60E-03
BIOCARTA Cytokines and Inflammatory Response 3 5.2 9.90E-03
BIOCARTA SODD/TNFR1 Signaling Pathway 2 3.4 6.00E-02
BIOCARTA Free Radical Induced Apoptosis 2 3.4 6.60E-02
BIOCARTA Adhesion and Diapedesis of Lymphocytes 2 3.4 8.20E-02
BIOCARTA Regulation of hematopoiesis by cytokines 2 3.4 8.20E-02
KEGG CYTOKINE-CYTOKINE RECEPTOR INTERACTION 7 12 1.70E-03
KEGG ADIPOCYTOKINE SIGNALING PATHWAY 3 5.2 5.40E-02
KEGG MAPK SIGNALING PATHWAY 5 8.6 5.50E-02
KEGG APOPTOSIS 3 5.2 8.60E-02
KEGG TOLL-LIKE RECEPTOR SIGNALING PATHWAY 3 5.2 9.10E-02
KEGG T CELL RECEPTOR SIGNALING PATHWAY 3 5.2 9.30E-02
tmut 12h / -12h
Database Pathway Count % P_value
BIOCARTA NFkB activation by Nontypeable Hemophilus influenzae 4 5.6 1.50E-03
BIOCARTA CD40L Signaling Pathway 3 4.2 8.00E-03
BIOCARTA Cadmium induces DNA synthesis and proliferation in macrophages 3 4.2 1.00E-02
BIOCARTA TNFR2 Signaling Pathway 3 4.2 1.20E-02
BIOCARTA Cells and Molecules involved in local acute inflammatory response 3 4.2 1.30E-02
BIOCARTA Adhesion and Diapedesis of Granulocytes 3 4.2 1.30E-02
BIOCARTA NF-kB Signaling Pathway 3 4.2 2.00E-02
BIOCARTA Cytokines and Inflammatory Response 3 4.2 2.70E-02
BIOCARTA Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) 3 4.2 8.60E-02
BIOCARTA Erythropoietin mediated neuroprotection through NF-kB 2 2.8 9.90E-02
BIOCARTA SODD/TNFR1 Signaling Pathway 2 2.8 9.90E-02
KEGG EPITHELIAL CELL SIGNALING IN HELICOBACTER PYLORI INFECTION 4 5.6 3.50E-03
KEGG TOLL-LIKE RECEPTOR SIGNALING PATHWAY 5 6.9 3.60E-03
KEGG T CELL RECEPTOR SIGNALING PATHWAY 5 6.9 3.80E-03
KEGG CYTOKINE-CYTOKINE RECEPTOR INTERACTION 7 9.7 6.30E-03
KEGG MAPK SIGNALING PATHWAY 7 9.7 9.20E-03
KEGG ADIPOCYTOKINE SIGNALING PATHWAY 4 5.6 1.20E-02
KEGG APOPTOSIS 4 5.6 2.40E-02
KEGG B CELL RECEPTOR SIGNALING PATHWAY 3 4.2 7.90E-02
+wt9h/-12h
Database Pathway Count % P value
BIOCARTA CDK Regulation of DNA Replication 4 0.3 6.90E-03
BIOCARTA Cyclins and Cell Cycle Regulation 5 0.4 4.20E-02
BIOCARTA Role of BRCA1 5 0.4 5.30E-02
BIOCARTA Cell Cycle 5 0.4 8.10E-02
BIOCARTA ATM Signaling Pathway 4 0.3 8.80E-02
KEGG CELL CYCLE 25 2 1.00E-07
KEGG PYRIMIDINE METABOLISM 23 1.8 1.10E-07
KEGG HISTIDINE METABOLISM 11 0.9 1.40E-03
KEGG RNA POLYMERASE 8 0.6 1.50E-03
KEGG FRUCTOSE AND MANNOSE METABOLISM 10 0.8 2.10E-03
KEGG NITROBENZENE DEGRADATION 6 0.5 2.50E-03
KEGG PURINE METABOLISM 21 1.7 2.90E-03
KEGG SELENOAMINO ACID METABOLISM 8 0.6 5.80E-03
KEGG AMINOPHOSPHONATE METABOLISM 6 0.5 9.10E-03
KEGG GLYCOLYSIS / GLUCONEOGENESIS 10 0.8 1.80E-02
KEGG ANDROGEN AND ESTROGEN METABOLISM 9 0.7 2.00E-02
KEGG TYROSINE METABOLISM 9 0.7 3.60E-02
KEGG ARGININE AND PROLINE METABOLISM 8 0.6 7.00E-02
KEGG DNA POLYMERASE 5 0.4 7.20E-02
(Table 3.7 part 1)
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+wt 12h/-12h
Database Pathway Count % P_value
BIOCARTA Role of BRCA1 11 0.4 1.10E-03
BIOCARTA Role of Mitochondria in Apoptotic Signaling 10 0.4 1.20E-03
BIOCARTA Cyclins and Cell Cycle Regulation 9 0.3 9.50E-03
BIOCARTA Spliceosomal Assembly 7 0.3 1.10E-02
BIOCARTA Cell Cycle 10 0.4 1.20E-02
BIOCARTA Regulation of p27 Phosphorylation during Cell Cycle Progression 6 0.2 2.40E-02
BIOCARTA Induction of apoptosis through DR3 and DR4/5 Death Receptors 9 0.3 3.50E-02
BIOCARTA Role of Erk5 in Neuronal Survival 6 0.2 5.50E-02
BIOCARTA Calcium Signaling by HBx of Hepatitis B virus 5 0.2 5.60E-02
BIOCARTA p53 Signaling Pathway 6 0.2 6.80E-02
BIOCARTA Trka Receptor Signaling Pathway 6 0.2 6.80E-02
BIOCARTA CDK Regulation of DNA Replication 4 0.1 7.00E-02
BIOCARTA EPO Signaling Pathway 7 0.3 7.50E-02
BIOCARTA RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage 5 0.2 9.20E-02
BIOCARTA IL-2 Receptor Beta Chain in T cell Activation 10 0.4 9.80E-02
KEGG CELL CYCLE 42 1.5 2.00E-09
KEGG PYRIMIDINE METABOLISM 33 1.2 1.50E-06
KEGG SELENOAMINO ACID METABOLISM 16 0.6 3.10E-05
KEGG NITROBENZENE DEGRADATION 10 0.4 9.50E-05
KEGG HISTIDINE METABOLISM 19 0.7 1.50E-04
KEGG AMINOPHOSPHONATE METABOLISM 11 0.4 2.40E-04
KEGG ANDROGEN AND ESTROGEN METABOLISM 19 0.7 2.60E-04
KEGG RNA POLYMERASE 12 0.4 8.90E-04
KEGG FRUCTOSE AND MANNOSE METABOLISM 16 0.6 1.10E-03
KEGG OXIDATIVE PHOSPHORYLATION 34 1.2 1.80E-03
KEGG GLYCOLYSIS / GLUCONEOGENESIS 19 0.7 2.00E-03
KEGG PURINE METABOLISM 36 1.3 4.90E-03
KEGG TYROSINE METABOLISM 17 0.6 7.40E-03
KEGG GLYCEROPHOSPHOLIPID METABOLISM 20 0.7 1.20E-02
KEGG ONE CARBON POOL BY FOLATE 7 0.3 1.80E-02
KEGG APOPTOSIS 21 0.8 3.30E-02
KEGG SULFUR METABOLISM 6 0.2 3.70E-02
KEGG PYRUVATE METABOLISM 12 0.4 3.80E-02
KEGG GLYCOSPHINGOLIPID METABOLISM 12 0.4 3.80E-02
KEGG VALINE, LEUCINE AND ISOLEUCINE DEGRADATION 14 0.5 5.10E-02
KEGG DNA POLYMERASE 8 0.3 5.20E-02
KEGG LYSINE DEGRADATION 15 0.5 5.30E-02
KEGG METHIONINE METABOLISM 6 0.2 6.30E-02
KEGG TRYPTOPHAN METABOLISM 19 0.7 7.00E-02
KEGG LIMONENE AND PINENE DEGRADATION 9 0.3 7.20E-02
KEGG BUTANOATE METABOLISM 13 0.5 7.80E-02
KEGG GLYCOSYLPHOSPHATIDYLINOSITOL(GPI)-ANCHOR BIOSYNTHESIS 7 0.3 7.90E-02
KEGG GALACTOSE METABOLISM 9 0.3 8.30E-02
KEGG ALKALOID BIOSYNTHESIS II 7 0.3 9.40E-02
KEGG ETHYLBENZENE DEGRADATION 6 0.2 9.80E-02
+wt 9h 1 *mut 9h
Database Pathway Count % P value
BIOCARTA -
KEGG
(Table 3.7 part 2)
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+wt 12h / +mut 12h
Database Pathway Count % P_value
BIOCARTA Trefoil Factors Initiate Mucosal Healing 8 0.4 1.20E-02
BIOCARTA Role of Erk5 in Neuronal Survival 6 0.3 2.30E-02
BIOCARTA Role of Mitochondria in Apoptotic Signaling 7 0.4 2.30E-02
BIOCARTA PTEN dependent cell cycle arrest and apoptosis 7 0.4 2.80E-02
BIOCARTA Cell Cycle 8 0.4 3.10E-02
BIOCARTA Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha) 11 0.6 3.60E-02
BIOCARTA NFkB activation by Nontypeable Hemophilus influenzae 7 0.4 4.10E-02
BIOCARTA Influence of Ras and Rho proteins on G1 to S Transition 7 0.4 4.10E-02
BIOCARTA EGF Signaling Pathway 8 0.4 4.30E-02
BIOCARTA Integrin Signaling Pathway 9 0.5 4.30E-02
BIOCARTA Regulation of BAD phosphorylation 6 0.3 4.40E-02
BIOCARTA Regulation of p27 Phosphorylation during Cell Cycle Progression 5 0.3 4.50E-02
BIOCARTA Human Cytomegalovirus and Map Kinase Pathways 5 0.3 4.50E-02
BIOCARTA Agrin in Postsynaptic Differentiation 8 0.4 4.90E-02
BIOCARTA Acetylation and Deacetylation of RelA in The Nucleus 5 0.3 5.70E-02
BIOCARTA Ceramide Signaling Pathway 6 0.3 6.40E-02
BIOCARTA Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phos. 6 0.3 6.40E-02
BIOCARTA p38 MAPK Signaling Pathway 8 0.4 6.40E-02
BIOCARTA IL-2 Receptor Beta Chain in T cell Activation 9 0.5 6.90E-02
BIOCARTA BTG family proteins and cell cycle regulation 4 0.2 7.20E-02
BIOCARTA Transcription factor CREB and its extracellular signals 6 0.3 7.50E-02
BIOCARTA Apoptotic Signaling in Response to DNA Damage 6 0.3 8.70E-02
BIOCARTA NF-kB Signaling Pathway 6 0.3 8.70E-02
BIOCARTA SODD/TNFR1 Signaling Pathway 4 0.2 9.20E-02
BIOCARTA E2F1 Destruction Pathway 4 0.2 9.20E-02
KEGG APOPTOSIS 22 1.1 8.20E-04
KEGG NITROBENZENE DEGRADATION 7 0.4 5.10E-03
KEGG AMINOPHOSPHONATE METABOLISM 8 0.4 5.30E-03
KEGG GLYCOSPHINGOLIPID METABOLISM 12 0.6 6.30E-03
KEGG PYRIMIDINE METABOLISM 20 1 7.70E-03
KEGG SELENOAMINO ACID METABOLISM 10 0.5 1.10E-02
KEGG ANDROGEN AND ESTROGEN METABOLISM 13 0.7 1.20E-02
KEGG PURINE METABOLISM 28 1.4 1.40E-02
KEGG GLYCOLYSIS / GLUCONEOGENESIS 14 0.7 1.70E-02
KEGG CELL CYCLE 21 1.1 1.90E-02
KEGG SULFUR METABOLISM 5 0.3 5.80E-02
KEGG GLYCEROLIPID METABOLISM 11 0.6 7.20E-02
KEGG GLYCOSYLPHOSPHATIDYLINOSITOL(GPI)-ANCHOR BIOSYNTHESIS 6 0.3 8.40E-02
KEGG OXIDATIVE PHOSPHORYLATION 22 1.1 8.50E-02
(Table 3.7 part 3)
Table 3.7. Gene ontology: Pathways with altered gene expression in HT29 cells
infected with EPEC, using VSN normalisation and SAM analysis. Genes with statistically
significant fold-change (false discovery rate 0.1, P<0.05) were subjected to functional
annotation pathway enrichment search via DAVID functional annotation tool
(http://david.abcc.ncifcrf.gov/tools.isp). Results of both BIOCARTA and KEGG functional
pathway databases included. The number of differentially expressed genes found in the
pathway is displayed under 'Count', and as a percentage (%) of the total number of
differentially expressed genes. P_value = modified Fisher Exact P-value for gene enrichment





MSH2 MSH3 MSH4 MSH5 MSH6 MLH1 MLH3
-Oh / -12h 1.06 1.06 -1.47 -1.20 -1.12 -1.13 -1.23
+mut 9h /-12h -2.22 -1.02 -1.05 1.01 -1.88 -1.82 -1.06
+mut 12h / -12h -1.94 1.04 -1.08 -1.02 -1.72 -1.76 -1.18
+wt 9h / -12h -3.05 -1.11 -1.26 1.21 -2.74 -2.59 -1.51
+wt 12h / -12h -3.90 -1.29 -1.16 1.12 -2.56 -3.02 -1.56
+wt 9h / +mut 9h -1.37 -1.09 -1.20 1.21 -1.46 -1.42 -1.42
+wt 12h / +mut 12h -2.02 -1.35 -1.07 1.14 -1.49 -1.72 -1.32
Table 3.8. Mismatch repair gene expression in HT29 cells co-cultured with EPEC,
using VSN normalisation and T-test. Table shows fold-change values calculated with
T-test, numbers in bold have fold-change > 2, with P<0.05.
Expression
comparison
MSH2 MSH3 MSH4 MSH5 MSH6 MLH1 MLH3
-Oh / -12h X X X X X X X
+mut 9h /-12h X X X X X X X
+mut 12h / -12h X X X X X X X
+wt 9h / -12h -3.05 X X X -2.74 -2.59 X
+wt 12h / -12h -3.90 X X X -2.56 -3.02 X
+wt 9h / +mut 9h X X X X X X X
+wt 12h / +mut 12h -2.02 X X X X X X
Table 3.9. Mismatch repair gene expression in HT29 cells co-cultured with EPEC,
using VSN normalisation and SAM. Table shows fold-change values calculated with
significance analysis of microarray (SAM; false discovery rate 0.1), numbers in bold have




a-catenin y-catenin E-cadherin Ezrin
-Oh / -12h -1.10 -1.02 -1.30 1.15 -1.32
+mut 9h /-12h -1.14 1.16 1.46 1.24 1.23
+mut 12h / -12h -1.31 1.21 1.43 1.27 1.24
+wt 9h / -12h -1.37 1.12 1.74 1.23 1.36
+wt 12h / -12h -2.55 1.11 1.55 1.04 1.37
+wt 9h / +mut 9h -1.27 -1.03 1.19 -1.01 1.10
+wt 12h / +mut 12h -2.47 -1.09 1.08 -1.22 1.11
Table 3.10. Cell-cell adhesion gene expression in HT29 cells co-cultured with EPEC,
using VSN normalisation and T-test. Table shows fold-change values calculated with
T-test, numbers in bold have fold-change > 2, with P<0.05.
Expression
comparison |3-catenin
a-catenin y-catenin E-cadherin Ezrin
-Oh / -12h X X X X X
+mut 9h / -12h X X X X X
+mut 12h / -12h X X X X X
+wt 9h / -12h X X X X X
+wt 12h / -12h -2.55 X -1.93 X X
+wt 9h / +mut 9h X X X X X
+wt 12h / +mut 12h -2.47 X -3.04 X X
Table 3.11. Cell-cell adhesion gene expression in HT29 cells co-cultured with EPEC,
using VSN normalisation and SAM. Table shows fold-change values calculated with
significance analysis of microarray (SAM; false discovery rate 0.1), numbers in bold have
fold-change > 2, with P<0.05. x = no statistically significant fold-change.
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3.3. Discussion
Co-culture of wild-type EPEC with HT29 cells for 12 hours was made possible by
washing away excess bacteria at 3 hour intervals. This procedure evidently prevented
bacterial overgrowth (and hence toxicity) without preventing attachment to and
colonisation of the cultured cells, as demonstrated by the FAS test and
immunofluorescence staining of EPEC. Detachment of cells from the culture flask
was expected and this phenomenon was observed, particularly after 12 hours co-
culture. The literature suggests that this is a result of EPEC induced disruption of
focal adhesions, adherens junctions and tight junctions (Shifrin et. al., 2002;
McNamara et. al., 2001; Malladi et. al., 2004). Other reports suggest that cell death
could be responsible for detachment (Abul-Milh et. al., 2001; Melo et. al., 2005).
However, a significant percentage of cells remained adherent after 12 hours
infection, and many were able to survive long term. Hence, despite heavy infection,
many cells did not undergo apoptosis or necrosis.
It was notable that in the initial recovery period (i.e. within 60 hours of starting
antibiotic treatment) cells continued to detach from the culture flask, hence it is
likely that the residual effects of EPEC (and residual EPEC themselves) continued to
disrupt cell adherence. Interestingly, cell division was also disrupted during this
period; cell division did not occur at noticeable levels until at least 4 days after
infection. This is a significant inhibitory effect, as the normal population doubling
time of HT29 cells is approximately 24 hours. This result supports the finding that
EPEC secreted cyclomodulins (such as Cif) are able to cause cell cycle arrest
(Marches et. al., 2003). This work also demonstrates that this effect is reversible on
removal of infection.
Proteomic analysis of intestinal epithelial cells co-cultured with EPEC for 4 hours
has revealed differential effects on the expression of a wide range of host cell
proteins (Hardwidge et. al., 2004). It was hypothesised that 12 hours co-culture with
EPEC would not result in non-specific toxicity for host cells, and that differential
effects on host protein expression would continue to be seen after 12 hours infection.
89
Electrophoresis demonstrated that EPEC infection had a clear influence on global
protein expression in HT29 cells. The effect of EPEC on protein expression were
differential i.e. while the expression of some proteins was either upregulated or
suppressed, the expression of many others remained relatively constant. Mass
spectrometry provided a convenient means to identify some of the proteins revealed
by electrophoresis. Proteins within diverse functional groups were identified, and
proteins within the same functional groups (e.g. actin binding and protein-
processing) were subject to increased / reduced or unchanged expression
simultaneously. It should be noted that mass spectrometry does not provide
unequivocal protein identification. Hence, further analysis by amino acid sequencing
/ western blot / immunocytochemistry would be required to confirm the identity of
these proteins and their expression after EPEC infection. It would also be desirable to
compare protein changes induced by wild-type EPEC to those caused by UMD864.
UMD864 adhered to HT29 cells in a localised adherence pattern, demonstrating that
a functional TTSS is required not only for intimate attachment, but also for the
widespread epithelial cell colonisation characteristic of the wild-type EPEC.
Adherence of the UMD864 is likely to be the result of Bfp binding only; hence
washing removed the majority ofUMD864 but not the intimately attached E2348/69.
It was also observed that cells infected with UMD864 showed less detachment after
12 hours co-culture, and recovered post infection quicker than E2348/69 (not
shown). These observations suggest that the ability of E2348/69 to cause detachment
and slow cell division are TTSS and / or intimin signalling specific. Hence UMD864
represents a useful negative control that will help to distinguish between specific
effects (i.e. due to TTSS or intimin signalling), and non-specific effects (i.e. due to
contact with bacterial surface antigens, changes in media nutrient composition or pH)
caused by in vitro infection.
This study presents a genome-wide analysis of the effect of EPEC infection on host
cell gene expression, potentially the first study of this type performed with EPEC. As
with the proteomic analysis, gene expression analysis demonstrated differential
effects due to EPEC infection, i.e. up- and downregulated expression of some genes,
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while the expression of others was unaffected. Small changes in gene expression
profile were seen due to the experimental washing process, supporting the use of
uninfected, washed cells as an experimental control. Also, many changes in gene
expression were observed due to UMD864 infection, these effects are likely to be
due to contact with surface antigens including bfp, and the changes in the cell culture
environment due to infection. Direct comparison of gene expression in UMD864 and
E2348/69 infected cells revealed that the expression of many genes was influenced
differently by these types of EPEC, revealing that TTSS / intimin signalling
dependent effects occurred.
EPEC induced changes in gene expression within a number of functional pathways
were observed. Notable amongst these pathways were the cell cycle (which was
strongly represented), this observation potentially correlates with cell cycle effects
observed in this study and in the literature. In addition, both wild-type and mutant
EPEC infection influenced apoptotic pathways, notably, wild-type EPEC had effects
on both pro- and anti-apoptotic signalling pathways. These observations also
correlate well with the effects of EPEC on apoptosis reported by the literature and
discussed earlier in this report. Furthermore, pathway analysis also reflected novel
changes due to wild-type EPEC infection that corresponded to protein expression
results (from mass spectrometry analysis) e.g. effects on the BRCA1 pathway.
Of specific interest was the effect of wild-type EPEC infection on genes encoding
DNA MMR and Wnt signalling / cell-cell adhesion proteins. E2348/69 caused the
downregulation of MSH2, MSH6 and MLH1 genes, while the expression of other
mutS and mutL homologue genes remained relatively constant. E2348/69 also
induced the downregulation of (3- and y-catenin. These findings therefore suggest
that EPEC infection may influence the classic genetic pathways of colorectal cancer.
Although microarray analysis has provided many interesting results, it is
acknowledged that microarray techniques are not definitive in the quantification of
gene expression. These results therefore represent a preliminary study into the
transcriptomic effects of EPEC and identify many target genes that could be
investigated further. Confirmation and validation of gene expression results could be
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achieved with quantitative real-time PCR, the translation of transcriptomic effects
into protein expression could be analysed by western blot and immunocytochemistry.
Overall the objective of developing an extended time-course EPEC co-culture model
was achieved. The model was validated by a number of methods, which consistently
produced results in line with previously published data on the in vitro effects of
EPEC. This model therefore represents a reliable, repeatable and relevant model for
EPEC infection of the human colonic epithelium.
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Chapter 4.
Development and validation in vivo and ex vivo models of EPEC infection and
the prevalence ofAE E. coli infection in cancer patients.
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4.1. Introduction
4.1.1. In vivo mouse models for EPEC infection
In parallel to establishing a reliable in vitro model for EPEC infection, an aim of this
study was to develop a relevant in vivo model. The aim in establishing this model
was to provide a system in which to analyse both the molecular and pathological
effects of EPEC infection. Thus making it possible to determine whether any effects
observed in vitro also occurred in a whole animal, and most importantly whether
these changes incurred long-term consequences.
Citrobacter rodentium (formerly Citrobacter freundii biotype 4280) is a mouse
pathogen responsible for transmissible murine colonic hyperplasia (TMCH) and
provides a well-established, convenient model for infection by AE bacteria (Schauer
et. al., 1995). In laboratory mice C. rodentium attaches intimately in large numbers
to the surface mucosa of the descending colon within 4 days of inoculation.
Hyperplasia of the descending and sometimes the transverse colon rapidly develops,
reaching maximal levels after approximately 16 days (Barthold, 1980). Hence mice
infected with C. rodentium have colonic crypts up to 3 times longer than uninfected
animals (Barthold, 1979). EPEC and C. rodentium share a number of genetic and
phenotypic traits; C. rodentium carry a chromosomal copy of the eae gene and form
AE lesions when attaching to the colonic mucosa (Schauer & Falkow, 1993),
C. rodentium also secrete a translocated intimin receptor (Tir), which is tyrosine
phosphorylated in host cells (Deng et. al., 2003). In similarity to EPEC, acute
C. rodentium infection induces diarrhoea, though this not generally profuse or watery
(Barthold, 1980).
Experiments using mice infected with C. rodentium have helped to establish a link
between AE bacteria and tumourigenesis. A report published 30 years ago analysed
the time taken for tumours to occur in mice injected with the carcinogen DMH (1,2-
dimethylhydrazine) and infected with C. rodentium (Barthold & Jonas, 1977). It was
found that C. rodentium infection reduced the latent period for appearance of early
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DMH tumours from 2 months to 1 month, the percentage incidence of tumours was
also more than double in infected mice compared to controls after 2 months. In a
more recent study, ApcMm,+ mice (heterozygous for the multiple intestinal neoplasia
[Min] allele, which is a germline mutation in the Ape tumour suppressor gene) were
infected with C. rodentium (Newman et. al., 2001). Five months after infection,
significantly more adenomas were found in infected ApcMml+ mice (average 2.8
tumours / animal) compared to uninfected ApcUml+ mice (0.8) or infected wild-type
mice (0.0).
A recently published report establishes an alternative in vivo model by infecting mice
directly with EPEC (Savkovic et. al., 2005). By using EPEC, this model is a
potentially more relevant system for studying EPEC pathogenesis in man. Savkovic
et. al. (2005) report that in C57B1/6 mice, EPEC E2348/69 colonises and adheres to
the intestinal epithelium, causing the effacement of microvilli, actin rearrangement
and the recruitment of immune cells. These are interesting results considering EPEC
E2348/69 is generally accepted as a purely human pathogen. In vitro studies
analysing the ability of EPEC to adhere to mouse colorectal (CMT-93 & Colon-26)
cells found that adherence was remarkably low compared to human colonic (Caco-2)
cell adhesion (Tobe & Sasakawa, 2002). The authors attributed the species
specificity of EPEC to selective binding by bundle forming pili.
4.1.2. Ex vivo models for EPEC infection
The availability of fresh human colon tissue from surgical patients presented the
opportunity to develop an ex vivo model for EPEC infection. The aim of developing
this model was to gain an understanding of the behaviour of EPEC within the human
colon. As colon cancer is generally a disease of middle age, adult colon tissue
represents the most biologically relevant tissue for this model. As with the in vitro
model, a long time-course of infection was used. A number of published in vitro
organ culture (IVOC) experiments have been carried out to analyse the pathogenesis
of EPEC in association with human tissue. These studies generally use small
intestine biopsy tissue removed from children and are specifically concerned with the
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AE process itself. These studies show that wild-type EPEC (E2348/69) colonise the
surface of human small intestine mucosa, producing AE lesions after 6-8 hours
incubation (Table 4.1).
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Table 4.1. Published reports using in vitro organ culture (IVOC) methods for co-
culture with EPEC. Studies generally used small intestine tissue and in all but one case this
tissue came from children.
Hicks et. al. (1996) used IVOC of paediatric transverse colon to investigate the
adhesion properties of EAEC, finding that EAEC adhered to colonic mucosa and that
colon tissue incubated with EAEC had larger crypt openings than uninfected tissue.
EPEC strain KH1/8 (that displayed localised adherence to Hep-2 cells) was used as a
control and did not adhere to the colon mucosa (Hicks et. al., 1996). A study by
Phillips & Frankel (2000) included the use of paediatric colon tissue to evaluate the
effect of intimin sub-type expression on tissue binding specificity. Using EPEC
strain CVD206 (E2348/69 eae~) transformed to express intimin-a or intimin-y it was
found that intimin subtype did influence tissue specificity. Hence EPEC expressing
intimin-a adhered to small intestine (100% of samples), Peyer's patch (80%) and
colon (25%), whereas EPEC expressing intimin-y did not adhere to the colon, but did
adhere to the small intestine (14%) and Peyer's patch (83%). Hence EPEC have the
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ability to bind to paediatric colonic mucosa, depending on intimin type. This
therefore suggests that host cells display other surface receptors that bind intimin
(aside from Tir), and that intimin subtypes interact differently with these receptors.
The literature therefore provides little evidence on the normal behaviour of EPEC
within the adult colon. Hence a key aspect of this investigation was to analyse
whether EPEC attached to this tissue and if there were preferred binding sites. The
function and therefore structure of the human colon differs significantly from the
small intestine. The principal role of the colon is the absorption of salt and water
from the lumen contents. Unlike the small intestine mucosa, which is characterised
by villi that project into the lumen, the colonic mucosa is flat, and pitted with tubular
crypts. The gut epithelium is a constitutively developing tissue, constantly
differentiating from stem cells throughout the life of the organism (de Santa Barbara
et. al., 2003). Stem cells lie near the base of colonic crypts, newly formed
undifferentiated cell are classed as proliferative progenitors, these cells migrate from
the crypt base towards the lumen. When proliferative cells reach the top third of the
crypt they differentiate terminally and are eventually shed from the epithelium due to
apoptosis or physical processes (Sancho et. al., 2004) (Figure 4.1). Colorectal cancer
is thought to arise from transformation of undifferentiated proliferative cells within
the crypts (van der Wettering et. al., 2002). It was therefore an aim of this study to
investigate whether EPEC could influence to biology of these cells by entering
colonic crypts.
4.1.3. E. coli in colorectal cancer patients
Previous studies have identified the presence of tumour-associated E. coli in
colorectal cancer patients, but did not identify E. coli of the AE phenotype
(Swidinski et. al., 1998; Martin et. al., 2004). The central hypothesis of this study is
based on the theory that chronic EPEC infection would help to initiate
tumourigenesis in the healthy colon, and not necessarily affect the development of an
in situ tumour. Hence the presence of adherent E. coli on adenocarcinomas could
indicate a residual infection that contributed to the initial formation of the tumour. A
97
further aim was therefore to investigate whether tumour-associated E. coli of AE
phenotype were present in a sample of colorectal cancer patients. A high incidence of
EPEC infection in cancer patients would also suggest a link with tumourigenesis.
However, it is difficult to know what the baseline EPEC-infection rate in the healthy










Figure 4.1. Schematic diagram representing cell compartments within the colonic
crypt. Proliferative progenitors are amplified by constant division along the bottom two-thirds
of the crypts, cell cycle arrest and differentiation occur when progenitors reach the top third
of the crypts. Crypt progenitors divide every 12-16 h, generating 200 cells per crypt per day.
Three mechanisms maintain epithelial homeostasis; (i) shedding of differentiated cells from
the surface epithelium, (ii) continuous upward migration of proliferative and differentiated
cells, (iii) proliferative and differentiated compartments are maintained as cells transit along




4.2.1 In vivo mouse model for EPEC infection
4.2.1.1. Infection of C57B1/6 mice with Citrobacter rodentium and EPEC
As expected, C57B1/6 mice infected with wild-type C. rodentium developed a gross
thickening of the colon due to hyperplasia manifest by increased crypt length.
Whereas, uninfected and mutant C. rodentium infected mice showed no hyperplasia,
demonstrating the necessity of eae in initiating the pathological response (Figure
4.2). By comparison, C57B1/6 mice infected with EPEC did not display hyperplasia,
despite receiving a higher bacterial inoculum (Figure 4.3).
To further validate the EPEC mouse model and to quantify the infection present
within the lower GI tract bacterial counts were performed. The number of adherent
and non-adherent EPEC present in the lower intestine were counted by growing
homogenised tissue and gut contents on selective agar. In C57B1/6 mice, low
average levels of adherent EPEC were counted in the ileum (1,917), cecum (752),
proximal (2,637) and distal colon (97), 24 hours post infection. After 48 hours,
similar numbers of adherent EPEC were counted in the cecum (1,505) and proximal
colon (1,956), but none were present in the ileum or distal colon. After 72 hours, no
adherent EPEC were detected in any of the tissues (Figure 4.4a). Non-adherent
bacteria showed a similar time-course of infection, peaking after only 24 hours with
an average of 89,367 EPEC in the cecum. After 72 hours, only the cecum contained
any non-adherent EPEC, but numbers were low (4,667) (Figure 4.4b).
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Figure 4.2. Effect of Citrobacter rodentium on colon pathology in C57BI/6 mice.
C57BI/6 mice were either uninfected or received mutant (DBS255) or wild-type
(DBS100) Citrobacter rodentium (~1 x 108) via gavage. After 14 days animals were
killed, the colon was excised, rolled, fixed and then embedded in paraffin.
Immunosections were stained with haematoxylin and eosin. Original magnification of
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Figure 4.3. Effect of EPEC on colon pathology in C57BI/6 mice. C57BI/6 mice
were either uninfected or received mutant (UMD864) or wild-type (E2348/69) EPEC
(~2 x 108) via gavage. After 14 days animals were killed, the colon was excised,
rolled, fixed and then embedded in paraffin. Immunosections were stained with
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Figure 4.4. Quantification of bacterial load in C57BI/6 mice infected with EPEC.
Mice (n = 9) received wild-type (E2348/69) EPEC (~2 x 108) via gavage. At 24 h
intervals post-infection animals (n = 3) were killed, the lower Gl tract was removed
and cut into sections, the homogenised tissue and lumen contents from each section
was plated onto selective MacConkey agar to count EPEC colony forming units
(CFU). EPEC colonies grown from tissue homogenates (a) were classified as
representing the number of adherent EPEC, and colonies grown from lumen contents
(b), non-adherent EPEC.
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In comparison with the published results, and considering the number of bacteria the
C57B1/6 mice received (~2 x 10 ), the numbers of adherent and non-adherent
bacteria were low. Evidently, the time-course of infection was also short, with no
adherent bacteria identified after 72 hours. It was hypothesised that other strains of
mice would be more susceptible to EPEC infection and hence provide a better model.
C3H/HeN mice are highly susceptible to C. rodentium infection, which is potentially
fatal to these animals (Vallance et. al., 2003).
4.2.1.2. Infection of C3H/HeN mice with EPEC
Higher numbers of adherent and non-adherent EPEC were counted in the cecum of
C3H/HeN mice compared to EPEC infected C57B1/6 mice. Hence, an average of
9,203 adherent EPEC were counted in the cecum after 48 hours infection. However,
numbers dropped rapidly, and after 72 hours only 284 EPEC were counted in the
cecum. Less EPEC were counted in the proximal colon after 24 hours (1,090) or 48
hours (572) than in C57/B16 mice, however at 72 hours numbers were higher (445)
in the C3H/HeN animals. Very few adherent EPEC were detected in the ileum or
distal colon of C3H/HeN mice at any time-point. In contrast to C57B1/6 mice,
infection persisted (at low levels) for at least 72 hours in the cecum and proximal
colon. In summary, more non-adherent EPEC were counted in C3H versus C57
mice, but the majority of adherent EPEC were confined to the cecum, and overall
numbers remained relatively low, particularly after 72 hours (Figure 4.5a).
C3H/HeN mice were infected with a higher inoculum of EPEC than the C57 mice,
and this translated into greater average numbers of non-adherent EPEC in the cecum,
and colon. Hence, after 24 hours the cecum (157,767), proximal (38,000) and distal
colon (142,100) of C3H mice contained more EPEC than C57 mice (cecum 89,367;
proximal colon 33,567; distal colon 55,067). In the C3H mice, non-adherent EPEC
were also present in higher numbers after 72 hours in the cecum (50,067) proximal
(25,533) and distal colon (15,867) versus C57 mice (cecum 4,667; proximal colon 0;
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Figure 4.5. Quantification of bacterial load in C3H/HeN mice infected with
EPEC. Mice (n = 9) received wild-type (E2348/69) EPEC (~1 x 109) via gavage. At
24 h intervals post-infection animals (n = 3) were killed, the lower Gl tract was
removed and cut into sections, the homogenised tissue and lumen contents from
each section was plated onto selective MacConkey agar to count EPEC colony
forming units (CFU). EPEC colonies grown from tissue homogenates (a) were
classified as representing the number of adherent EPEC, and colonies grown from























Figure 4.6. Effect of EPEC on colon pathology in C3H/HeN mice. C3H/HeN mice
were either uninfected or received wild-type (E2348/69) EPEC (~1 x 109) via gavage.
After 2 days animals were killed, the colon (a) and cecum (b) were excised, rolled,
fixed and then embedded in paraffin. Immunosections were stained with haematoxylin
and eosin. Original magnification of panels on left; x 20, on right; x 40.
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To test whether EPEC infection was able to persist in C3H/HeN mice long term,
cecum and proximal colon tissue and contents were analysed for EPEC 5 weeks after
infection (Table 4.2). No EPEC were identified, and tissue did not display the crude
signs of hyperplasia that were clearly visible in C57B1/6 mice infected with
C. rodentium. No symptoms or changes in behaviour were observed in the C3H/HeN
mice during the 5-week period. Haematoxylin and eosin staining of C3H/HeN cecum
and colon tissue after short-term (48 hours) infection with EPEC also revealed
normal pathology (Figure 4.6).
Adherent EPEC (CFU) Non-adherent EPEC (CFU)
Cecum Prox. colon Cecum Prox. Colon
Animal 1 0 0 0 0
Animal 2 0 0 0 0
Animal 3 0 0 0 0
Table 4.2. Quantification of bacterial load in C3H/HeN mice 5 weeks after
infection with EPEC. Mice received wild-type (E2348/69) EPEC (~2 x 109) via
gavage. After 5 weeks animals were killed, the cecum and proximal colon were
removed. Homogenised tissue and gut contents were plated onto selective
MacConkey agar to count EPEC colony forming units (CFU). Colonies grown from
tissue homogenate were classified as adherent EPEC, and colonies grown from gut
contents as non-adherent EPEC.
4.2.1.3. Co-culture ofmouse colorectal cells with C. rodentium and EPEC
As a further test for the validity of a mouse model for EPEC infection, EPEC was co-
cultured with the mouse derived intestinal epithelial cell line CMT93. Co-culture
experiments with human cell lines in this study revealed that EPEC infection
downregulated the expression of certain cell-adhesion and DNA repair proteins
(Chapter 5). It was hypothesised that EPEC or Citrobacter rodentium infection
would have the similar effects on protein expression in CMT93 cells.
Co-culture of EPEC with CMT93 cells for 12 hours did not cause downregulation of
cell adhesion (beta-catenin) and DNA repair (MSH2 and MLH1) proteins (Figure
4.7a). By viewing co-cultured cells under a light microscope, it was noticeable that
far fewer EPEC were adherent to CMT93 cells than to human (HT29 cells) after 12
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hours co-culture (not shown). Despite the fact that Citrobacter rodentium is a
murine AE pathogen, no change in the expression of MSH2 or MLH1 expression
was observed after co-culture with CMT93 cells (Figure 4.7b). These results
demonstrate not only the species specificity of AE bacteria adherence, but also the
potential species specificity of the molecular effects of AE bacteria.
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Figure 4.7. Co-culture of CMT93 cells with EPEC or Citrobacter rodentium.
Western blots of CMT93 cells that were either uninfected (-) or co-cultured with wild-
type (E2348/69) or mutant (UMD864) EPEC (a), or with mutant (DBS255) or wild-
type (DBS100) Citrobacter rodentium for 12 hours (b).
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4.2.2. Ex vivo human tissue model for EPEC infection
The architecture of uninfected tissue (fixed soon after removal from the patient) was
compared with adjacent tissue (from the same patient) that had been co-cultured with
EPEC for 12 hours. Despite the co-culture period, general mucosa structure appeared
normal, the surface epithelial layer remained intact and crypt structure was
maintained (Figure 4.8).
It was hypothesised that EPEC could enter human colonic crypts, with the potential
to influence to molecular biology of proliferative progenitor cells. Due to the lack of
a commercial antibody to specifically identify EPEC, a generic anti-E.coli antibody
was used. Immunofluorescent staining of fixed sections of colon mucosa co-cultured
with EPEC frequently revealed the presence of E. coli in crypts (Figure 4.9). Images
show that the E. coli closely associated with the surface epithelium (marked by ezrin
staining). It can also be seen that the bacteria were found in the mid-region of the
crypts. Immunofluorescent staining of Ki67, a marker for cells capable of
proliferation (Sancho et. al., 2004) shows that E. coli were identified in the region of
the crypt containing proliferative progenitor cells (Figure 4.10).
In order to quantify the frequency of crypt infection, and to confirm that ex vivo
tissue did not harbour endogenous E. coli prior to co-culture, the number of crypts
containing E. coli was counted. In tissue co-cultured with EPEC for 12 hours, 10.6%
of crypts contained E. coli, in uninfected tissue E. coli was not identified anywhere
within the tissue (Figure 4.11). This result helps to confirm that the human tissue
used did not harbour endogenous E. coli prior to co-culture, and that observations
were based on identification of EPEC. PCR amplification for eae confirms that AE
E. coli were absent in uninfected ex vivo tissue, but were present in tissue co-cultured
with EPEC (Figure 4.14). Therefore, results strongly support the conclusion that
EPEC is able to enter a significant proportion of crypts in normal, adult human colon
tissue.
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Figure 4.8. Co-culture of human ex vivo colon mucosa with EPEC.
Normal, full thickness colon tissue was removed from surgical patients, the
mucosa was separated from the muscularis and washed several times. Pieces of
mucosa were either fixed in formalin immediately (Uninfected, Oh), or co-cultured
with wild-type EPEC for 12 h (+ wt EPEC, 12h) then washed and fixed in formalin.
Fixed tissue was embedded in paraffin, immunosections were stained with
haematoxylin and eosin. Broken black boxes delineate areas of magnification
shown in subsequent images.
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Figure 4.9. EPEC enters colonic crypts of ex vivo human colonic mucosa.
Colon mucosa was separated from full thickness colon tissue removed from surgical
patients. Mucosa was co-cultured with wild-type (E2348/69) EPEC for 12 h then
washed and fixed in formalin. Immunosections were stained for E. coli (red) and
ezrin (green), nuclei were counter stained with DAPI (blue). Broken white boxes
delineate area of magnification in subsequent image.
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Figure 4.10. EPEC enters proliferative compartment of colonic crypts.
Colon mucosa was separated from full thickness colon tissue removed from
surgical patients. Mucosa was co-cultured with wild-type (E2348/69) EPEC
for 12 h then washed and fixed in formalin. Immunosections were stained for
E. coli (red) and ki67 (green), nuclei were counter stained with DAPI (blue).
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Figure 4.11. Frequency of crypt infection in ex vivo human colon tissue. Colon
mucosa was separated from full thickness colon tissue removed from surgical
patients (n = 3). Uninfected pieces of mucosa were washed and fixed in formalin.
Matched pieces of mucosa were washed and then co-cultured with wild-type
(E2348/69) EPEC for 12 hours, then washed and fixed in formalin. Immunosections
were stained for E. coli and the number of crypts containing E. coli were counted
and calculated as a percentage of total crypts (>300 crypts counted in each
instance). Error bars represent standard error of mean.
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4.2.3. Prevalence of AE E. coli infection and eae in colorectal cancer patients
It was hypothesised that EPEC infection is a risk factor in the development of colon
cancer in man, and therefore, that tissue from colorectal cancer patients would
harbour residual EPEC infection. Formalin fixed, paraffin embedded samples of
colorectal adenocarcinoma and normal colon tissue from 20 randomly selected
patients were obtained from archives of the Department of Histopathology,
Edinburgh University. Due to the absence of a commercial antibody for EPEC it
was not possible to unambiguously identify EPEC. However, by using a generic
anti-E. coli antibody and PCR for intimin, it was possible to confirm the presence of
E. coli with AE ability.
Immunofluorescent staining revealed the presence of mucosa associated E. coli in
colonic crypts of normal tissue (Figure 4.12). Within adenocarcinoma tissue large
numbers of E. coli were found. In a number of cases the E. coli were closely
associated with the mucosa, often within (tubulo-villus) crypts and sometimes
seemingly integrated into the adenocarcinoma tissue itself (Figure 4.13). PCR
amplification identified the presence of eae in a number of normal and tumour tissue
samples (Figure 4.14). One adenocarcinoma showed a particularly high level of
E. coli infection, with bacteria penetrating deep into the crypts and hundreds of E.
coli very closely associated with the surface epithelium (Figure 4.15b). A repeat PCR
on this tissue confirmed the presence of the bacterial eae gene (Figure 4.15c).
Overall it was found that 95% of adenocarcinomas had mucus associated E. coli, and
50% had mucosa associated E. coli. Of the normal tissue samples, 60% held mucus
associated E. coli and 15% had mucosa associated E. coli. The presence of the
bacterial eae gene was identified in 25% of adenocarcinomas and 0% of normal
tissue samples (Table 4.3). These results therefore show that a significant percentage
of cancer patients harboured AE E. coli within their colon, and that AE E. coli were
frequently associated with tumour rather than normal tissue in these patients.
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Figure 4.12. Identifying E. coli in normal human colon tissue. Normal tissue from
20 colorectal cancer patients was tested for the presence of E. coli (red) by
immunofluorescence, nuclei were counterstained with DAPI (blue). Dashed boxes
delineate magnified field to the right. Case numbers in top left corner of first image in
sequence. E. coli can be seen as mucosa associated (284), mucus associated (283,
335 & 342) or absent (503). Original magnification shown in bottom right-hand corner
of each image.
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Figure 4.13. Identifying E. coli in human adenocarcinoma tissue.
Adenocarcinoma tissue from 20 patients was tested for the presence of E. coli (red) by
immunofluorescence, nuclei were counterstained with DAPI (blue). Dashed boxes
delineate magnified field to the right. Case numbers in top left corner of first image in
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Figure 4.14. Detection of eae in human normal and adenocarcinoma tissue.
Paraffin embedded sections (20pm) of normal mucosa (a) and adenocarcinoma (b) from
20 randomly selected patients were deparaffinised and subjected to proteinase K
digestion. DNA was obtained by phenol chloroform extraction and PCR for the AE
bacteria gene eae was performed. Uninfected (- EPEC) and EPEC infected (+ EPEC)
human ex vivo tissue sections were used as negative and positive controls. DNA
extracted directly from overnight culture of EPEC was also used as a positive control
(EPEC). *Cases judged positive. PCR reactions performed by Scott Bader.
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a
Figure 4.15. Example of an adenocarcinoma highly infected with adherent AE E. coli.
Adenocarcinoma case 342 immunostained for E. coli (red), nuclei were counterstained with
DAPI (blue). E. coli were identified in tubulovillus crypts on the surface of the tissue (a) and
deeper within the adenocarcinoma (b). A repeat PCR for eae was performed on tissue
sections using a different reverse primer (c). Human ex vivo colon tissue sections infected
with wild-type EPEC (+ EPEC) or uninfected (- EPEC) were used as additional positive and
















170 + - + -
186 - - -
187 - + -
199 - + -
208 ++ ++ + ♦
217 + +++ +++
247 - + +
283 + +++ -
284 ++ +++ +
318 + ++ +
319 ++ + -
335 + + + ♦
336 ++ ++ -
342 ++ + +++ +++ ♦
351 +++ + ++ + ♦
361 - + -
387 - + -
472 - ++ + ♦
486 - + -














Table 4.3. E. coli infection and eae identification in human colon tissue.
Paraffin embedded adenocarcinoma and matched normal tissue from 20 patients
was tested for the presence of £. coli by immunofluorescence and for expression
of the eae gene (encoding intimin) by PCR (♦). The level of E. coli infection was
scored as zero (-), tens (+), hundreds (++) or thousands (+++) of bacteria. Both
mucus associated and mucosa associated E. coli were evaluated.
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4.3. Discussion
Citrobacter rodentium produced characteristic hyperplasia in C57B1/6 mice, whereas
mice infected with EPEC did not display any signs of hyperplasia. In man, EPEC
infection is not known to cause hyperplasia, this initial result therefore suggests that
infection of mice with EPEC rather than C. rodentium might represent a more
pathologically relevant model. However, counts of adherent and non-adherent EPEC
in the lower gut of infected animals revealed low levels of EPEC and a short time-
course of infection. After 3 days, no adherent EPEC were detected in the cecum or
colon. Savkovic et. al. (2005) report that after 3 days infection of C57B1/6 mice with
EPEC, cecum (-16,300) CFU) and colon (-6,500 CFU) tissue held relatively high
levels of adherent EPEC. In an attempt to improve the model (i.e. to increase gut
colonisation by EPEC) C3H/HeN mice were infected, this strain shows greater
susceptibility to C. rodentium infection (Vallance et. al., 2003). Higher levels of
adherent and non-adherent EPEC were found in these animals compared to C57B1/6
mice, however, the levels were still low in comparison the published data.
Furthermore, infection did not persist in these animals in the medium term.
The inability to recreate this model may be attributable to a number of factors,
including differences in the host animals and differences in technique. Tissue was
homogenised using curved scissors and syringing, whereas the paper of Savkovic et.
al. (2005) is unclear as to the methods of homogenisation. Agar supplemented with
nalidixic acid rather than ampicillin was used to count bacteria, a difference in
selectivity / potency of these antibiotics may account for greater counts in the
published report. Host gut microflora would have a direct effect on colonisation by
foreign bacteria. Mice used in this study were obtained from a different supplier than
those in the published report; hence differences in the commensal organism
populations within the mice would be expected to differ. However, despite any
differences in mice, it was notable that it was possible to recreate the C. rodentium
infection model with ease. Overall, results suggest that establishing EPEC infection
model in mice is not straightforward.
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In light of in vivo mouse results, co-culture studies were performed to evaluate the
species-specific properties of EPEC and C. rodentium in vitro. Infection of a mouse
colon cancer cell line with EPEC did not produce the same characteristic changes in
protein expression seen in human cells. Furthermore, infection of mouse cells with
C. rodentium also failed to produce the characteristic protein changes caused by
EPEC in human cells. It was also noted that adherence of both EPEC and
C. rodentium to CMT-93 cells was considerably lower than for EPEC with HT29
cells, supporting the results of Tobe and Sasakawa (2002). It is possible therefore
that CMT-93 cells do not have surface residues conducive to bacterial attachment.
However, these results do suggest that EPEC pathology (and potentially adherence)
are species specific, and conflict with the conclusions of Savkovic et. al. (2005) that
mice provide a viable animal model for EPEC infection.
In summary, the pathological effects of C. rodentium infection in mice are unlike
those of EPEC in man, and are in fact analogous to inflammatory bowel disease in
humans (Newman et. al., 2001). Hence, although C. rodentium may provide a
convenient model for the AE process per se, it does not necessarily represent a viable
model for the biological consequences of EPEC infection in man. The C. rodentium
model could however be potentially used to study how inflammatory diseases such
as Crohn's disease and Ulcerative Colitis predispose to cancer in man. Due to the
inability to induce persistent EPEC infection in mice, and the species specific effects
observed in cell lines, it was concluded that infection of C57B1/6 and C3H/HeN mice
with EPEC did not represent viable models for EPEC infection in man either. After
observing the in vitro specificity of EPEC, further enhancement of the mouse model
was not attempted. However, as one possible modification, pre-treatment of mice
(with antibiotics) to reduce numbers of commensal bacteria would have been likely
to increase infection. Another more complex approach would be to engineer EPEC
strains with enhanced affinity for mouse tissue. In studying intimin subtypes, Phillips
& Frankel (2000) constructed EPEC expressing chimera intimin-a/y. A similar
approach, using C. rodentium derived adhesion factors could allow human virulent
EPEC strains to attach more effectively to the mouse gut.
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Evidently, at the same time as the experiments in this study were being performed,
other workers were drawing the same conclusions about the validity of the EPEC
mouse model. Mundy et. al. (2006) also studied EPEC infection in mice, using
C57B1/6 and C3H/HeJ strains, comparing their results to C. rodentium infection and
also non-pathogenic (commensal) E. coli. The authors used homogenised tissue
bacterial counts to assess adherent bacteria, and stool counts for non-adherent
bacteria. Although Mundy et. al. (2006) report higher levels of adherent bacteria, and
longer time-course of infection than this study, the authors conclude that EPEC: were
unable to effectively colonise the colonic epithelium; were unable to expand in vivo;
demonstrate a commensal rather than pathogenic organism in the mouse; and that
infection of mice with EPEC has very limited usefulness. The authors note that their
results are supported by aspects of a recent study that showed EPEC did not colonise
mice (Klapproth et. al. 2005) and conflict with Savkovic et. al. (2005).
By adapting published organ culture protocols a system to co-culture viable colonic
mucosa with EPEC for 12 hours was established. Co-culture resulted in the
migration of EPEC into the colonic crypts, hence after 12 hours just over 1 in 10
crypts held EPEC. Additionally, EPEC were found in the mid-crypt region, often
half way down the crypt. Although staining of ezrin did not conclusively
demonstrate AE lesion formation, ezrin accumulation below EPEC was noted in
some cases. It was clear that EPEC associated very closely with the surface of the
crypt epithelial cells. Immunofluorescence also confirmed that EPEC penetrated far
enough into the crypts to reach the proliferative progenitor cell compartment. It was
also notable that EPEC rarely associated with cells of the surface epithelium.
Importantly, these results demonstrate - potentially for the first time - how EPEC
might behave within the healthy adult colon.
Undifferentiated proliferative progenitor cells lie in the lower two-thirds of colonic
crypts (Sancho et. al., 2004), and are thought to have the potential to initiate tumour
formation (van der Wettering et. al., 2002). Loss of control over differentiation /
apoptosis or cell cycle by these cells (e.g. due to mutation induced by dietary
carcinogens) would almost certainly facilitate tumourigenesis. If EPEC intimately
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attach to crypt progenitor cells in vivo, it is quite possible that EPEC induced
changes in host cell signalling pathways could influence the susceptibility of these
cells to cancer development.
Elsing enhanced immunostaining and microscopy techniques in conjunction with this
model would make it possible to clarify whether EPEC is able to form AE lesions
and attach intimately within crypts. Scanning electron microscopy (SEM) and
particularly transmission electronic microscopy (TEM) would be capable of this. In
situ staining of proteins such as Nek, N-WASP and Tir (as recently demonstrated by
Schuller et. al., 2007) would help to identify actin pedestals. Directly staining actin
with fitc-phalloidin (an adapted FAS test) was attempted in this study, however this
method failed to stain actin consistently in fixed tissue (not shown). Using frozen
rather than formalin fixed tissue would probably have improved results. Similar
methods could also be used to analyse EPEC induced protein changes in host cells.
The ability of EPEC to enter crypts is potentially achieved via propulsion by flagella.
This could be tested by comparing the behaviour of EPEC cultured in DMEM
(which inhibits flagella expression: Zhou et. al., 2003) versus EPEC grown in other
media.
In fixed normal and adenocarcinoma tissue from colorectal cancer patients EPEC
was most often seen in the mucus layer, mucosa associated bacteria were found on
half of the adenocarcinomas but only on a few normal tissue samples. The bacterial
gene for intimin eae was also more prevalent in the tumour compared to normal
tissue, and was identified in a quarter of tumours. Within the sample of 20 cases,
E. coli and AE E. coli were more commonly found in association with tumour tissue
than normal tissue in the human colon. These results support the findings of
Swidsinski et. al. (1998) and Martin et. al. (2004) who also found E. coli more
commonly associated with tumour rather than normal tissue in colorectal cancer
patients. This is also potentially the first study to find an association between AE
E. coli and colorectal adenocarcinoma. Martin et. al. (2004) attribute the apparent
preferential binding to the expression of bacterial adhesins with specificity for
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"oncofetal" carbohydrate antigens over-expressed by mucosal glycoconjugates in
cancer.
It is well established that cancer cells display altered surface characteristics
compared to normal cells; these include the appearance of new antigens,
proteoglycans, glycolipids and mucins (Kufe et. al., 2003). Aberrant glycosylation is
thought to be a key factor in these changes, and may result from three processes:
attenuated synthesis of normally expressed carbohydrate chains; activation of
glycosyltranferase enzymes; or reorganisation of tumour cell membrane glycolipids
(Kufe et. al., 2003). These changes represent a realistic basis for altered adhesion by
AE E. coli. At present the exact residue(s) to which EPEC binds on host cells
remains unclear. By screening a range of glyco- and phospholipids, Barnett-Foster et.
al. (1999) found that EPEC and EHEC bound in a specific and dose dependent
manner to phosphatidylethanolamine and correlated this to bfp expression. Other
candidate receptors include gangliotriaosylceramide, and gangliotetraosylceramide,
32-33 kDa glycoproteins and lactosamine sequences lacking sialic acid (reviewed by
Tobe and Sasakawa, 2002). Carbohydrates, such as D-mannose also influence EPEC
binding to epithelial cells, with the ability to enhance or inhibit adherence depending
on concentration (Schaeffer et. al., 1980).
Although eae was not identified in any normal tissue samples by PCR, three samples
had mucosa associated E. coli, and in at least one case these seemed to be adherent to
crypt cells. This supports the findings from the ex vivo model where EPEC
apparently bound preferentially to colonic crypt epithelial cells within adult colon
tissue. Higher numbers of E. coli were clearly found on tumour samples compared to
normal tissue. Aside from differences in surface residues, the difference in detection
of E. coli and eae between normal and tumour tissue may be partially explained by
the architecture of tumour versus normal tissue. The vastly increased surface area of
adenocarcinoma provides more opportunities for binding. Also, the bacteria enclosed
within folds of the tumour would be less likely to be shed in vivo or washed off while
tissue was prepared and fixed. Hence AE E. coli numbers may have been too low in
normal tissue (and some tumour samples) to detect eae by standard PCR.
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A potential explanation for the apparent affinity of EPEC for crypt cells is the change
in expression of mucosal surface glycoproteins during migration of epithelial cells
from crypt to surface epithelium (Kim et. al., 1971; Etzler & Branstrator, 1974).
Within the crypts, mitotically active, undifferentiated crypt cells (in similarity to
fetal cells) express active glycosyltransferase enzymes and acceptor sites that are
glycoproteins with incomplete polysaccharide chains (Weiser, 1973). A selective
ability to bind to these residues could also provide an explanation for the affinity of
AE E. coli for tumour tissue, and possibly for the more severe pathology of EPEC
infection in the infant intestine. The ability of EPEC to enter crypts of the adult
human colon and to adhere to cells in the proliferative region are novel findings, and
illustrate a potential niche environment for EPEC in the (asymptomatic) adult colon.
Further study of tissue from cancer patients would help to confirm an association
between AE E. coli and cancer. One of the limitations of this study was that fixed
tissue was used. Elence, PCR was performed on small numbers of bacteria that had
been embedded in paraffin for a number of years, probably leading to nucleic acid
degradation and cross-linking. Fresh tissue would be preferable to fixed tissue as
bacteria could be sub-cultured and identified more readily (e.g. by PCR and
phenotypic assays such as FAS test). Due to time limitations, only PCR for eae was
performed, although this confirmed the presence of AE E. coli, it did not confirm
that these were EPEC. Further PCR for stx, the gene for shiga toxin, expressed only
by EHEC would have enabled us to differentiate between EHEC and EPEC. It would
also be very interesting to find out what the levels of EPEC carriage are amongst the
healthy adult population; analysis of stool samples or biopsy tissue could help to
achieve this. This data could then be compared to carriage levels in cancer patients.
Furthermore, long-term follow-up of EPEC carriers would fundamentally determine
any link between EPEC and colon cancer.
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Chapter 5.
Effect of EPEC infection on DNA mismatch repair protein expression
and apoptosis in human colorectal cell lines.
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5.1. Introduction
5.1.1. DNA mismatch repair
The hypothesis that EPEC increases susceptibility to colon cancer is founded on the
contention that the molecular effects of infection are oncogenic. Microarray analysis
of gene expression in cells co-cultured with EPEC provides evidence of molecular
changes with the potential to increase the susceptibility of infected cells to mutation.
Genes encoding DNA mismatch repair proteins showed a greater than two-fold
reduction in expression after co-culture of HT29 cells with wild-type EPEC (Chapter
3). DNA mismatch repair disruption is a causative factor in the development of both
familial and sporadic colorectal cancer. Helicobacter pylori infection has been
shown to impair DNA mismatch repair (MMR) via reduction in MSH2 and MLH1
protein levels in gastric epithelial cells (Kim et al., 2002; Park et al., 2005). Patients
with MSI-positive tumours are also more likely to have active H. pylori infection
than patients with MSI-negative tumours (Leung et. al., 2000). An aim of this study
was therefore to investigate the effects of EPEC infection on the expression of DNA
mismatch repair proteins using the extended time-course co-culture model.
The presence of mechanisms for the correction of DNA base pair mismatches were
first identified using E. coli, in which the MutS and MutL proteins are key
components of the MMR pathway (Modrich et al., 1991). Human 'MutS
homologues' (Msh2, Msh3, Msh6) and 'MutL homologues' (Mlhl, Mlh3, Pmsl,
Pms2) are the principal proteins of MMR pathways in man (Peltomaki, 2001). The
MMR genes can be described as indirect tumour suppressor genes. Their role is to
correct post-replication DNA base pair mismatches and insertion-deletion loops
created by DNA polymerases (Jiricny, 2000a). Failure of the DNA MMR system
confers significant genomic instability, promoting rapid accumulation of point and
frame-shift mutations in repeated sequence motifs (Jiricny, 2000b), a scenario termed
microsatellite instability (Thibodeau et. al., 1993). Mutation of MMR genes,
resulting in microsatellite instability (MSI) is the defining genetic characteristic of
the most common form of inherited colorectal cancer, Hereditary Non-Polyposis
Colorectal Cancer (HNPCC) (Lynch & de la Chapelle 1999). MMR gene mutation
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and MSI are also found in approximately 15% of sporadic cases of colorectal cancer
(Liu et al., 1995). The genomic instability resulting from MMR disruption is
implicated in cancer development by facilitating and accelerating the accumulation
of mutations in tumour suppressor and oncogenes such as APC, TP53 and K-ras.
Hence, cancers with disrupted MMR function are said to display a 'mutator'
phenotype.
5.1.2. DNA mismatch repair protein apoptosis signalling
In addition to their role in DNA repair, MMR proteins also have a vital role in
signalling DNA damage induced apoptosis. Cytotoxic and carcinogenic chemical
agents (such as 5-fluorouracil, cisplatin, alkylating agents and methylating agents)
create DNA damage that is recognised by the MMR system (Jascur & Boland, 2006).
In detecting severe DNA damage, MMR proteins can either direct cell cycle arrest
(in order to allow more time for repair), or if the damage is too great, apoptosis
(Bernstein et. al., 2002). Hence the absence of functional MMR proteins
significantly reduces the ability of cytotoxic agents to cause apoptosis. MMR protein
pro-apoptotic signalling can occur via stabilisation of the anti-apoptotic mediators
p53 (Luo et. al., 2004), or p73 (Shimodaira et. al., 2003). Furthermore, these studies
showed that p53 and p73 mediated apoptosis are dependent on MMR protein
expression. When overexpression of MSH2 or MLH1 protein is induced in repair
proficient or deficient cells, apoptosis is triggered, and in cells isolated from MSH2
null mice, the ability to undergo mutagen induced apoptosis is lost (Zhang et. al.,
1999).
In the colon epithelium (and elsewhere) induction of apoptosis is an essential
mechanism for maintaining normal tissue homeostasis and also preventing the clonal
expansion of cells with tumourigenic mutations. The role of MMR proteins in pro-
apoptotic signalling therefore provides an additional mechanism by which the
disruption ofMMR can increase susceptibility of cells to transformation. MSH2 null
mice (Msh2~'~) are predisposed to malignancy (Toft et. al., 1999). Although, mice
carrying a specific homozygous mutation in Msh2 (that attenuates mismatch repair
but not apoptosis signalling) are still highly prone to tumours, tumourigenesis occurs
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more slowly in comparison to MSH2 null animals (Lin et. al., 2004). This
experiment therefore proves that disruption of MMR does indeed promote
tumourigenesis by (at least) two mechanisms, i.e. attenuation of DNA repair and
DNA damage induced apoptosis signalling.
5.1.3. DNA mismatch repair protein regulation
Although much research has been carried out into the mechanisms by which MMR
proteins undertake DNA repair (discussed in Chapter 1), less information exists on
how the expression of these proteins is regulated. A confounding factor in defining
MMR protein regulation mechanisms is that a wide range of processes trigger
changes in MMR protein expression. At the transcriptional level, MMR protein
expression can be suppressed by hypoxia (Koshiji et. al., 2005), and in colon cancer
both by DNA methylation (Fang et, al., 2006) and Bcl-2 over expression (Youn et.
al., 2005). Whereas, increased transcription of MMR genes has been observed in
response to stimulated cell growth (Iwanaga et. al., 2004) and PKC activation
(Humbert et. al., 2003). Aspirin treatment also causes a marked upregulation of
MMR protein in vitro (Goel et. al., 2003).
At the post-translational level, phosphorylation of MMR proteins by PKCC induces
activation and nuclear translocation (Hernandez-Pigeon et. al., 2005). Ubiquitination
is an established mechanism for DNA repair protein regulation (Huang & Andrea,
2006), and MMR protein degradation can occur via ubiquitination initiated
proteosomal degradation (Hernandez-Pigeon et. al., 2004). However, this process is
blocked via PKCt, catalysed MMR protein phosphorylation (Hernandez-Pigeon et.
al., 2005). Additionally, MMR proteins achieve a degree of self-regulation, whereby
the expression of MSH2 and MLH1 dictate the level of MSH3, MSH6 and PMS2
protein (Chang et. al., 2000). Hence, in the absence of MSH2 protein, MSH3 and
MSH6 are not expressed, and without MLH1 protein, the expression of PMS2
protein is suppressed, despite the presence of PMS2 mRNA. Chang et. al. (2000)
also demonstrated that MSH2 (followed by MLH1) was the most abundant MMR
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protein in MMR proficient cells, further qualifying the importance of these two
proteins.
The half-life of MSH2 in human epithelial (HeLa) cells can be estimated by
extrapolating the results of Hernandez-Pigeon et. al. (2004) who studied the turnover
of MMR proteins by inhibiting de novo protein synthesis using cyclohexamine. It is
notable that MSH2 and MSH6 protein half-lives varied considerably between cell
lines. In HeLa cells MSH2 half-life can be estimated as approximately 80 hours and
the half-life of MSH6 approximately 30 hours. HeLa cells were the only epithelial
cell line tested, and expressed relatively high baseline levels of MMR protein. In
U937 (monocytic) cells and HL-60 (myelocytic) cells MSH2 half-life was 14 hours
and 8 hours respectively (Hernandez-Pigeon et. al., 2004).
5.1.4. Experimental evidence for the consequences of DNA MMR disruption
The rate of endogenous DNA damage is estimated to be from 104 - 106 damages per
cell, per day (Ames et. al., 1991; Holmquist, 1998), and reactive oxygen species are
thought to be a major causative factor in this process. Cells exposed to exogenous
genotoxic agents have much higher rates of damage (Bernstein et. al., 2002). Mouse
models using gene knockout techniques have proven that MMR disruption prevents
cells from dealing appropriately with DNA damage caused by endogenous and
exogenous stimuli, directly resulting in increased mutation rates and tumour
formation. Hence, mice heterozygous or homozygous for Mlhl gene knockout are
predisposed to gastrointestinal tumour formation, and generate tumours deficient in
Ape protein (Edelmann et. al., 1999). Tumour growth in response to X-ray radiation
is also enhanced by loss of Mlhl (Tokairin et. al., 2006). In Msh2 null mice,
spontaneous mutation frequency is 8 - 9 fold higher in all parts of the colon
compared to Msh2 competent mice (Zhang et. al., 2002). Consequently, the food
borne mutagen PhIP (2-amino-l-methyl-l-6-phenolimidazo[4,5-b]pyridine) induces
a significantly greater increase in mutation frequency in Msh2 null verses normal
mice (Zhang et. al., 2001). The methylating agent and mutagen DMH (1,2-
dimethylhydrazine) induces apoptosis of colonic epithelial cells dependant on Msh2
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expression, and accelerates the death of Msh2 null mice (versus Msh2 competent
mice) due to colorectal tumours and lymphomas (Colussi et. al., 2001).
Significantly, Msh2 knockout also enhances somatic mutation of Ape and p53 in
Apc^Mlhl'1' mice. Sohn et. al. (2003) report that Apc+l'Mlhl+/+ mice generate
tumours via Ape LOH, but in Apc+l'Mlhl'/' mice tumours originate via somatic
mutation of the remaining Ape allele (i.e. without LOH). Furthermore, 45% of
adenomas from Apc+/~Mlhr/~ mice carried p53 mutations, whereas Apc+l"Mlhl+/+
tumours did not carry this mutation. The authors conclude that Msh2 deficiency
causes a state of hypermutabilty. These results also suggest that somatic mutations
occur more rapidly than LOH as the cause ofApe gene silencing in Msh2 deficiency.
5.1.5. Mutation frequency analysis
Based on the link between MMR protein expression and mutation, the effect of
EPEC infection on mutation frequency was analysed. Mutation frequency can be
analysed in vitro by exposing cells to toxins that depend on the expression of specific
genes to trigger cell death. Mutation of these genes allows cells to survive toxicity;
hence the number of surviving cells indicates the number of cells that have acquired
mutations. In our initial mutation frequency experiments we used the toxin ouabain,
which causes cell death via blockade of Na+,K+-ATPase (Capella et. al., 2001). As
an alternative method for mutation frequency analysis we used inter-Alu PCR.
Repeated Alu sequences are scattered throughout the human genome and are
preferential targets of replication errors. When inter-Alu PCR products are resolved
through polyacrylamide gels 40-60 bands are detected. Inter-Alu PCR has been used
to detect changes in these repeated sequences in cancer patients; Krajinovic et. al.
(1996) compared DNA from normal tissue to DNA extracted from microsatellite
unstable tumours and found differences in 20% of bands. Changes in band signal
intensities were common, and loss or gain of bands also occurred, hence inter-Alu
PCR was able to detect the mutator phenotype in cancer cells.
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5.2. Results
5.2.1. Effect ofEPEC infection on MSH2 and MLH1 protein expression
Western blots revealed that the expression of MSH2 and MLH1 was reduced
considerably in HT29 cells (relative to actin and PCNA expression) after 9-12 hours
co-culture with wild-type EPEC (Figure 5.1a). In HT29 cells co-cultured with non-
AE mutant EPEC, MSH2 and MLH1 expression remained relatively strong after 9-
12 hours (Figure 5.1b). Removal of wild-type EPEC (by treatment with antibiotics)
subsequent to co-culture allowed MSH2 and MLE11 expression to return to pre-
infection levels after 36-39 hours (Figure 5.1c). As cell division does not occur until
after 48-60 hours of recovery (Section 3.2, Figure 3.1) it can be concluded that the
recovery of MHS2 and MLH1 expression cannot be accounted for by newly formed
daughter cells. Therefore, MSH2 and MLH1 protein downregulation is a reversible
consequence of intimate attachment ofEPEC to HT29 cells.
Western blots of SW480 cells showed that MSH2 and MLH1 expression was also
downregulated by wild-type EPEC infection (Figure 5.2a). The effects of EPEC on
LS513 cells were less pronounced: MSH2 expression remained strong after 9 hours
co-culture with wild-type EPEC, after 12 hours expression was reduced but
detectable. MLH1 expression was reduced but still detectable after 9 hours and
below detection after 12 hours (Figure 5.2b).
Immunofluorescent staining of E1T29 cells allowed analysis of changes in protein
expression in situ. In untreated HT29 cells, MSH2 and MLH1 staining was localised
to cell nuclei. Most nuclei showed intermediate staining intensity, some cells showed
very strong staining intensity and a small number of cells had no visible nuclear
stain. In mutant EPEC infected controls nuclear MSH2 and MLH1 staining showed a
similar pattern to uninfected controls, with most cells demonstrating intermediate
nuclear staining intensity. In cells infected with wild-type EPEC for 9 hours a shift
in staining pattern was observed; although most cells showed intermediate nuclear
staining, very few showed strong nuclear staining, with many more cells having no
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nuclear MSH2 or MLH1 signal compared to controls. After 12 hours co-culture with
wild-type EPEC no cells showed strong nuclear staining, a small number of cells
showed intermediate staining with almost all cells having no nuclear stain. Nuclear
expression of PCNA (western blot loading control) was retained by cells co-cultured
with wild-type EPEC, showing a small reduction after 12 hours (Figure 5.3). Similar
trends in MSH2, MLH1 and PCNA protein expression respectively were observed in
SW480 cells (Figure 5.4).
In order to more accurately quantify the observed changes in nuclear MSE12 and
MLH1 staining digital images of immunofluorescent stained HT29 cells were
analysed with image analysis software. In uninfected and 9 hours mutant infected
controls approximately 90% of cells displayed intermediate or strong nuclear MSE12
and MLH1 staining. However, after 9 hours co-culture with wild-type EPEC only
60-70% of cells had intermediate or strong staining. After 12 hours co-culture 75-
80% of mutant infected cells retained intermediate or strong nuclear staining for
MSH2 and MLH1, whereas in wild-type infected cells only 5% displayed
intermediate staining with all other cells showing no nuclear staining (Figure 5.5a,b).
As a positive control, nuclear PCNA signal was also analysed. In uninfected and
mutant infected controls PCNA staining showed a similar pattern to MSH2 and
MLH1 staining, with the vast majority of cells showing intermediate or strong
staining. Although a small reduction in positive cells was observed after 9 and 12
hours co-culture with wild-type EPEC, the reduction was far less than that seen for
MLH1 and MSH2. After 9 and 12 hours co-culture with wild-type EPEC, 72% and
64% of cells showed intermediate or strong PCNA staining respectively (Figure
5.5c). Immunofluorescent staining ofMLH1, MSH2 and PCNA was also performed
with SW480 cells co-cultured with mutant and wild-type EPEC. Image analysis
revealed the same respective trends in nuclear staining of these proteins. However, in
SW480 cells the downregulation of MSH2 and MLH1 protein expression was more
rapid compared to HT29 cells; i.e. approximately 95% of SW480 cells had no
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Figure 5.1. Western blots of HT29 cells co-cultured with EPEC. Cells were
either uninfected (-) or co-cultured with mutant (UMD864) or wild-type (E2348/69)
EPEC (a & b). Removal of EPEC by treatment with antibiotics for 39 -36 hours
(9h* & 12h* respectively) allowed cells to recover from infection (c). Whole cell
protein extracts were resolved through polyacrylamide gels and transferred to
PVDF membranes which were probed with primary and secondary antibodies.
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Figure 5.2. Western blots of other colorectal cell lines co-cultured with EPEC
SW480 (a) or LS513 (b) cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 - 12h. Whole cell protein extracts
were resolved through polyacrylamide gels and transferred to PVDF membranes
which were probed with primary and secondary antibodies. Cell culture & western
blot in (b) performed by Scott Bader.
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Figure 5.3. Immunofluorescence staining of mismatch repair proteins in HT29 cells
co-cultured with EPEC. Ceils were either uninfected (-) or co-cuitured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9-12 hours. Cells were stained for MSH2,
MLH1 (green) and PCNA (red), nuclei were counterstained with DAPI (blue). Images
used are representative of images used for quantitative image analysis. Original
magnification, x 40.
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Figure 5.4. Immunofluorescence staining of mismatch repair proteins in SW480
cells co-cultured with EPEC. Cells were either uninfected (-) or co-cultured with
mutant (UMD864) or wild-type (E2348/69) EPEC for 9-12 hours. Cells were stained for
MSH2 , MLH1 (green) and PCNA (red), nuclei were counterstained with DAPI (blue).
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Figure 5.5. Quantitative image analysis of immunostained HT29 cells. Digital
images of MSH2 (a), MLH1 (b) and PCNA (c) protein immunofluorescence staining
in HT29 cells co-cultured with EPEC were quantitatively analysed with IPlab®
software. Based on nuclear staining intensity values, cells were categorized as
having either very low (-), intermediate (+) or very strong (++) signal. Error bars
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Figure 5.6. Quantitative image analysis of immunostained SW480 cells. Digital
images of MSH2 (a), MLH1 (b) and PCNA (c) protein immunofluorescence staining
in HT29 cells co-cultured with EPEC were quantitatively analysed with IPlab®
software. Based on nuclear staining intensity values, cells were categorized as
having either very low (-), intermediate (+) or very strong (++) signal. Error bars
represent standard error of mean (n = 3).
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5.2.2. Effect of EPEC infection on cell death and relation to MLH1 expression
It was notable from DAPI staining that a change in nuclear morphology of some
HT29 cells occurred after infection with wild-type EPEC. This study therefore
investigated whether the effects of EPEC infection on MMR protein expression in
HT29 cells were associated with induction of apoptotic or necrotic mechanisms.
An in situ (TUNEL) cell death detection kit was used to identify cells undergoing
necrosis / late stage apoptosis. Images show that the majority of cells co-cultured
with EPEC for 9 or 12 hours were not apoptotic or necrotic (Figure 5.7). Counts
revealed that less than 1% of uninfected and mutant infected HT29 cells were
TUNEL positive. In cells co-cultured with wild-type EPEC for 9 and 12 hours, 3%
and 7% of cells were TUNEL positive respectively (Figure 5.8). This sub-population
of apoptotic cells was therefore far too small to co-segregate with cells showing
down-regulation of MMR proteins. Furthermore, images reveal that many cells
showing low or no nuclear MLH1 stain subsequent to EPEC infection were not
identified as apoptotic / necrotic (Figure 5.9).
Cells undergoing the early stages of apoptosis are not identified by TUNEL staining.
Cytochrome c staining was performed to identify cells committed to apoptosis but
not at a stage advanced enough for TUNEL detection. Immunofluorescent staining
of cytochrome c in uninfected control cells revealed strong punctate staining
localised to mitochondria (confirmed by MTC02 staining). Cells infected for 9 or
12 hours with wild-type EPEC also showed discrete cytochrome c distribution
localised to mitochondria. Cell treated with Etoposide for 2 hours acted as positive
controls for apoptosis and displayed diffuse cytochrome c staining, indicating the
release of mitochondrial contents, an early marker of commitment to apoptosis
(Figure 5.10). Simultaneous staining of MLH1 protein confirmed that MLH1
expression was downregulated in non-apoptotic cells subsequent to EPEC infection,
and that MLH1 expression remained strong in cells committed to apoptosis
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Figure 5.8. Quantification of in situ cell death in HT29 cells co-cultured
with EPEC. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC. Cells undergoing late stage
apoptosis / necrosis were identified using an in situ cell death (TUNEL)
detection kit and counted as a percentage of total cells (at least 300 cells




















Figure 5.9. In situ cell death detection and MLH1 expression in HT29
cells. Cells were either uninfected (-) or co-cultured with wild-type
(E2348/69) EPEC for 9-12h. Apoptotic / necrotic cells (red) were identified
with an in situ cell death (TUNEL) detection kit and stained for MLH1
(green). The immunostaining and image capture used in (b) were
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Figure 5.11. Co-immunofluorescence staining of caspase co-activator
cytochrome c and MLH1 in HT29 cells. Cells were either uninfected (-)
or co-cultured with wild-type (E2348/69) EPEC or treated with etoposide.
Cells were immunostained for cytochrome c (red) and MLH1 (green),
nuclei were counterstained with DAPI (blue). The immunostaining and
image capture used in this figure were performed under my supervision by
Abigail Short. Original magnification x 100.
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5.2.3. Effect of EPEC infection on mutation frequency in vitro
The consequences of MMR protein downregulation on the mutation frequency of
cells co-cultured with EPEC were investigated. It was hypothesised that cells
infected with wild-type EPEC would accumulate mutations (caused by endogenous
factors) at a greater rate than uninfected or mutant EPEC infected cells. In initial
mutation frequency experiments the toxin ouabain and HT29 cells were used. Firstly
a baseline mutation frequency rate was established (Table 5.1). Unfortunately,
repeated experiments (not shown) showed a wide variation in baseline mutation
frequency values. The observed variability was most likely due to the relatively low
mutation frequency of HT29 cells as detected by ouabain resistance, hence many
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Table 5.1. Calculating baseline mutation frequency in HT29 cells. Cells were seeded at
various densities and grown in the presence of ouabain for 12 days, surviving colonies were
stained with crystal violet and counted. Cells grown the absence (-) of ouabain (3 dishes)
were used to calculate the plating efficiency. Mutation frequency (mutants / million) was
calculated with the equation above.
Due to this baseline variability, inter-Alu PCR was employed as an alternative
method for mutation frequency analysis. For these experiments SW480 cells were
used, as MMR protein downregulation was seen to be more rapid in these cells
compared to HT29 cells. To test the reproducibility of this method repeat (n = 10)
inter-Alu PCR reactions on DNA isolated from three separate populations of cells
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were performed. Over 30 bands were detected, and band patterns were consistent
across all samples, indicating good reproducibility (Figure 5.12). Comparison of
PCR product bands from cells that were untreated or co-cultured with wild-type or
mutant EPEC did not reveal any overt differences in band pattern (Figure 5.13).
Hence there was no observable difference in mutation frequency between the
samples tested.
Uninfected 1 Uninfected 2 Uninfected 3
Figure 5.12. Inter-Alu PCR: method reproducibility. DNA was isolated from three flasks
of uninfected SW480 cells. Inter-Alu PCR (10 repeat reactions / flask) was performed.
Radiolabeled (P33) products were resolved through denaturing 6% polyacrylamide gels and
visualised by exposure of dried gels to radiographic film.
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Uninfected + mut EPEC + wt EPEC
Figure 5.13. Inter-Alu PCR mutation frequency analysis. Single flasks of SW480 cells
were either uninfected or co-cultured with mutant (+ mut EPEC) or wild-type EPEC (+wt
EPEC) for 12 hours. Cells were treated with antibiotics and allowed to recover from
infection, after reaching confluency, flasks were split into 10 new flasks and grown to
confluency. DNA was isolated from each flask and Inter-Alu PCR was performed.
Radiolabeled (P33) products were resolved through denaturing 6% polyacrylamide gels and
visualised by exposure of dried gels to radiographic film.
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5.3. Discussion
EPEC (E2348/69) was clearly able to cause a dramatic reduction in MSH2 and
MLH1 protein levels in colorectal cancer cell lines. The inability of mutant EPEC
(UMD864) to induce the same effects suggests that MMR downregulation is
mediated specifically via EPEC effector protein translocation and / or intimin
signalling. EPEC induced MMR protein downregulation was only detected (in HT29
cells) after 9 hours infection, demonstrating the value of an extended time-course co-
culture model. The ability of cells to recover MMR protein expression post-infection
further demonstrates that this was an EPEC specific effect, and that infection was not
overtly toxic. It was notable that in SW480 cells MMR protein downregulation was
more complete than in HT29 cells after 9 hours, implying that that this effect is more
rapid in SW480 cells. Conversely, in LS513 cells the effects of EPEC on MMR
proteins were less marked than in HT29 cells. The differences between cell types
could be due to differences in cell signalling / protein metabolism pathways; hence
further investigation could provide an insight into the mechanism of EPEC's effects.
In addition, SW480 cells show less features of differentiation (e.g. brush border) than
HT29 cells (Chantret et. al., 1988). The preferential binding ofEPEC to crypt cells in
ex vivo tissue (Chapter 4) suggests that EPEC has higher affinity for the surface of
undifferentiated cells. In addition, it is possible that HT29 and LS513 cells are
partially protected form EPEC adhesion by increased mucus secretion. LS513 cells
were derived from a mucus-secreting tumour, and in culture both HT29 and LS513
cells were observed to produce more secretions than SW480 cells.
There is overwhelming evidence that attenuated MSH2 and MLH1 protein
expression results in increased mutation frequency and reduced DNA damage
induced apoptosis (leading to enhanced colorectal tumourigenesis). Inter-Alu PCR
would be expected to detect mutations caused by disruption of MMR as Alu
sequences are microsatellite repeats susceptible to DNA replication errors normally
corrected by MMR. Despite establishing a reproducible inter-Alu PCR assay, no
change in mutation frequency due to EPEC infection was detected. This was either
because no increase in mutation frequency occurred, or because the method used was
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not sensitive enough. Mutations caused by endogenous factors (e.g. DNA
polymerase slippage) occur most frequently during DNA replication (prior to cell
division). As very little cell division occurred during the period in which MMR
protein was downregulated (i.e. between 9-12 hours of infection and during some of
the recovery period) it is unlikely that many mutations would have occurred. In vivo,
EPEC induced MMR downregulation would have greater potential to increase
mutation frequency due to the presence of exogenous (e.g. food borne) mutagens.
Also, infection of individual cells by EPEC in vivo could occur over a chronic period
(i.e. days), extending the time period over which MMR protein is downregulated.
Therefore, future mutation frequency analysis experiments could include the addition
of mutagens (such as PhIP or DMH), or use repeated infections (on the same
population of cells) to more closely replicate in vivo conditions.
Inter-Alu PCR provided highly reproducible results, a key requirement in mutation
frequency analysis experiments. Hence further use of this method (in conjunction
with the modifications stated above) in detecting mutations due to MMR disruption
could be made. Alternative (and potentially more sensitive) mutation frequency
analysis techniques could also be employed. One such method involves transfecting
a DNA plasmid (containing microsatellite repeats) into cells and then after several
days, extracting the plasmid to check for mutations (Diem & Runger, 1998).
Insertion of plasmids containing mismatched bases and a fluorescent reporter has
been used to measure DNA mismatch repair capability in live cells (Lei et. al.,
2004). It would also be interesting to evaluate EPEC induced mutation in cells
deficient in DNA repair (e.g. HCT116 cells lacking MLH1). This could replicate the
effect of EPEC infection on an individual carrying MMR gene mutation(s).
It was notable that the nuclei of cells infected with wild-type EPEC often showed
altered nuclear DNA staining compared to uninfected or mutant EPEC infected cells.
Cells undergoing apoptosis display changes in nuclear morphology and DNA
organisation. These changes result from the activation of DNAse enzymes that
cleave DNA during apoptosis. Activation of protease enzymes (such as caspases)
also occurs during apoptosis. These enzymes degrade proteins (e.g. DNA repair
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proteins) that, by their normal action, oppose apoptotic changes (i.e. DNA damage)
(Bernstein et. al., 2002). In cancer cells treated with etoposide to induce apoptosis,
MLH1 is proteolysed by caspase-3 (Chen et. al., 2004). The literature reports pro-
and anti-apoptotic responses to EPEC infection in vitro, however, this study uses a
longer time-course co-culture model than those used previously. Therefore it was
possible that EPEC induced MMR protein degradation in this model was caused by
induction of pro-apoptotic mechanisms leading to DNA cleavage and proteolysis of
MMR proteins.
To identify cells undergoing late stage apoptosis or necrosis, a cell death detection
kit designed to label DNA strand breaks was used. Results show that although cells
infected with wild-type EPEC displayed higher levels of cell death than control cells,
only a small fraction (3-7%) of the infected cells tested positive for cell death. These
results therefore demonstrate that EPEC induced MMR protein downregulation was
not a non-specific consequence of apoptosis or necrosis. Nuclear and DNA
alterations caused by EPEC infection have previously been reported, and were
attributed to disruption of the cell cycle rather than apoptosis (Marches et. al., 2003).
This study (i.e. the results of this chapter and chapter 3) therefore support these
findings. It has been claimed that these nuclear 'cytopathic' effects of EPEC are non¬
reversible (Nougayrede et. al., 2001), however this study shows that cells are not
irreversibly damaged by EPEC infection. The relationship between EPEC infection,
cell cycle arrest, DNA changes and apoptosis therefore requires further investigation.
As a marker of early apoptosis cytochrome c distribution was analysed. Early in the
execution of apoptosis, a multimeric complex of dATP, Apaf-1 and cytochrome c
(termed the apoptosome) is formed. This complex activates caspase-9, which causes
the downstream activation of caspase-3, leading to proteolysis (reviewed by
Bernstein et. al., 2002). In order to join the apoptosome, cytochrome c must first be
released from the mitochondria. In cells co-cultured with or without EPEC,
cytochrome c distribution was limited to mitochondria; indicating cells had not
entered early apoptosis. Furthermore, treatment of cells with etoposide (to induce
apoptosis) did not cause MLH1 degradation but did cause cytochrome c release,
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demonstrating that apoptotic MLH1 cleavage takes time to occur even when
apoptosis has been initiated.
As it has been established that EPEC did not cause MSH2 and MLH1
downregulation via non-specific apoptotic effects, it is important to consider the
mechanism by which this change occurred. As previously mentioned, MMR protein
regulation can occur by a variety of transcriptional and post-translational pathways.
Microarray analysis has revealed that EPEC infection suppressed MSH2 and MLH1
expression (chapter 3). Suppression of MSH2 has been observed in cancer cells via
inhibition of the transcription factor E2F by Bcl-2 (Youn et. al., 2005). In order to
become active, Bcl-2 requires phosphorylation (Ito et. al., 1997), a task carried out
by mitochondrial PKCa (Ruvolo et. al., 1998). EPEC increases membrane bound
PKCa activity and the PKCa content of cancer cell membranes (Crane & Oh, 1997).
It is therefore possible that EPEC induced activation of PKCa leads to Bcl-2
activation, followed by suppression ofMMR protein transcription.
In support of this proposed mechanism, microarray analysis revealed a 2.6 fold
increase in PKCa expression, and an 11.0 fold increase in the expression of the
PKCa activator endothelin-2 in response to EPEC infection. The rapidity and extent
of EPEC's effects on MSH2 and MLH1 strongly suggest that degradation of protein,
as well as transcriptional silencing has a role in MMR protein downregulation in this
model. This is certainly true if the half-life of MSH2 in HT29 and SW480 cells is
similar to that in HeLa cells. The homology between mammalian and bacterial MMR
proteins is well established, and it has been demonstrated that human MLH1
interacts with bacterial MutS and MutL proteins when expressed in E. coli,
subverting their function (Quaresima et. al., 2003). This raises the possibility that
E. coli secreted proteins are able to directly interact with MMR proteins to influence
their expression.
Bcl-2 can mediate anti-apoptotic effects by preventing mitochondrial cytochrome c
release (Yang et. al., 1997; Kluck et. al., 1997), and is overexpressed in many
cancers. Although it has been previously reported that EPEC infection induces
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cytochrome c release from mitochondria via EspF signalling (Nougayrede &
Donnenberg, 2004), this did not occur in the present study. Therefore, EPEC induced
activation of Bcl-2 also provides a mechanism to support the failure of EPEC to
induce cytochrome c release in our experiments. The lack of widespread apoptosis in
response to EPEC could also be a feature of MMR protein downregulation itself, as
induction of apoptosis can be dependent on MMR protein expression (Luo et. al.,
2004; Shimodaira et. al., 2003; Zhang et. al., 1999). Prevention ofMMR protein pro-
apoptotic signalling could in fact be main advantage of MMR protein
downregulation to EPEC.
The ability of EPEC to cause a reduction in MSH2 and MLH1 protein is a potentially
significant finding, as it provides a direct link between EPEC infection and
molecular aberrations known to be a causative factors in the development of
colorectal cancer. If this in vitro effect is also able to manifest itself during in vivo
infection, EPEC has the potential to increase mutation frequency and suppress DNA
damage induced apoptosis in the colonic epithelium. These changes would strongly
predispose infected epithelial cells to the effects of exogenous mutagens and
therefore tumourigenesis.
The key aim of further work would therefore be to establish whether EPEC induces
MMR protein downregulation in human tissue. Use of the ex vivo model established
in this study could be used for this purpose. The mechanism of EPEC induced MMR
protein downregulation may be complex due to the variety of pathways potentially
involved. Establishing the normal half-life ofMSH2 and MLH1 in HT29 and SW480
cells would help to reveal whether transcriptional or post-translational mechanisms
dominate the regulation of these proteins. Also, using proteosome inhibitors during
EPEC infection could reveal whether EPEC induces active proteolysis ofMSH2 and
MLH1. Quantitative real-time PCR could be used to confirm the MMR gene
expression results generated by microarray analysis. It is important to consider that
elucidating the mechanism of EPEC induced MMR protein downregulation is less
important than establishing whether these effects occur in vivo (though the former
may assist in the latter); as EPEC's effects can be prevented without any knowledge
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of the mechanism, simply by eradicating the bacteria. The finding that Aspirin
induces MMR protein upregulation could partly explain its protective effect from
colorectal cancer. Hence it would be interesting to know whether Aspirin can inhibit




Effect of EPEC infection on the expression of (3-catenin, cell-cell adhesion
and cytoskeletal proteins in vitro.
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6.1 Introduction
6.1.1. p-catenin signalling and distribution
The majority of colorectal cancers, at some point in their development, gain
mutations of the APC gene. Inactivating APC mutations prevent phosphorylation
and ubiquitination of (3-catenin, resulting in cytoplasmic (3-catenin accumulation and
activation of oncogenic Wnt target genes. In vitro EPEC infection has been shown to
alter (3-catenin distribution (from the plasma membrane to the cytoplasm) after 3
hours (Malladi et. al., 2004). It was hypothesised that intimate attachement of EPEC
to human colonic epithelial cells could increase susceptibility to cancer by promoting
|3-catenin signalling in the in vitro model. Hence, an aim of this study was to analyse
the effect of EPEC on the expression (3-catenin and its associated adhesion proteins
in HT29 and SW480 cells after 9-12 hours infection.
Bacterial activation of (3-catenin has been previously reported in HeLa and T84 cells
infected with Salmonella typhimurium. Sun et. al. (2004) found that cells infected
with a non-pathogenic S. typhimurium displayed nuclear accumulation of (3-catenin
and activation of |3-catenin/TCF signalling, leading to enhanced cell proliferation.
This effect was shown to occur via inhibition of (3-catenin ubiquitination, and be
dependent on the S. typhimurium secreted effector protein AvrA. Hence a link
between bacterial attachment and insertion of effector molecules with a pathway
central to tumourigenesis within the human intestine has been established.
Investigation of EPEC induced disruption of cell-cell adherens junctions in Caco-2
cells has revealed that wild-type EPEC caused dissociation of E-cadherin from
(3-catenin (Malladi et. al., 2004). This dissociation was a result of PKCa activation
and contributes to EPEC induced epithelial barrier disruption. A potentially more
important consequence of EPEC induced adherens junction breakdown is the
subsequent release of (3-catenin into the cytoplasm, with potential to initiate
oncogenic Wnt signalling pathways. Indeed, after 3 hours EPEC infection (3-catenin
was shown to translocate from the plasma membrane to the cytoplasm, however,
downstream Wnt signalling was not investigated (Malladi et. al., 2004).
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6.1.2. [3-catenin associated proteins
In addition to the effects caused by (3-catenin signalling, disruption of adherens
junctions has the potential to induce other tumourigenic effects. Within adherens
junctions, catenins (including a- catenin, (3-catenin and y-catenin) anchor E-cadherin
to actin fdaments of the cytoskeleton (Alberts et. al., 2002). Downregulation of the
E-cadherin/catenin/cytoskeleton complex is a common finding in cancer, and is
thought to be a key step in the transition to an invasive i.e. malignant phenotype
(Mareel et. al., 1997). Suppression of E-cadherin expression is observed in gastric
and other cancers, it has been proposed that loss of E-cadherin mediated cell-cell
adhesion is essential for tumour cell invasion and metastasis formation (reviewed by
Chan, 2006). y-catenin (also known as plakoglobin) is structurally related to, and has
similar functions in signalling and cell-cell adhesion as [3-catenin (Peifer et. al.,
1992). y-catenin is found in association with cadherins in both cell-cell desmosomes
and adherens junctions (Alberts et. al., 2002). Functional loss of y-catenin has been
implicated in the development of prostate, lung and bladder cancer (Shiina et. al.,
2005; Winn et. al., 2002; Syrigos et. al., 1998). Unlike adherens junctions,
desmosomes connect intracellularly to intermediate fdaments (Alberts et. al., 2002),
a cytoskeletal network also modulated by EPEC infection (reviewed by Caron et. al.,
2006).
Another molecule tasked with anchoring the cytoskeleton to the plasma membrane is
ezrin. Ezrin interacts with both E-cadherin and (3-catenin, and has been found to
regulate cell-cell and cell-matrix adhesion (Hiscox & Jiang, 1999). Suppression of
ezrin expression in colorectal cancer cells causes reduced cell-cell adhesion and gain
in motile and invasive behaviour (Hiscox & Jiang, 1999). In vitro EPEC infection
causes activation (via phosphorylation) of ezrin, increasing ezrin association with the
cytoskeleton, resulting in tight junction disruption after 3 hours (Simonovic et. al.,
2001). Goosney et. al. (2001) report that ezrin is recruited to EPEC induced
pedestals, hence it is probable that ezrin has a function in the anchorage of
cytoskeletal components to the plasma membrane within these structures. Despite
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causing re-distribution and phosphorylation of ezrin, the total cellular concentration
of ezrin is unchanged after (5 hours) co-culture with EPEC (Simonovic et. al., 2001).
The effects of EPEC attachment on actin are well known; high concentrations of
cytoskeletal actin are a prominent feature ofAE lesions (Knutton et. al., 1989; Finlay
et. al., 1992). It is possible that some of the actin accumulated in AE pedestals is
remodelled from microvilli that have been effaced. Also, actin that has dissociated
from adherens junctions (via EPEC induced effects on catenins and ezrin) could
contribute to pedestals. The actin cytoskeleton plays a key role in the regulation of
many cellular processes, including migration, locomotion, cytokinesis and cell
polarity (Caron et. al., 2006). It has been proposed that disruption of the actin
cytoskeleton within intestinal epithelial cells could prevent normal cell migration
within the crypt, and that this could be a uniquely important mechanism of tumour
formation in gut tissue (Nathke, 2006).
The carcinogenic bacterium Helicobacterpylori has recently been found to influence
cell-cell adhesion pathways in gastric cells. H. pylori induces scattering of cultured
gastric epithelial cells, an effect related to disruption of E-cadherin / catenin
containing adherens junctions, and dependent on insertion of the effector molecule
CagA (Suzuki et. al., 2005). In rat gastric epithelium oncogenic H. pylori caused
CagA dependent (3-catenin activation, and nuclear accumulation of (3-catenin was
observed in gastric epithelium from humans infected with Cag+ but not Cag"
H. pylori (Franco et. al., 2005). In vitro co-culture experiments have demonstrated
disruption of epithelial junctional [3-catenin expression (without nuclear
accumulation) in response to pathogenic H. pylori, but independent of Cag (Bebb et.
al., 2006). CagA has also been shown to physically interact with E-cadherin, thus
impairing (3-catenin / E-cadherin complexation, resulting in nuclear and cytoplasmic
(3-catenin accumulation (Murata-Kamiya et. al., 2007).
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6.2. Results
6.2.1. Effect of EPEC on |3-catenin expression in vitro
Western blots of HT29 cells show that wild-type EPEC infection clearly caused a
downregulation in the expression of |3-catenin after 9 or 12 hours co-culture
(Figure 6.1a). It was notable that |3-catenin expression was also reduced (but by a
lesser degree) in uninfected washed control cells (-, 12h) and mutant EPEC infected
cells versus uninfected, untreated control cells (-, Oh). This suggests that the
experimental protocol may have influenced [3-catenin expression in this instance.
Immunofluorescent staining of HT29 cells also demonstrated that wild-type EPEC
infection caused |3-catenin downregulation (Figure 6.1b). In uninfected and mutant-
EPEC infected cells, (3-catenin was located at the periphery of cells in the plasma
membrane. Co-culture with wild-type EPEC for 9 hours resulted in reduced
peripheral |3-catenin expression, with some staining seen in the cytoplasm, and after
12 hours co-culture, no peripheral |3-catenin expression was detected, although some
low level nuclear staining was observed, but may have been due to background.
Using an antibody for non-phosphorylated |3-catenin (targeted to the N-terminal)
produced similar results to the C-terminal antibody (described above). Thus
demonstrating the absence of significant levels of phosphorylated [3-catenin in either
infected or uninfected cells (Figure 6.2a,b).
Western blots of SW480 cells co-cultured with EPEC revealed the same trends in
|3-catenin expression: while cells co-cultured with mutant EPEC retained (3-catenin
expression, wild-type EPEC infection caused a clear reduction in expression (Figure
6.3a). There is also little difference in [3-catenin detection between C-terminal and N-














Figure 6.1. Total p-catenin expression in HT29 cells co-cultured with EPEC. Cells
were either uninfected (-) or co-cultured with mutant (UMD864) or wild-type (E2348/69)
EPEC for 9-12 hours. Western blots were performed on whole cell protein extracts and
probed with an anti-p-catenin C-terminal antibody (a). Fixed cells were immunostained















Figure 6.2. Non-phosphorylated p-catenin expression in HT29 cells co-cuitured
with EPEC. Cells were either uninfected (-) or co-cultured with mutant (UMD864) or
wild-type (E2348/69) EPEC for 9 -12 h. Western blots were performed on whole cell
protein extracts and probed with a anti-non-phosphorylated p-catenin (NP) antibody (a).
Fixed cells were immunostained with the same antibody (green), nuclei were counter
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Figure 6.3. p-catenin expression in SW480 cells co-cultured with EPEC. Cells
were either uninfected (-) or co-cultured with mutant (UMD864) or wild-type
(E2348/69) EPEC for 9 -12 h. Western blots were performed on whole cell protein
extracts and probed with anti-p-catenin (c-terminal) (a) or with a anti-non-
phosphorylated p-catenin (NP) antibody (b).
6.2.2 Effect of EPEC on y-catenin expression in vitro
Western blots show that y-eatenin expression was also reduced after co-culture of
HT29 cells with wild-type EPEC. In mutant EPEC infected cells, y-catenin
expression was strong after 9 hours (possibly showing increased expression) and
remained comparable to uninfected cells after 12 hours (Figure 6.4a). Like
P-catenin, y-catenin is also expressed in the periphery of epithelial cells. As with
P-catenin, immunofluorescent staining of y-catenin revealed a loss of peripheral
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expression after 12 hours co-culture with wild-type EPEC, with possible residual
nuclear expression (Figure 6.4b). Images show that cells infected with mutant EPEC















Figure 6.4. y-catenin expression in HT29 cells co-cultured with EPEC. Cells were
either uninfected (-) or co-cultured with mutant (UMD864) or wild-type (E2348/69) EPEC
for 9 -12 h. Western blots were performed on whole cell protein extracts and probed
with anti-y-catenin (a). Fixed cells were immunostained with anti-y-catenin (green),
nuclei were counter stained with DAPI (blue) (b). Original magnification x 100.
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6.2.3 Effect of EPEC on E-cadherin expression in vitro
Based on expression of the loading controls actin and PCNA, western blots of HT29
cells co-cultured with EPEC show that unlike y-catenin and (3-catenin, expression of
E-cadherin remains relatively constant under all experimental conditions, except
perhaps after 9 hours co-culture with wild-type EPEC (Figure 6.5a). E-cadherin
expression is potentially increased in HT29 cells. In cells co-cultured with mutant
EPEC, E-cadherin expression levels are similar to the levels seen in uninfected
controls. E-cadherin expression in SW480 cells was too low to detect via western
blot.
Immunofluorescent staining of HT29 cells gave a more accurate picture of
E-cadherin expression and allowed comparison of E-cadherin distribution with the
location of adherent EPEC. Images of E-cadherin expression and EPEC location
were taken in both the nuclear plane (middle - base of cell) and the apical plane
(surface of cell) and at high (x 100), medium (x 40) and low (x 16) magnification.
High magnification images in the nuclear focal plane show that E-cadherin is
strongly expressed in the periphery (i.e. plasma membrane) of uninfected cells where
adjacent cells meet (Figure 6.5b). Co-culture with mutant EPEC for 9 hours had
little effect on E-cadherin expression. However, after 12 hours with mutant EPEC,
the E-cadherin distribution was disrupted so that instead of continuous, uniform
peripheral expression, E-cadherin is present in small discrete spots within the
membrane. In HT29 cells co-cultured with wild-type EPEC for 9 hours, E-cadherin
expression was similar to that seen in uninfected cells, however, in some areas,
strong E-cadherin expression potentially co-localised with EPEC. After 12 hours co-
culture with wild-type EPEC, peripheral expression of E-cadherin was seen in most
cells. However, peripheral expression is lower than in uninfected cells and
expression was also detected in the cytoplasm and in discrete nuclear regions of
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Figure 6.5. Co-localisation of E-cadherin and E .coli in HT29 cells co-cultured
with EPEC: Nuclear x 100. Cells were either uninfected (-) or co-cultured with
mutant (UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Western blots were
performed on whole cell protein extracts (a). Fixed cells were immunostained for
E-cadherin (green) and E. coli (red), nuclei were counter stained with DAPI (blue) (b).
Arrow heads indicate areas of nuclear E-cadherin accumulation. Nuclear focal plane,
original magnification x 100.
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Figure 6.6. Co-localisation of E-cadherin and E .coli in HT29 cells co-cultured
with EPEC: Apical x 100. Cells were either uninfected (-) or co-cultured with
mutant (UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for E-cadherin (green) and E. coli (red), nuclei were counter
stained with DAPI (blue) (b). Apical focal plane, original magnification x 100.
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Figure 6.7. Co-localisation of E-cadherin and E .coli in HT29 cells co-cultured
with EPEC: Nuclear x 40. Cells were either uninfected (-) or co-cultured with
mutant (UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for E-cadherin (green) and E. coli (red), nuclei were counter stained
with DAPI (blue). Nuclear focal plane, original magnification x 40.
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Figure 6.8. Co-localisation of E-cadherin and E .coli in HT29 cells co-cultured
with EPEC: Apical x 40. Cells were either uninfected (-) or co-cultured with
mutant (UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for E-cadherin (green) and E. coli (red), nuclei were counter
















Figure 6.9. Co-localisation of E-cadherin and £ .coli in HT29 cells co-cultured
with EPEC: x 16. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Original magnification x 16.
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High magnification images in the apical focal plane show E-cadherin localised to
sites of EPEC adherence (Figure 6.6). In uninfected cells E-cadherin is expressed
diffusely at the apical surface of cells, with stronger staining at cell boundaries. Co-
culture with mutant EPEC for 9 hours had little effect on E-cadherin distribution,
however, after 12 hours patches ofmutant EPEC (attached by "localised adherence")
co-localise with strong E-cadherin expression. Evidence of E-cadherin-EPEC co-
localisation was also seen after co-culture with wild-type EPEC, particularly after 9
hours.
Images taken at intermediate magnification also show EPEC induced disruption of
E-cadherin expression in nuclear focal plane (Figure 6.7), and accumulation of
E-cadherin where adherent EPEC were detected in the apical focal plane (Figure
6.8). When viewed at low magnification, the accumulation of E-cadherin at sites of
EPEC adherence is clear, particularly in mutant infected cells where discrete colonies
of EPEC correspond to the sites of highest E-cadherin expression (Figure 6.9). In
cells co-cultured with wild-type EPEC for 12 hours it is more difficult to discern co-
localisation due to widespread EPEC staining, however, overall E-cadherin
expression is seen to be strong.
6.2.4. Effect of EPEC on Ezrin expression in vitro
Western blots show that in HT29 cells, ezrin expression was reduced after co-culture
with wild-type but not mutant EPEC (Figure 6.10a). However, unlike (3-catenin and
y-catenin expression, the reduction was relatively small, and ezrin was still expressed
in HT29 cells (at approximately equal levels) after 9 and 12 hours co-culture.
Western blots demonstrated that co-culture of wild-type EPEC with SW480 cells
also resulted in reduction of ezrin expression (Figure 6.10b). However, in SW480
cells the reduction in ezrin appeared to be more severe as expression was below
levels of detection. This difference may be accounted for by the relatively low
expression of ezrin in SW480 cells compared to HT29 cells. Immunostaining of
HT29 cells for ezrin was unsuccessful due an apparent lack of affinity of the
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Figure 6.10. Ezrin expression in human colorectal cells co-cultured with EPEC.
HT29 (a) or SW480 (b) cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Western blots were performed
on whole cell protein extracts and probed for ezrin.
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6.2.5. Effect of EPEC on actin expression in vitro
Actin, in the form of filamentous actin (F-actin) is known to accumulate at the apical
membrane where EPEC adheres to cells. Elaving used actin as a loading control for
western blots we wished to confirm the effects of EPEC infection on actin expression
in situ. In the nuclear focal plane of uninfected HT29 cells, actin was expressed in
the cytoplasm and at the periphery of cells. Although, actin expression was quite
evenly distributed, some small spots of high expression were visible. After infection
with mutant EPEC for 9 and 12 hours, actin continues to be expressed within the
cytoplasm; however, its distribution was more granular than seen in uninfected cells.
In cells infected with wild-type EPEC, actin expression was more diffuse than in
control cells, with several relatively large, very strong spots of expression (Figure
6.11). In the apical focal plane, accumulation of actin at sites of mutant and wild-
type EPEC adherence was evident. However, wild-type EPEC induced much larger
and more concentrated spots of actin than mutant bacteria (Figure 6.12).
Intermediate magnification images of HT29 cells clearly show that in wild-type
EPEC infected cells actin expression was reduced in the nuclear focal plane,
particularly after 12 hours co-culture (Figure 6.13). However, in the apical focal
plane actin is highly expressed in wild-type infected cells and is distributed in highly
concentrated spots, which are likely to correspond with adherent EPEC (Figure
6.14). Low magnification images of co-cultured cells support the ability of EPEC
infection to cause actin remodelling but also show that overall expression levels are
similar in uninfected, mutant EPEC infected and wild-type EPEC infected cells
(Figure 6.15). Therefore the use of actin as a loading control for western blots is
justified.
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Figure 6.11. Co-localisation of actin and E .coli in HT29 cells co-cultured with
EPEC: Nuclear x 100. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Nuclear focal plane, original magnification x 100.
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Figure 6.12. Co-localisation of actin and E .coli in HT29 cells co-cultured with
EPEC: Apical x 100. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Apical focal plane, original magnification x 100.
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Figure 6.13. Co-localisation of actin and E .coli in HT29 cells co-cultured with
EPEC: Nuclear x 40. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Nuclear focal plane, original magnification x 40.
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Figure 6.14. Co-localisation of actin and E .coli in HT29 cells co-cultured with
EPEC: Apical x 40. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 9 -12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Apical focal plane, original magnification x 40.
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Figure 6.15. Co-localisation of actin and E .coli in HT29 cells co-cultured
with EPEC: x 16. Cells were either uninfected (-) or co-cultured with mutant
(UMD864) or wild-type (E2348/69) EPEC for 12 h. Fixed cells were
immunostained for actin (green) and E. coli (red), nuclei were counter stained with
DAPI (blue). Original magnification x 16.
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Protein
(3-catenin Y-catenin E-cadherin Ezrin Actin
HT29 cells 1 1 11** ~/i
SW480 cells 1 ND ND 1
Table 6.1. EPEC induced changes in protein expression: results summary. Changes in
protein expression in response to wild-type EPEC infection in HT29 and SW480 cells.
Y-catenin and E-cadherin were not detected (ND) in SW480 cells.
6.3. Discussion
EPEC E2348/69 clearly downregulated total (3-catenin expression in HT29 and
SW480 cells after 9-12 hours co-culture. Images also suggest that redistribution of
(3-catenin (from the periphery to the cytoplasm) may have occurred, particularly after
9 hours. EPEC UMD864 also influenced (3-catenin expression, but to a lesser degree
than the wild-type bacteria, causing a reduction in expression most notable after 12
hours co-culture. Canonical (3-catenin degradation involves serine/threonine
phosphorylation at its amino terminal (catalysed by glycogen synthase kinase-3|3
complexed with APC and axin), followed by ubiquitination and proteosomal
degradation (reviewed by Kolligs et. al., 2002). Using different antibodies we
determined that the vast majority of (3-catenin (in uninfected and infected HT29
cells) was in a non-phosphorylated form, this is a logical finding as phosphorylated
(3-catenin is rapidly degraded and is hardly detectable (1-2% of total (3-catenin) in
normal cultured cells (Sadot et. al., 2002).
These results therefore fit the canonical model of (3-catenin degradation as the
mechanism for EPEC induced (3-catenin downregulation. However, like most colon
cancer cells, both HT29 and SW480 cells carry mutations in their APC genes.
Consequently both cell lines express truncated APC protein and have reduced
(3-catenin degradation ability compared to normal cells (Sadot et. al., 2002). Hence it
is possible that EPEC induced (3-catenin degradation in these cells is supplemented
by additional mechanisms. EPEC induced PKCa activation (Crane & Oh, 1997) has
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the potential to fulfil this role. Breast cancer cells over-expressing of PKCa have
reduced (3-catenin stability (Williams & Noti, 2001). Furthermore, chemical
activation of PKCa results in amino-terminal serine phosphorylation and degradation
of [3-catenin in vitro (Gwak et. al., 2006), although this is presumably via the APC-
Axin-GSK-3|3 pathway. In HT29 cells, y-catenin expression changed in response to
EPEC infection in a similar way to (3-catenin expression. After 9 hours infection with
wild-type EPEC, y-catenin expression was reduced to roughly half the control levels,
and by 12 hours, expression was virtually undetectable. Whereas, cells infected with
mutant EPEC retained strong y-catenin expression. This is unsurprising considering
the structural and functional similarities between y-catenin and (3-catenin. y-catenin
contains a glycogen synthase kinase-3|3 consensus motif phosphorylation site (Shiina
et. al., 2005), suggesting its degradation occurs via the same pathways as (3-catenin.
Hence EPEC induced degradation of y-catenin may well occur via the same
pathways as (3-catenin.
In contrast to catenins, E-cadherin expression was unchanged or even upregulated
after 9 hours co-culture with EPEC. This response was unexpected as EPEC is
observed to cause a reduction in cell-cell adhesion, usually a feature of E-cadherin
downregulation. That elevated levels of E-cadherin were observed in cells showing
reduced cell-cell adhesion can be explained by the inability of E-cadherin to function
properly in the absence of (3-catenin (and possibly y-catenin). That is, without
(3-catenin, the cytoplasmic domain of E-cadherin is unstructured and does not link to
the cytoskeleton (Huber et. al., 2001). It is possible that increased E-cadherin
expression was triggered in infected cells as an attempt to overcome loss of cell-cell
adhesion. It was notable that E-cadherin accumulated in the apical plane of cells at
sites ofwild-type and mutant EPEC adherence, this suggests E-cadherin could play a
role in non-intimate attachment of EPEC. Listeria monocytogenes is a human enteric
pathogen that adheres to the intestinal epithelium via E-cadherin binding.
L. monocytogenes uses E-cadherin as a receptor for the bacterial protein internalin,
which is required for entry of the bacteria into epithelial cells (Mengaud et. al.,
1996). Though EPEC is generally accepted not to enter cells, it is possible that
E-cadherin could be involved in surface adherence ofEPEC.
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Although wild-type EPEC induced a reduction in ezrin expression in HT29 cells and
SW480 cells, this reduction was not as marked in HT29 cells as with catenin
expression. Hence, ezrin expression was retained in HT29 cells after 9-12 hours co-
culture with EPEC, but was below detection in SW480 cells. EPEC infection has
been shown to activate ezrin via phosphorylation in human intestinal epithelial (T84)
cells, without reducing overall expression (Simonovic et. al., 2001). It is possible
that in our extended time-course model degradation of ezrin occurs subsequent to
phosphorylation. The difference between the two cell lines may be a consequence of
divergent cell signalling pathways in these cell lines. Alternatively the apparent
difference in mucus secretion by these cell lines (HT29 cells were observed to
release more mucus than SW480 cells) may account for a protective effect in HT29
cells, as with MMR protein changes (Chapter 5).
EPEC infection undoubtedly had marked effects on actin distribution within HT29
cells, causing actin condensation at sites of EPEC attachment, without changing its
overall expression. These results correlate with the fluorescent staining test results,
which utilised phalloidin to stain actin in EPEC induced pedestals (Chapter 3). This
was expected, as actin rearrangement is a fundamental feature of EPEC attachment
(Knutton et. al., 1989; Finlay et. al., 1992). Preservation of actin expression can
therefore be viewed as an important strategy for EPEC pathogenesis. These finding
help to further characterise the pathways involved in EPEC induced loss of cell-cell
and cell-lamina adhesion, contributing to epithelial barrier disruption.
Although actin rearrangement and disruption of cell-cell adhesion are beneficial to
EPEC, the consequences to the host cells should also be considered. The literature
suggests that EPEC infection could promote carcinogenesis by causing cytoplasmic
accumulation of (3-catenin, leading to the activation of Wnt target genes. However,
this study shows that after 9-12 hours infection, EPEC in fact caused a marked
downregulation of (3-catenin. Therefore, in terms of the canonical Wnt/APC pathway
of colonic tumourigenesis, this change should prevent rather than promote cancer.
However, as (3-catenin is a multi-functional molecule its downregulation may
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promote tumourigenesis via another pathway, i.e. cell-cell adhesion. Although
downregulation of adhesion proteins is usually associated with advanced tumours,
changes in these proteins within the normal colon could also be related to
tumourigenesis.
A recent review draws attention to the role of the actin cytoskeleton in cells
migrating within the intestinal epithelium, suggesting that disturbance of cell
architecture could prevent normal migration (Nathke, 2006). The rapid turnover of
cells within the intestinal epithelium protects from tumourigenesis by ejecting cells
before they have a chance to accumulate sufficient mutations to become cancerous.
Retardation of cellular migration within the crypt would have the potential to extend
the life of cells within the relatively toxic environment of the gut, providing a greater
chance for mutations to accumulate, and also potentially expose cells to
inappropriate cues. Hence, it is "mandatory that any event that can induce tumours
has to include a 'brake' to allow cells to remain in the tissue" (Nathke, 2006).
Aberrant expression of adhesion proteins is also likely to perturb migration, as cell-
cell signalling via direct contact would be interrupted. The ability of cells to organise
their distribution based on surface protein expression is illustrated by cadherin
dependent cell sorting. Cells are able to arrange themselves either based on
expression of different forms of cadherin (e.g. E-cadherin versus N-cadherin), or
based on expression levels of the same cadherin (e.g. low versus high E-cadherin
expression) (Alberts et. al., 2002). This study shows that EPEC has profound effects
on cytoskeletal and cell adhesion pathways in vitro. Translation of these effects into
colonic proliferative progenitor cells in vivo would be highly likely to disturb normal
migration and hence provide a braking effect, hence increasing susceptibility to
tumourigenesis in the healthy colon.
These results constitute a preliminary investigation into the effects of EPEC on cell-
cell adhesion and cytoskeletal pathways in an extended time-course in vitro model.
Confirmation of the exact changes in protein distribution would help to clarify
EPEC's effects. Separating nuclear, cytoplasmic and cell membrane fractions prior to
probing for protein expression could help to achieve this. The mechanisms
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underlying the observed changes in protein expression also warrant further
investigation. A more thorough investigation into protein phosphorylation
(particularly of (3-catenin) would help to determine degradation mechanisms. Using
additional phosphorylation specific antibodies could aid this process. Comparing the
response to EPEC of cell lines expressing wild-type APC and (3-catenin (such as
HCA7) with HT29 and SW480 cells would also be of value. Also, use of enzyme
inhibitors (such as sphingosine and bisindolylmaleimide to inhibit PKC) would help
to establish the involvement of specific enzymes in protein degradation.
The association of proteins of interest with potential degradation enzymes could be
analysed, immunoprecipitation could be utilised for this purpose. The consequences
of EPEC induced changes on cell migration and expression of Wnt target genes
(such as c-myc and cyclin D1) could also be investigated. The ability of E-cadherin
to act as an adhesion protein for EPEC could be assessed by blocking free E-cadherin
with antibodies prior to incubation with EPEC. Most importantly, the translation of






The aim of this study was to test the hypothesis that infection of colonic epithelial
cells by EPEC can increase the susceptibility of these cells to neoplastic
transformation in man. It was not possible to establish an in vivo mouse model of
EPEC infection, largely due to the species specificity of EPEC E2348/69.
Biologically relevant and repeatable in vitro and ex vivo models for EPEC infection
were established and provided a means to test the hypothesis. Consequently this
study has provided novel insights into the behaviour of EPEC in the adult colon and
the effects of EPEC on the classic molecular pathways of colorectal carcinogenesis.
That is, the ability of EPEC to downregulate MSE12, MLH1 and (3-catenin protein
expression. Additionally, this study has established that EPEC enter the crypts of
normal human colonic mucosa, and associate with proliferative epithelial cells. This
illustrates a potential niche environment for chronic EPEC infection in man, and
more importantly, places EPEC in a position to exert its effects on cells capable of
initiating tumour formation.
Translation of the in vitro effects of EPEC to the human colon in vivo would have
potentially serious implications for infected crypt cells. Prolonged reduction of
MSH2 and MLH1 protein expression is likely to confer significant genomic
instability, and reduce DNA damage associated apoptosis signalling. This study
shows that cell division is slowed by EPEC infection and that alterations in host cell
DNA occur subsequent to infection; this supports a previous study, which found that
EPEC induces cell cycle arrest without stopping DNA replication (Marches et. al.,
2003). Continued replication of DNA in the absence of functional DNA mismatch
repair or DNA damage associated apoptotic signalling would present an environment
highly conducive to the accumulation of mutations. MMR disruption is proven to
facilitate mutation of tumour suppressor and oncogenes within the colon, leading to
enhanced tumour formation (Sohn et. al., 2003). Elence EPEC could induce a
paradoxical situation whereby cell cycle arrest promotes rather than inhibits
accumulation of mutations. This study also supports the ability of EPEC to disrupt
the host cytoskeleton and cell-cell adhesion mechanisms. Induction of these changes
in vivo would have the potential to retard epithelial cell migration, thus extending
cell life and delaying differentiation. Infected cells would consequently be exposed
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to food borne carcinogens for longer, and sustain increased exposure to proliferative
signals (supplied to cells while in the lower two thirds of the crypt). The combined
effect of these molecular changes therefore represents a significant increase in the
risk of cell transformation.
A reduction in host cell apoptotic signalling and cell migration (both resulting in
extended cell life) would be potentially beneficial for an attaching and effacing
bacteria such as EPEC. The AE process requires a significant investment of bacterial
cell resources, and results in a highly specialised binding site, potentially providing
access to nutrients and a degree of protection from immune cells. By extending the
life of the host cell, EPEC would preserve this favourable situation. EPEC has the
ability to move across the apical surface of epithelial cells (Narato & Kaper, 1998).
Therefore, once anchored within the colonic crypt it is possible that EPEC could
move (downwards) from cell to cell, perpetuating its residence within the crypt.
Bacterial migration would also allow cells at one time infected, to become free of
infection. This study has shown that even cells exposed to high levels of EPEC
infection for an extended time-course can recover from infection and undergo
division. Daughter cells produced from a progenitor exposed to chronic EPEC
infection would, for the reasons already discussed, have an increased chance of
inheriting mutations. Further cell division and clonal expansion could therefore result
in tumour formation.
In addition to the in vitro and ex vivo findings, analysis of human adenocarcinomas
for AE E. coli has revealed an association between these bacteria and tumour tissue.
This is also a novel finding and although it does not necessarily imply a causative
role for adherent E. coli in tumourigenesis, it does perhaps provide an explanation
for bacteria induced carcinogenesis. Initially it seems counter intuitive that a bacteria
could derive benefit from inducing a lethal disease in its host organism, and that this
would be unlikely to confer an evolutionary advantage to the bacteria. Firstly, it must
be remembered that colorectal cancer takes decades to develop; more than enough
time for EPEC to propagate and infect (via the faecal oral route) further hosts.
Secondly, as this study has demonstrated, adenocarcinomas provide an excellent
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environment for EPEC. Tumours have vastly increased surface area compared to
normal mucosa, and evidently surface antigens that are preferable to normal tissue
for AE E. coli adhesion. These results support previous studies that have found that
adherent E. coli associate with tumour tissue in preference to normal mucosa (Martin
et. al., 2004; Swidsinski et al., 1998). Therefore, carcinogenesis of the colon could
actually be an advantage to EPEC, providing an opportunity for population
expansion, leading to increased bacterial shedding and hence increased propensity
for the host to pass on infection to others.
The precise surface antigens to which EPEC initially binds are unknown. The results
of this study demonstrate that within the adult human colon, EPEC binds selectively
to crypt proliferative progenitor cells and to tumour tissue. The severe pathology of
EPEC infection in infants suggests that the infant intestinal epithelium also
represents an excellent binding surface. Surface residues shared by these tissues are
therefore candidate targets for EPEC adherence. A similarity between these cell
types is that they are more mitotically active and 'less differentiated' than cells at the
surface epithelium of the adult colon, where EPEC did not adhere. In normal tissue,
mitotically active, undifferentiated cells express active glycosyltransferase enzymes,
resulting in the expression of surface glycoproteins with incomplete polysaccharide
chains (Weiser, 1973). Cancer cells also express active glycosyltransferase enzymes
and have different surface antigens compared to normal, differentiated cells.
It has already been acknowledged that the surface antigens of fetal and tumour cells
display some homology, leading to the suggestion by Martin et. al. (2004) that
adherent E. coli bind to 'oncofetal' surface antigens. The present study suggests that
mitotically active, undifferentiated crypt cells also express 'oncofetal' surface
antigens. It is logical that EPEC would target more immature cells when invading a
host. Firstly, these cells are likely to live for longer than differentiated cells,
providing a longer lasting binding site. Secondly, it is possible that EPEC's
molecular and cellular effects are more easily translated in undifferentiated cells,
where cell fate is yet to be decided. The observation that MMR protein
downregulation was more rapid in SW480 cells versus HT29 cells supports this
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theory. Although the surface antigens expressed in infants are not necessarily the
same as those in the fetal intestine, it is logical to assume that the infant intestine
contains a higher percentage of immature cells than the adult, as organ growth is still
occurring. In conclusion, it seems likely that EPEC binds preferentially to
undifferentiated cells, and that this binding affinity can explain; (a) the severe
pathology of EPEC infection in children, (b) the ability of adults to carry EPEC
without symptoms, potentially in the niche of the colonic crypts, and (c) the
association ofAE E. coli with adenocarcinoma.
There are striking similarities between the behaviour and effects of EPEC and those
of Helicobacterpylori, a bacterium responsible for carcinogenesis in the stomach. In
similarity to EPEC, H. pylori downregulates DNA mismatch repair proteins in
gastric epithelial cancer cells in vitro (Kim et. al., 2002); an effect found to translate
to the gastric epithelium in vivo (Park et. al., 2005). H. pylori also reduces cell-cell
adhesion by disrupting E-cadherin / catenin adherens junctions (Suzuki et. al., 2005).
Like EPEC, H. pylori associates closely with the host epithelium and inserts effector
molecules via a bacterial secretion system. Based on the observation that not all
H. pylori strains are carcinogenic, recent work on H. pylori induced carcinogenesis
has focussed on strains carrying the cag pathogenicity island. The EPEC LEE
pathogenicity island and cag are analogous in that they both encode multiple genes
for secretion systems and secreted effector molecules. H. pylori strains that harbour
cag have increased ability to cause cancer versus cag negative strains (Blaser et. al.,
1995). It is also notable that despite the ability to cause cancer in its host, H. pylori is
able to thrive among the human population. As with H. pylori, it is true that many
more people harbour E. coli than develop colorectal cancer. It is therefore an
appealing hypothesis that the difference between carcinogenic and non-carcinogenic
bacteria is the possession of virulence determinants that allow bacterial attachment
and insertion of effector molecules into the host epithelium.
If EPEC is indeed able to increase the risk of colorectal cancer, this raises a paradox,
in that EPEC infection is more prevalent in developing countries where colorectal
cancer rates are lower than in the developed world. This could be explained by a
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number of factors. Firstly, modern epidemiological information on EPEC in
developed countries is severely lacking. The reduction in infant mortality due to
EPEC in developed countries means routine screening is no longer performed in
hospitals; hence EPEC carriage by adults in developed countries is virtually
unknown and may be higher than expected. Secondly, it is probable that the diet in
developed countries contains a greater variety, and higher concentrations of
carcinogens (e.g. in processed food) compared to the more natural diet of developing
countries. Therefore, if EPEC increases the susceptibility of colonic cells to
mutation, it would have a greater chance of initiating cancer in developed countries.
A more accurate evaluation of EPEC carriage amongst adults in developed countries
would be extremely useful in evaluating a relationship between EPEC and cancer.
Presently, studies on the prevalence of EPEC infection focus on children, and show
that up to 11% of asymptomatic (i.e. healthy) children carry EPEC in developed
countries. It is quite possible that a similar proportion of adults also carry EPEC. In
this study AE E. coli (i.e. EPEC / EE1EC) were identified in 25% of patients with
adenocarcinoma, results suggest that this proportion may have been higher with more
sensitive detection techniques or if fresh samples had been used. Even so, a 25%
detection rate is approximately double the combined prevalence EPEC and EE1EC in
studies on children in developed countries. Therefore, not only does this study
support the carriage of EPEC by adults in the UK, it also suggests that patients with
colorectal cancer may have a higher prevalence of EPEC carriage than individuals
without cancer (assuming adult EPEC carriage is -10%). This crucial result is
potentially of genuine significance and establishes the need for further
epidemiological investigation of EPEC, particularly in comparing EPEC carriage in
adults with and without colorectal cancer.
In addition to the specific changes in protein expression analysed in this study, the
wider proteomic and transcriptomic effects observed demonstrate the complexity and
variety of EPEC's effects. Though this study has not focussed on the mechanisms of
these changes there are a number of clues to suggest how EPEC causes its effects.
The inability of the mutant EPEC strain to induce the same changes as wild-type
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strain indicates that secreted effector proteins and / or intimin signalling are key to
the transduction of molecular effects in the host. Reference to the literature has
provided putative mechanisms for EPEC induced MMR and adhesion protein
downregulation. Protein kinase enzymes are activated by EPEC (Crane & Oh, 1997)
and represent prime candidates to mediate many of the effects identified in this
study; PKCa is particularly conspicuous in this respect. The diversity of
transcriptomic and proteomic effects demonstrated by this and other studies (e.g.
Hardwidge et. al., 2004) in response to EPEC infection should encourage the
research of EPEC to extend beyond simply AE lesion formation and diarrhoea. If
adult populations do indeed carry EPEC, further exploration of the role of this
pathogen in more complex adult diseases such as inflammatory bowel disease and
intestinal cancers is warranted.
In conclusion, this study has met its initial aims, and adds support to the hypothesis
that infection of colonic epithelial cells by enteropathogenic Escherichia coli can
increase the susceptibility of these cells to neoplastic transformation in man. In
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Appendix 2. Microarray functional annotation clustering.
Gene ontology: Pathways with altered gene expression in HT29 cells infected with
EPEC, using VSN normalisation and SAM analysis. Genes with statistically significant
fold-change (false discovery rate 0.1, P<0.05) were subjected to functional annotation
clustering searches via DAVID functional annotation tool
(http://david.abcc.ncifcrf.gov/tools.ispt. The enrichment score for the group is based on the
P-value of each term member; the higher the score the more enriched. The number of
differentially expressed genes found in the pathway is displayed under 'Count'. P_value =
modified Fisher Exact P-value for gene enrichment analysis (or EASE score); the smaller the
value the more enriched the pathway, 0 represents perfect enrichment.
-Oh / -12h
Cluster 1. Enrichment Score: 0.6 Count P_Value
lipid metabolism 3 1.60E-02
primary metabolism 4 5.30E-01
cellular metabolism 4 5.70E-01
intracellular 3 8.20E-01
Cluster 2. Enrichment Score: 0.39 Count P_Value
cellular physiological process 6 2.20E-01
metabolism 5 3.00E-01
physiological process 6 4.70E-01
cellular process 6 5.30E-01
cell 5 6.70E-01
+mut 9h / -12h
Cluster 1. Enrichment Score: 2.68 Count P_Value
apoptosis 10 5.50E-05
programmed cell death 10 5.70E-05
cell death 10 7.40E-05
death 10 7.80E-05
negative regulation of apoptosis 6 8.50E-05
negative regulation of programmed cell death 6 8.80E-05
regulation of apoptosis 7 8.40E-04
negative regulation of cellular physiological process 9 8.50E-04
regulation of programmed cell death 7 8.70E-04
negative regulation of physiological process 9 1.10E-03
negative regulation of cellular process 9 1.60E-03
apoptosis 5 2.00E-03
negative regulation of biological process 9 2.60E-03
anti-apoptosis 4 7.10E-03
regulation of biological process 19 3.50E-02
positive regulation of biological process 5 1.40E-01
positive regulation of physiological process 4 1.90E-01
positive regulation of cellular physiological process 3 4.20E-01
positive regulation of cellular process 3 5.10E-01
Cluster 2. Enrichment Score: 2.06 Count P_Value
angiogenesis 4 1.30E-03
vasculature development 4 1.50E-03
blood vessel development 4 1.50E-03
blood vessel morphogenesis 4 1.50E-03
angiogenesis 3 2.80E-03
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differentiation 4 1.50E-02
organ morphogenesis 4 3.10E-02
morphogenesis 6 4.00E-02
developmental protein 4 9.00E-02
organ development 4 2.40E-01
Cluster 3. Enrichment Score: 1.91 Count P_Value
cytokine 7 3.00E-06
cytokine activity 8 3.80E-06
receptor binding 11 1.20E-05
extracellular space 9 6.40E-05
response to stress 13 1.20E-04
Small chemokine, C-X-C/lnterleukin 8 3 6.60E-04
signal 15 8.70E-04
response to external stimulus 8 1.10E-03
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 7 1.70E-03
extracellular region 11 5.30E-03




chemokine activity 3 7.30E-03
chemokine receptor binding 3 7.30E-03
inflammatory response 3 7.50E-03
locomotory behavior 4 8.00E-03
response to wounding 6 8.20E-03
chemotaxis 3 9.30E-03
Cytokines and Inflammatory Response 3 9.90E-03
cell fraction 8 1.00E-02
G-protein-coupled receptor binding 3 1.00E-02
response to stimulus 16 1.60E-02
soluble fraction 4 2.40E-02
behavior 4 2.40E-02
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cell-cell signaling 6 2.70E-02
response to pest, pathogen or parasite 6 3.30E-02
response to chemical stimulus 5 3.50E-02
cell communication 18 3.50E-02
growth factor 3 3.90E-02
response to other organism 6 4.10E-02
signal transducer activity 15 4 20E-02
signal peptide 14 5.20E-02
response to abiotic stimulus 5 5.40E-02
immune response 8 6.70E-02
signal transduction 16 6.80E-02
growth factor activity 3 9.20E-02
defense response 8 1.00E-01
response to biotic stimulus 8 1.20E-01
inflammatory response 3 1.50E-01
glycoprotein 11 2.10E-01
cell surface receptor linked signal transduction 8 2.60E-01
sensory transduction 3 3.40E-01
organismal physiological process 10 3.80E-01
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glycosylation site:N-linked (GlcNAc...) 9 8.20E-01
Cluster 4. Enrichment Score: 1.77 Count P_Value
epidermis development 4 2.30E-03
ectoderm development 4 3.20E-03
tissue development 4 2.20E-02
structural molecule activity 4 5.10E-01
Cluster 5. Enrichment Score: 1.76 Count P_Value
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negative regulation of physiological process 9 1.10E-03
negative regulation of cellular process 9 1.60E-03
negative regulation of biological process 9 2.60E-03
cell cycle arrest 3 1.90E-02
regulation of progression through cell cycle 5 6.00E-02
regulation of cell cycle 5 6.10E-02
negative regulation of progression through cell cycle 3 8.90E-02
cell cycle 5 1.90E-01
cell proliferation 3 5.10E-01
Cluster 6. Enrichment Score: 1.63 Count P_Value
cell differentiation 7 5.10E-03
repeat: 1 4 2.40E-02
repeat:2 4 2.40E-02
repeat:3 3 1.00E-01
Cluster 7. Enrichment Score: 1.58 Count P_Value
Cells and Molecules involved in local acute inflammatory response 3 4.60E-03
Adhesion and Diapedesis of Granulocytes 3 4.60E-03
58.(CD40L)_immnosurveillance 3 1.50E-02
18.Cytokine astocytes 3 1.50E-02
INFECTION 3 3.60E-02
IMMUNE 5 1.40E-01
cell adhesion 4 3.70E-01






Cluster 9. Enrichment Score: 0.96 Count P_Value
domain:Leucine-zipper 4 3.10E-03
transcription cofactor activity 5 5.20E-03
nuclear protein 15 7.00E-03
Basic-leucine zipper (bZIP) transcription factor 3 8.80E-03
BRLZ 3 9.20E-03
transcription factor binding 5 9.70E-03
protein dimerization activity 4 1.10E-02
dna-binding 9 1.90E-02
transcription corepressor activity 3 2.50E-02
regulation of cellular physiological process 18 2.50E-02
regulation of physiological process 18 3.30E-02
regulation of biological process 19 3.50E-02
regulation of cellular process 18 3.90E-02
transcription regulation 8 5.00E-02
transcription factor activity 7 5.20E-02
DNA-binding region:Basic motif 3 5.30E-02
DNA binding 4 7.50E-02
repressor 3 9.10E-02
transcription 7 1.10E-01
sequence-specific DNA binding 4 1.20E-01
DNA binding 10 1.50E-01
transcription regulator activity 7 1.70E-01
transcription from RNA polymerase II promoter 4 2.00E-01
regulation of transcription, DNA-dependent 10 2.40E-01
transcription, DNA-dependent 10 2.70E-01
regulation of metabolism 11 2.80E-01
regulation of transcription 10 3.10E-01
regulation of nucleobase, nucleoside, nucleotide & nucleic acid metabolism 10 3.20E-01
transcription 10 3.60E-01
nucleus 15 3.70E-01
regulation of cellular metabolism 10 3.90E-01
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 12 6.00E-01
nucleic acid binding 10 6.40E-01
intracellular organelle 21 7.40E-01
organelle 21 7.40E-01
intracellular membrane-bound organelle 17 7.90E-01
membrane-bound organelle 17 7.90E-01
intracellular 24 8.50E-01
primary metabolism 20 9.60E-01
metabolism 22 9.70E-01
cellular metabolism 20 9.80E-01
Cluster 10. Enrichment Score: 0.31 Count P_Value
cellular process 45 1.80E-01
cellular physiological process 34 7.70E-01
physiological process 39 8.90E-01
Cluster 11. Enrichment Score: 0.26 Count P_Value
immunoglobulin domain 3 4.20E-01
Immunoglobulin subtype 3 5.20E-01
IG 3 5.50E-01
Immunoglobulin-like 3 6.20E-01
plasma membrane 6 6.50E-01
Cluster 12. Enrichment Score: 0.16 Count P Value
transmembrane protein 4 2.40E-01
membrane 11 3.40E-01
plasma membrane 6 6.50E-01
integral to plasma membrane 4 7.50E-01
intrinsic to plasma membrane 4 7.50E-01
transmembrane 7 8.60E-01
transmembrane region 7 9.70E-01
membrane 13 9.80E-01
integral to membrane 9 9.80E-01
intrinsic to membrane 9 9.80E-01
Cluster 13. Enrichment Score: 0.16 Count P Value
structural molecule activity 4 5.10E-01
cytoskeleton 4 5.50E-01
non-membrane-bound organelle 5 7.90E-01
intracellular non-membrane-bound organelle 5 7.90E-01
cell organization and biogenesis 4 8.80E-01
Cluster 14. Enrichment Score: 0.08 Count P Value
plasma membrane 6 6.50E-01
transmembrane receptor activity 3 9.20E-01
receptor activity 4 9.50E-01
Cluster 15. Enrichment Score: 0.05 Count P Value
metal-binding 6 5.90E-01
zinc-finger 3 8.60E-01
transition metal ion binding 5 9.20E-01
zinc 3 9.20E-01
ion binding 7 9.60E-01
metal ion binding 7 9.60E-01
cation binding 6 9.70E-01
zinc ion binding 3 9.80E-01
Cluster 16. Enrichment Score: 0.04 Count P_Value
establishment of localization 8 8.80E-01
localization 8 8.80E-01
transport 6 9.60E-01
Cluster 17. Enrichment Score: 0.03 Count P_Value
nucleotide-binding 3 8.30E-01
purine nucleotide binding 3 9.70E-01
nucleotide binding 3 9.80E-01
Cluster 18. Enrichment Score: 0.03 Count P_Value
phosphorus metabolism 3 8.10E-01
phosphate metabolism 3 8.10E-01
protein modification 4 9.20E-01
biopolymer modification 4 9.30E-01
biopolymer metabolism 5 9.90E-01
protein metabolism 6 9.90E-01
cellular protein metabolism 4 1
cellular macromolecule metabolism 4 1
macromolecule metabolism 7 1
+mut 12h / 12h
Cluster 1. Enrichment Score: 3.53 Count P_Value
negative regulation of cellular process 17 1.10E-08
negative regulation of cellular physiological process 16 2.10E-08
negative regulation of biological process 17 3.10E-08
negative regulation of physiological process 16 3.40E-08
apoptosis 13 1.70E-06
programmed cell death 13 1.70E-06
cell death 13 2.50E-06
death 13 2.60E-06
apoptosis 7 7.80E-05
regulation of progression through cell cycle 10 8.90E-05
regulation of cell cycle 10 9.00E-05
cell cycle arrest 5 1.50E-04
negative regulation of apoptosis 6 2.50E-04
negative regulation of programmed cell death 6 2.60E-04
negative regulation of progression through cell cycle 6 4.00E-04
cell cycle 11 4.80E-04
regulation of apoptosis 8 5.00E-04
regulation of programmed cell death 8 5.10E-04
anti-apoptosis 4 1.30E-02
positive regulation of biological process 6 1.10E-01
induction of programmed cell death 3 1.10E-01
induction of apoptosis 3 1.10E-01
positive regulation of physiological process 5 1.20E-01
positive regulation of apoptosis 3 1.40E-01
positive regulation of programmed cell death 3 1.40E-01
mutagenesis site 7 2.60E-01
positive regulation of cellular physiological process 4 2.70E-01
positive regulation of cellular process 4 3.60E-01
Cluster 2. Enrichment Score: 3.05 Count P Value
Basic leucine zipper 4 2.20E-05
Basic-leucine zipper (bZIP) transcription factor 5 3.10E-05
BRLZ 5 6.90E-05
protein dimerization activity 6 2.30E-04
Fos transforming protein 3 3.70E-04
SF001719:fos transforming protein 3 6.00E-04
domain:Leucine-zipper 5 7.10E-04
DNA-binding region:Basic motif 5 1.70E-03
transcription factor binding 6 3.20E-03
transcription from RNA polymerase II promoter 7 1.30E-02
sequence-specific DNA binding 6 1.40E-02
repressor 3 1.50E-01
Cluster 3. Enrichment Score: 2.71 Count P_Value
response to stress 20 2.50E-08
cytokine 9 6.20E-08
cytokine activity 10 7.70E-08
receptor binding 13 1.50E-06
response to external stimulus 12 5.20E-06
extracellular space 11 8.20E-06
Small chemokine, C-X-C/lnterleukin 8 4 1.50E-05
response to wounding 10 2.50E-05
response to stimulus 25 4.30E-05
response to chemical stimulus 9 1.50E-04
signal 19 2.60E-04
response to pest, pathogen or parasite 10 3.70E-04
Small chemokine, interleukin-8-like 4 3.70E-04
response to abiotic stimulus 9 4.00E-04
chemokine activity 4 4.80E-04
chemokine receptor binding 4 4.80E-04
response to other organism 10 5.70E-04
SCY 4 6.60E-04
inflammatory response 4 6.90E-04
G-protein-coupled receptor binding 4 8.30E-04
behavior 6 1.10E-03
extracellular region 14 1.10E-03
Small chemokine, C-X-C 3 1.20E-03
chemotaxis 5 1.50E-03
taxis 5 1.50E-03
inflammatory response 6 1.50E-03
SF002522:beta-thromboglobulin 3 1.60E-03
locomotory behavior 5 1.80E-03
immune response 12 4.90E-03
response to biotic stimulus 13 5.00E-03
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 7 6.30E-03
soluble fraction 5 7.70E-03
growth factor 4 8.10E-03
defense response 12 1.00E-02
chemotaxis 3 1.60E-02
cell-cell signaling 7 2.00E-02
growth factor activity 4 2.30E-02
signal peptide 18 4.80E-02
organismal physiological process 15 1.00E-01
regulation of cell proliferation 4 1.20E-01
negative regulation of cell proliferation 3 1.20E-01
signal transducer activity 15 1.40E-01
disulfide bond 15 1.40E-01
cell proliferation 5 1.70E-01
glycoprotein 13 2.90E-01
cell surface receptor linked signal transduction 9 3.20E-01
sensory transduction 3 4.80E-01
sensory perception 3 7.90E-01
neurophysiological process 3 9.00E-01
G-protein coupled receptor protein signaling pathway 3 9.40E-01
glycosylation site:N-linked (GlcNAc...) 10 9.60E-01
Cluster 4. Enrichment Score: 1.92 Count P_Value
TOLL-LIKE RECEPTOR SIGNALING PATHWAY 5 3.60E-03
T CELL RECEPTOR SIGNALING PATHWAY 5 3.80E-03
Cadmium induces DNA synthesis and proliferation in macrophages 3 1.00E-02
ADIPOCYTOKINE SIGNALING PATHWAY 4 1.20E-02
APOPTOSIS 4 2.40E-02
B CELL RECEPTOR SIGNALING PATHWAY 3 7.90E-02
Cluster 5. Enrichment Score: 1.73 Count P_Value
angiogenesis 4 2.50E-03
blood vessel morphogenesis 4 2.90E-03
blood vessel development 4 2.90E-03
vasculature development 4 2.90E-03
angiogenesis 3 4.80E-03
cell differentiation 7 1.50E-02
differentiation 4 3.10E-02
organ morphogenesis 4 5.50E-02
developmental protein 4 1.70E-01
morphogenesis 5 2.20E-01
organ development 4 3.60E-01
Cluster 6. Enrichment Score: 1.69 Count P_Value
cell communication 23 1.30E-02
signal transduction 21 2.10E-02
intracellular signaling cascade 10 3.20E-02
Cluster 7. Enrichment Score: 1.32 Count P Value
RESTENOSIS 3 6.80E-03
Adhesion and Diapedesis of Granulocytes 3 1.30E-02
Cells and Molecules involved in local acute inflammatory response 3 1.30E-02
INFECTION 4 1 40E-02
TYPE 2 DIABETES 6 2.50E-02
18.Cytokine_astocytes 3 4.00E-02




SYSTEMIC LUPUS ERYTHEMATOSUS 4 8.00E-02
BREAST CANCER 3 1.10E-01
cell adhesion 5 2.80E-01
CARDIOVASCULAR 4 2.90E-01
NEURODEG 3 4.00E-01
Cluster 8. Enrichment Score: 1.19 Count P_Value
dna-binding 14 4.60E-04
nuclear protein 21 5.00E-04
regulation of cellular process 25 3.00E-03
transcription factor binding 6 3.20E-03
regulation of biological process 26 3.30E-03
regulation of cellular physiological process 24 3.60E-03
regulation of physiological process 24 5.30E-03
DNA binding 6 9.70E-03
transcription from RNA polymerase II promoter 7 1.30E-02
sequence-specific DNA binding 6 1.40E-02
DNA binding 14 2.40E-02
transcription regulation 10 3.40E-02
transcription cofactor activity 4 5.10E-02
transcription 9 7.20E-02
nucleus 22 8.10E-02
regulation of transcription, DNA-dependent 14 8.20E-02
transcription, DNA-dependent 14 9.80E-02
transcription factor activity 7 1.00E-01
regulation of transcription 14 1.20E-01
regulation of metabolism 15 1.30E-01
regulation of nucleobase, nucleoside, nucleotide & nucleic acid metabolism 14 1.30E-01
transcription 14 1.60E-01
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 19 1.60E-01
transcription regulator activity 8 1.60E-01
regulation of cellular metabolism 14 1.80E-01
nucleic acid binding 14 3.50E-01
intracellular membrane-bound organelle 25 4.10E-01
membrane-bound organelle 25 4.20E-01
intracellular organelle 29 4.60E-01
organelle 29 4.60E-01
cellular physiological process 45 5.10E-01
primary metabolism 30 7.10E-01
intracellular 32 7.10E-01
cellular metabolism 30 7.90E-01
metabolism 32 8.20E-01
cell 46 9.70E-01
Cluster 9. Enrichment Score: 1.17 Count P_Value
ank repeat 4 3.30E-02
repeat:ANK 5 3 4.00E-02
repeat:ANK 4 3 5.70E-02
Ankyrin 4 7.10E-02
ANK 4 7.50E-02
repeat:ANK 3 3 8.70E-02
repeat:ANK 1 3 1.10E-01
repeat:ANK 2 3 1.10E-01
Cluster 10. Enrichment Score: 1.13 Count P_Value
epidermis development 3 4.30E-02
ectoderm development 3 5.30E-02
tissue development 3 1.70E-01
Cluster 11. Enrichment Score: 1.02 Count P_Value
cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 3 3.7OE-03
DNA metabolism 4 5.10E-01
cell organization and biogenesis 7 5.80E-01
Cluster 12. Enrichment Score: 0.94 Count P Value
IMMUNE 8 4.30E-02
MULTIPLE SCLEROSIS 3 9.40E-02
TYPE 1 DIABETES 3 3.70E-01
Cluster 13. Enrichment Score: 0.75 Count P_Value
Has small GI Fase, Kho type 3 ' 5.90E-02
Ras small GTPase, Ras type 3 6.60E-02
Ras small GTPase, Rab type 3 8.50E-02
Small GTP-binding protein domain 3 1.00E-01
Ras GTPase 3 1.10E-01
nucleotide-binding 8 1.20E-01
gtp-binding 3 1.90E-01
nucleotide phosphate-binding region:GTP 3 2.50E-01
small GTPase mediated signal transduction 3 3.10E-01
GTP binding 3 3.80E-01
purine nucleotide binding 8 3.80E-01
guanyl nucleotide binding 3 3.80E-01
nucleotide binding 8 5.40E-01
Cluster 14. Enrichment Score: 0.57 Count P_Value
cellular process 57 6.90E-02
cellular physiological process 45 5.10E-01
physiological process 52 5.60E-01
Cluster 15. Enrichment Score: 0.37 Count P_Value
actin cytoskeleton organization and biogenesis 3 1.30E-01
actin filament-based process 3 1.50E-01
organelle organization and biogenesis 5 4.40E-01
cytoskeleton organization and biogenesis 3 4.80E-01
cell organization and biogenesis 7 5.80E-01
cytoskeleton 4 7.10E-01
intracellular non-membrane-bound organelle 6 8.00E-01
non-membrane-bound organelle 6 8.00E-01
Cluster 16. Enrichment Score: 0.35 Count P_Value
phosphorylation 13 9.30E-03
nucleotide-binding 8 1.20E-01
phosphoric monoester hydrolase activity 3 2.00E-01
kinase 5 2.30E-01
phosphotransferase activity, alcohol group as acceptor 5 2.50E-01
phosphoric ester hydrolase activity 3 3.00E-01
serine/threonine-protein kinase 3 3.00E-01
Serine/threonine protein kinase, active site 3 3.40E-01
protein kinase activity 4 3.70E-01
purine nucleotide binding 8 3.80E-01
active site: Proton acceptor 4 3.90E-01
hydrolase activity, acting on ester bonds 4 3.90E-01
atp-binding 5 4.10E-01
kinase activity 5 4.10E-01
protein serine/threonine kinase activity 3 4.20E-01
Tyrosine protein kinase 3 4.70E-01
Serine/threonine protein kinase 3 4.90E-01
domain:Protein kinase 3 5.20E-01
phosphorus metabolism 5 5.30E-01
phosphate metabolism 5 5.30E-01
transferase activity, transferring phosphorus-containing groups 5 5.30E-01
nucleotide binding 8 5.40E-01
Protein kinase 3 5.40E-01
biopolymer modification 8 5.50E-01
binding site:ATP 3 5.60E-01
hydrolase 5 5.80E-01
biopolymer metabolism 12 6.20E 01
hydrolase activity 8 6.20E-01
nucleotide phosphate-binding region:ATP 4 6.40E-01
ATP binding 5 6.70E-01
protein modification 7 6.80E-01
adenyl nucleotide binding 5 7.00E-01
protein amino acid phosphorylation 3 7.30E-01
transferase 4 7.60E-01
phosphorylation 3 8.30E-01
transferase activity 5 8.90E-01
Shatner's Bassoon macromolecule metabolism 16 8.90E-01
protein metabolism 11 9.20E-01
cellular protein metabolism 8 9.90E-01
cellular macromolecule metabolism 8 9.90E-01
Cluster 17. Enrichment Score: 0.18 Count P_Value
electron transport 3 5.40E-01
generation of precursor metabolites and energy 4 5.50E-01
transport 7 9.80E-01




transition metal ion binding 7 8.40E-01
zinc ion binding 5 9.20E-01
ion binding 9 9.40E-01
metal ion binding 9 9.40E-01
cation binding 7 9.80E-01
Cluster 19. Enrichment Score: 0.08 Count P_Value
membrane 14 3.30E-01
plasma membrane 6 8.30E-01
integral to plasma membrane 4 8.70E-01
intrinsic to plasma membrane 4 8.70E-01
transmembrane 8 9.40E-01
membrane 15 9.90E-01
transmembrane region 8 1
integral to membrane 10 1
intrinsic to membrane 10 1
Cluster 20. Enrichment Score: 0.02 Count P Value
establishment of localization 9 9.40E-01
localization 9 9.40E-01
transport 7 9.80E-01
+wt 9h / -12h
Cluster 1. Enrichment Score: 21.91 Count P_Value
nuclear protein 302 2.40E-45
intracellular membrane-bound organelle 469 8.50E-27
membrane-bound organelle 469 9.20E-27
nucleus 348 5.70E-22
intracellular 587 7.90E-22
intracellular organelle 514 2.30E-21
organelle 514 2.50E-21
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 293 1.60E-15
cell 719 7.70E-03
Cluster 2. Enrichment Score: 11.47 Count P_Value
primary metabolism 544 8.80E-21
metabolism 579 3.00E-18
cellular metabolism 549 3.70E-18
cellular physiological process 687 9.10E-16
physiological process 730 5.00E-05
cellular process 742 1.40E-04
cell 719 7.70E-03
Cluster 3. Enrichment Score: 11.25 Count P_Value
dna replication 24 1.00E-15
DNA replication 41 8.50E-13
DNA-dependent DNA replication 26 1.20E-11
DNA replication initiation 12 9.40E-08
Cluster 4. Enrichment Score: 8.2 Count P_Value
transit peptide 44 3~0E-11
mitochondrion 61 2.10E-10
transit peptide:Mitochondrion 44 1.00E-08
mitochondrion 66 2.40E-05
Cluster 5. Enrichment Score: 8.05 Count P_Value
membrane-enclosed lumen 66 2.20E-11
organelle lumen 66 2.20E-11
nuclear lumen 50 1.70E-08
nucleoplasm 29 7.80E-04
Cluster 6. Enrichment Score: 7.07 Count P_Value
DNA metabolism 89 8.60E-15
DNA repair 41 7.40E-11
response to DNA damage stimulus 42 4.90E-10
response to endogenous stimulus 43 1.00E-09
dna damage 21 5.50E-07
dna repair 19 1.60E-06
response to stress 79 9.50E-03
response to stimulus 118 1
Cluster 7. Enrichment Score: 5.45 Count P_Value
cell cycle 85 1.30E-11
regulation of progression through cell cycle 60 1.10E-09
regulation of cell cycle 60 1.20E-09
cell cycle 39 1.70E-08
negative regulation of progression through cell cycle 21 3.50E-04
negative regulation of cellular process 57 3.30E-03
negative regulation of cellular physiological process 52 4.30E-03
negative regulation of biological process 59 6.30E-03
negative regulation of physiological process 52 8.60E-03
Cluster 8. Enrichment Score: 5.34 Count P_Value
RNA processing 53 1.80E-10
RNA metabolism 58 4.50E-09
mrna processing 24 1.70E-07
mrna splicing 20 8.70E-07
RNA binding 54 1.60E-05
mRNA processing 28 2.30E-05
mRNA metabolism 30 3.30E-05
RNA splicing 23 3.50E-05
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 20 5.90E-05
nuclear mRNA splicing, via spliceosome 20 5.90E-05
RNA splicing, via transesterification reactions 20 5.90E-05
spliceosome complex 10 9.00E-03
Cluster 9. Enrichment Score: 5.07 Count P_Value
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 293 1.60E-15
nucleic acid binding 276 3.00E-14
transcription 118 1.50E-10
dna-binding 115 6.60E-09
transcription regulation 110 9.00E-08
DNA binding 168 3.40E-07
regulation of cellular physiological process 230 5.70E-05
regulation of physiological process 235 8.00E-05
regulation of cellular process 238 9.30E-05
regulation of biological process 251 1.30E-04
transcription 163 2.40E-03
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 157 3.50E-03
regulation of cellular metabolism 163 5.80E-03
regulation of metabolism 167 6.10E-03
regulation of transcription 152 8.10E-03
transcription, DNA-dependent 145 1.40E-02
regulation of transcription, DNA-dependent 138 2.70E-02
transcription regulator activity 69 7.00E-01
Cluster 10. Enrichment Score: 5.07 Count P Value




DNA-dependent ATPase activity 11 4.80E-05
Cluster 11. Enrichment Score: 4.69 Count P Value
macromolecule metabolism 363 1.80E-15
biopolymer metabolism 245 2.60E-14
protein metabolism 215 3.40E-02
cellular protein metabolism 192 1.30E-01
biopolymer modification 106 1.30E-01
cellular macromolecule metabolism 193 1.60E-01
protein modification 96 3.60E-01
Cluster 12. Enrichment Score: 3.43 Count P_Value
PYRIMIDINE METABOLISM 23 1.10E-07
nucleotidyltransferase 18 8.30E-07
nucleotidyltransferase activity 25 2.10E-06
dna-directed ma polymerase 10 6.00E-06
DNA-directed RNA polymerase I activity 8 1.60E-04
DNA-directed RNA polymerase II activity 8 1.60E-04
DNA-directed RNA polymerase III activity 8 1.60E-04
DNA-directed RNA polymerase activity 11 2.50E-04
RNA POLYMERASE 8 1.50E-03
PURINE METABOLISM 21 2.90E-03
DNA-directed RNA polymerase III complex 4 7.60E-03
transcription from RNA polymerase III promoter 6 1.10E-02
RNA polymerase complex 6 1.70E-02
obsolete molecular function 20 1.90E-01
DNA-directed RNA polymerase II, core complex 3 2.60E-01
Cluster 13. Enrichment Score: 3.37 Count P_Value
replication fork 9 8.30E-08
replisome 6 2.50E-05
replication fork (sensu Eukaryota) 6 2.50E-05
replisome (sensu Eukaryota) 6 2.50E-05
DNA replication factor A complex 4 6.40E-04
Nucleic acid-binding, OB-fold, subgroup 8 2.00E-02
nucleic acid binding, OB-fold, tRNA/helicase-type 4 2.30E-02
single-stranded DNA binding 6 3.20E-02
structure-specific DNA binding 7 4.40E-02
Cluster 14. Enrichment Score: 3.26 Count P_Value
AAA 19 7.40E-05
AAAATPase, central region 11 3.10E-04
AAAATPase 16 7.30E-03
Cluster 15. Enrichment Score: 3.02 Count P_Value
nuclease activity 24 7.~0E-06
exonuclease activity, active with ribo/deoxyribonucleic acids & producing 5'-phosphomonoesters 8 1.50E-05
rRNA metabolism 12 8.10E-05
ribosome biogenesis 13 1.30E-04
ribosome biogenesis and assembly 14 2.20E-04
exonuclease 8 4.40E-04
cytoplasm organization and biogenesis 15 5.40E-04
3'-5' exonuclease activity 8 5.60E-04
rRNA processing 10 7.80E-04
nuclease 11 2.40E-03
3'-5'-exoribonuclease activity 5 3.10E-03
exonuclease activity 10 3.10E-03
rrna processing 7 3.50E-03
exosome 4 5.10E-03
exoribonuclease activity, producing 5'-phosphomonoesters 5 5.40E-03
exoribonuclease activity 5 5.40E-03
exosome (RNase complex) 4 1.10E-02
Exoribonuclease 3 1.10E-01




zinc ion binding 138 1 60E-03
transition metal ion binding 160 2.90E-03
Zinc finger, C2H2-type 64 5.80E-03
metal ion binding 206 1.50E-01
ion binding 206 1.50E-01
cation binding 185 3.70E-01
Cluster 17. Enrichment Score: 2.88 Count P_Value
ribosomal protein 33 1.70E-09
ribonucleoprotein 34 7.60E-09
ribonucleoprotein complex 56 9.70E-05
cellular biosynthesis 95 5.30E-03
biosynthesis 101 1.40E-02
structural constituent of ribosome 29 8.40E-02
protein biosynthesis 53 1.20E-01
macromolecule biosynthesis 57 1.50E-01
ribosome 26 3.00E-01
structural molecule activity 55 3.60E-01
Cluster 18. Enrichment Score: 2.83 Count P_Value
ribonuclease activity 13 1.60E-04
exonuclease activity 10 3.10E-03
endonuclease activity 12 6.50E-03
Cluster 19. Enrichment Score: 2.59 Count P_Value
hereditary nonpolyposis colorectal cancer 5 9.70E-05
maintenance of fidelity during DNA-dependent DNA replication 6 1.30E-02
mismatch repair 6 1.30E-02
Cluster 20. Enrichment Score: 2.48 Count P_Value
exonuclease activity, active with ribo/deoxyribonucleic acids & producing 5'-phosphomonoesters 8 1.50E-05
exodeoxyribonuclease activity 3 1.40E-02
exodeoxyribonuclease activity, producing 5'-phosphomonoesters 3 1.40E-02
deoxyribonuclease activity 5 4.30E-02
Cluster 21. Enrichment Score: 2.46 Count P_Value
nucleotide-binding 107 1.30E-08
nucleoside-triphosphatase activity 45 6.10E-03
AAAATPase 16 7.30E-03
hydrolase activity, acting on acid anhydrides 47 7.90E-03
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 46 9.70E-03
pyrophosphatase activity 45 1 30E-02
ATPase activity, coupled 21 1.50E-01
ATPase activity 23 2.20E-01




RNA-binding region RNP-1 (RNA recognition motif) 21 2.50E-02
Nucleotide-binding, alpha-beta plait 21 6.30E-02
Cluster 23. Enrichment Score: 2.42 Count P_Value
delta-DNA polymerase cofactor complex 4 6.40E-04
SF004274:phage T4 DNA polymerase accessory protein 44 4 1.70E-03
obsolete cellular component 6 6.00E-03
Replication factor C conserved region 4 6.90E-03
DNA replication factor C complex 3 1.70E-02




transferase activity 147 2.00E-06
nucleotide phosphate-binding region:ATP 65 5.20E-05
nucleotide binding 149 7.60E-05
transferase activity, transferring phosphorus-containing groups 88 3.60E-04
purine nucleotide binding 126 6.10E-04
adenyl nucleotide binding 103 7.20E-04
ATP binding 100 7.30E-04
active site:Proton acceptor 43 2.20E-03
kinase 53 3.70E-03
phosphotransferase activity, alcohol group as acceptor 56 1 60E-02
serine/threonine-protein kinase 24 5.30E-02
protein kinase activity 44 8.10E-02
protein kinase CK2 activity 16 8.60E-02
kinase activity 63 8.70E-02
cyclic nucleotide-dependent protein kinase activity 16 9.80E-02
cAMP-dependent protein kinase activity 16 9.80E-02
binding site:ATP 29 1.10E-01
protein serine/threonine kinase activity 30 1.10E-01
biopolymer modification 106 1.30E-01
domain:Protein kinase 27 1.30E-01
protein amino acid phosphorylation 38 3.40E-01
S_TKc 16 3.50E-01
protein modification 96 3.60E-01
phosphorus metabolism 54 4.40E-01
phosphate metabolism 54 4.40E-01
Serine/threonine protein kinase, active site 21 4.90E-01
Serine/threonine protein kinase 28 5.10E-01
Protein kinase 30 5.70E-01
phosphorylation 43 5.70E-01
Tyrosine protein kinase 25 6.70E-01
Cluster 25. Enrichment Score: 2.19 Count P_Value
regulation of cyclin dependent protein kinase activity 10 3.20E-04
regulation of kinase activity 17 2.60E-03
regulation of protein kinase activity 17 2.60E-03
regulation of transferase activity 17 2.80E-03
regulation of enzyme activity 20 8.70E-02
MAPKKK cascade 9 1.40E-01
+wt 12h/-12h
Cluster 1. Enrichment Score: 42.08 Count P_Value
nuclear protein 580 5.10E-64
intracellular membrane-bound organelle 1000 4.80E-56
membrane-bound organelle 1000 5.80E-56
intracellular 1260 1.50E-46




Cluster 2. Enrichment Score: 27.24 Count P Value
mitochondrion 161 2.60E-37
transit peptide 102 1.00E-28
mitochondrion 178 3.60E-24
transit peptide:Mitochondrion 101 1.20E-21
Cluster 3. Enrichment Score: 18.64 Count P_Value
cellular physiological process 1473 2.00E-30
cellular metabolism 1128 5.80E-24
metabolism 1191 2.30E-23
primary metabolism 1093 4.60E-23
cellular process 1600 7.10E-08
physiological process 1567 1.70E-07
Cluster 4. Enrichment Score: 17.25 Count P_Value
membrane-enclosed lumen 139 5.40E-24
organelle lumen 139 5.40E-24
nuclear lumen 101 1.90E-15
nucleoplasm 65 1.80E-08
Cluster 5. Enrichment Score: 16.8 Count P_Value
cell cycle 167 5.50E-19
cell cycle 84 9.20E-18
regulation of cell cycle 120 5.30E-17
regulation of progression through cell cycle 119 2.30E-16
Cluster 6. Enrichment Score: 12.21 Count P_Value
RNA processing 107 1.40E-19
RNA binding 137 4.30E-19
RNA metabolism 121 4.80E-18
mrna processing 53 6.70E-17
mrna splicing 44 4.30E-15
mRNA processing 61 1.70E-11
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 44 5.70E-11
nuclear mRNA splicing, via spliceosome 44 5.70E-11
RNA splicing, via transesterification reactions 44 5.70E-11
RNA splicing 49 1.40E-10
mRNA metabolism 64 1.80E-10
spliceosome 19 4.70E-07
spliceosome complex 24 7.00E-07
Cluster 7. Enrichment Score: 10.97 Count P_Value
DNA metabolism 152 8.40E-16
response to DNA damage stimulus 76 2.80E-14
DNA repair 71 3.60E-14
response to endogenous stimulus 77 3.30E-13
dna damage 40 2.40E-11
dna repair 36 1.70E-10
response to stress 154 1.50E-02
Cluster 8. Enrichment Score: 10.68 Count P_Value
dna replication 32 2.00E-15
DNA replication 58 1.70E-10
DNA-dependent DNA replication 32 2.70E-08
Cluster 9. Enrichment Score: 7.49 Count P Value
ma-binding 103 6.60E-19
RRM 49 5.40E-07
RNA-binding region RNP-1 (RNA recognition motif) 50 2.00E-05
Nucleotide-binding, alpha-beta plait 54 2.10E-05
domain:RRM 21 2.50E-04
Cluster 10. Enrichment Score: 6.68 Count P_Value
nucleotide-binding 225 4.80E-15
atp-binding 168 5.90E-10
nucleotide binding 324 1.30E-09
purine nucleotide binding 266 2.90E-06
adenyl nucleotide binding 214 1.10E-05
nucleotide phosphate-binding region:ATP 126 1.10E-05
ATP binding 207 1.30E-05
kinase activity 121 2.30E-01
Cluster 11. Enrichment Score: 6.49 Count P_Value
methyltransferase 31 8.40E-09
methyltransferase activity 40 6.00E-08
transferase activity, transferring one-carbon groups 40 8.90E-08
S-adenosylmethionine-dependent methyltransferase activity 27 5.70E-06
SAM (and some other nucleotide) binding motif 19 1.40E-05
Cluster 12. Enrichment Score: 5.68 Count P_Value
macromolecule metabolism 743 1.10E-23
protein metabolism 473 4.10E-04
cellular protein metabolism 429 3.80E-03
cellular macromolecule metabolism 433 5.60E-03
biopolymer modification 233 1.60E-02
protein modification 220 5.50E-02
Cluster 13. Enrichment Score: 5.26 Count P_Value
negative regulation of progression through cell cycle 43 2~0E-07
negative regulation of biological process 131 7.80E-06
negative regulation of cellular process 123 9.10E-06
negative regulation of cellular physiological process 113 1.00E-05
negative regulation of physiological process 114 3.30E-05
Cluster 14. Enrichment Score: 5.12 Count P_Value
ribonucleoprotein 74 2.90E-19
ribosomal protein 62 9.70E-15
ribonucleoprotein complex 118 1.10E-08
biosynthesis 212 1.40E-03
cellular biosynthesis 192 1.80E-03
structural constituent of ribosome 62 1.30E-02
macromolecule biosynthesis 124 3.70E-02
protein biosynthesis 111 5.90E-02
ribosome 52 3.30E-01
structural molecule activity 106 7.60E-01
Cluster 15. Enrichment Score: 4.86 Count P_Value
unfolded protein binding 43 4.70E-06
chaperone 31 6.80E-06
protein folding 56 8.40E-05
Cluster 16. Enrichment Score: 4.72 Count P_Value
AAAATPase, central region 20 1.70E-06
AAA 32 8.20E-06
AAAATPase 31 4.80E-04
Cluster 17. Enrichment Score: 4.48 Count P_Value
ribosome biogenesis and assembly 25 3.80E-06
ribosome biogenesis 22 6.10E-06
cytoplasm organization and biogenesis 27 2.10E-05
rRNA metabolism 18 4.90E-05
rRNA processing 16 1.80E-04
rrna processing 12 2.90E-04
Cluster 18. Enrichment Score: 4.45 Count P Value
mitotic cell cycle 51 5.00E-07
M phase 45 1.40E-05
mitosis 24 2.00E-05
cell division 33 2.40E-05
M phase of mitotic cell cycle 37 2.50E-05
mitosis 36 4.50E-05
regulation of mitosis 15 2.30E-04
cell division 35 2.60E-03
Cluster 19. Enrichment Score: 4.45 Count P_Value
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 106 3.50E-06
nucleoside-triphosphatase activity 101 4.80E-06
hydrolase activity, acting on acid anhydrides 106 6.60E-06
pyrophosphatase activity 104 7.90E-06
ATPase activity 60 1.30E-03
ATPase activity, coupled 52 1.90E-03
Cluster 20. Enrichment Score: 4.43 Count P_Value
cell organization and biogenesis 241 6.10E-07
protein transport 59 3.60E-06
intracellular transport 106 2.20E-05
establishment of cellular localization 107 2.30E-05
cellular localization 107 3.30E-05
protein targeting 38 5.90E-05
protein transport 96 1.30E-04
protein localization 101 1.40E-04
establishment of protein localization 97 2.80E-04
intracellular protein transport 60 4.20E-04
Cluster 21. Enrichment Score: 3.92 Count P_Value
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 560 5.40E-16
nucleic acid binding 518 7.00E-13
transcription 209 8.10E-09
dna-binding 203 1.10E-06
transcription regulation 195 1.30E-05
regulation of cellular process 481 6.30E-05
regulation of biological process 509 9.20E-05
regulation of cellular physiological process 459 9.60E-05
DNA binding 302 2.20E-04
regulation of physiological process 466 3.50E-04
transcription 307 8.90E-02
transcription, DNA-dependent 277 1.70E-01
regulation of nucleobase, nucleoside, nucleotide & nucleic acid metabolism 289 2.10E-01
regulation of cellular metabolism 304 2.20E-01
regulation of metabolism 311 2.80E-01
regulation of transcription 280 3.30E-01
regulation of transcription, DNA-dependent 260 3.80E-01
transcription regulator activity 150 7.30E-01
Cluster 22. Enrichment Score: 3.74 Count P_Value
organelle membrane 90 1 .TOE-05
organelle envelope 61 3.70E-05
envelope 61 7.40E-05
mitochondrial envelope 43 1.10E-04
inner membrane 20 2.40E-04
mitochondrial membrane 38 5.60E-04
mitochondrial inner membrane 32 1 20E-03
organelle inner membrane 34 2.10E-03
Cluster 23. Enrichment Score: 3.74 Count P_Value
nucleotidyltransferase 28 2.60E-07
dna-directed rna polymerase 15 5.00E-07
PYRIMIDINE METABOLISM 33 1.50E-06
nucleotidyltransferase activity 38 1.00E-05
DNA-directed RNA polymerase III activity 12 2.40E-05
DNA-directed RNA polymerase 1 activity 12 2.40E-05
DNA-directed RNA polymerase II activity 12 2.40E-05
DNA-directed RNA polymerase activity 17 9.80E-05
RNA POLYMERASE 12 8.90E-04
PURINE METABOLISM 36 4.90E-03
DNA-directed RNA polymerase III complex 5 9.30E-03
RNA polymerase complex 9 1 40E-02
transcription from RNA polymerase III promoter 7 7.40E-02
DNA-directed RNA polymerase II, core complex 4 3.60E-01
Cluster 24, Enrichment Score: 3.57 Count P_Value
small nucleolar ribonucleoprotein complex 12 2.00E-04
Sm 9 2.20E-04
Like-Sm ribonucleoprotein, eukaryotic and archaea-type, core 10 2.80E-04
Like-Sm ribonucleoprotein, core 10 4.30E-04
Cluster 25. Enrichment Score: 3.51 Count P_Value
DNA replication initiation 13 3.00E-05




+mut 9h / +wt 9li
Cluster 1. Enrichment Score: 0.98 Count P_Value
intracellular signaling cascade 3 3.10E-02
protein binding 4 6.00E-02
organismal physiological process 3 1.30E-01
signal transduction 3 2.10E-01
cell communication 3 2.40E-01
Cluster 2. Enrichment Score: 0.96 Count P_Value
regulation of physiological process 5 3.00E-03
regulation of biological process 5 4.20E-03
regulation of cellular process 4 4.40E-02
protein binding 4 6.00E-02
binding 5 2.10E-01
regulation of cellular physiological process 3 2.20E-01
physiological process 5 5.50E-01
cellular process 5 6.00E-01
cell 5 6.70E-01
cellular physiological process 4 7.20E-01
Cluster 3. Enrichment Score: 0.38 Count P_Value
regulation of cellular process 4 4.40E-02
intracellular organelle 3 6.90E-01
organelle 3 6.90E-01
cellular physiological process 4 7.20E-01
intracellular 3 8.20E-01
+mut 12h / +wt 12h
Cluster 1. Enrichment Score: 17.73 Count P_Value
mitochondrion 115 1.90E-24
transit peptide 72 1.80E-18
mitochondrion 130 5.10E-17
transit peptide:Mitochondrion 73 6.90E-14
Cluster 2. Enrichment Score: 16.12 Count P_Value
intracellular membrane-bound organelle 695 2.20E-27
membrane-bound organelle 695 2.50E-27
intracellular 907 5.50E-27
nuclear protein 362 6.80E-23
intracellular organelle 776 1.10E-22
organelle 776 1.30E-22
nucleus 428 4.10E-06
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 363 1 30E-04
cell 1142 3.00E-04
nucleic acid binding 334 1 40E-03
Cluster 3. Enrichment Score: 12.55 Count P_Value
cellular physiological process 1077 4.40E-22
metabolism 863 5.10E-15
cellular metabolism 813 1.20E-14
primary metabolism 785 1.40E-13
cellular process 1180 3.20E-08
physiological process 1148 4.10E-06
Cluster 4. Enrichment Score: 9.52 Count P_Value
protein transport 66 3.70E-14
protein localization 104 3.60E-12
protein transport 99 5.40E-12
establishment of protein localization 101 7.10E-12
intracellular transport 101 9.40E-11
cellular localization 102 1.40E-10
establishment of cellular localization 101 2.00E-10
transport 147 1.50E-09
intracellular protein transport 59 6.10E-08
cell organization and biogenesis 186 4.90E-07
protein targeting 34 2.90E-06
Cluster 5. Enrichment Score: 9.44 Count P_Value
organelle lumen 96 3.30E-14
membrane-enclosed lumen 96 3.30E-14
nuclear lumen 66 6.60E-08
nucleoplasm 42 2.50E-04
Cluster 6. Enrichment Score: 8.23 Count P_Value
regulation of progression through cell cycle 83 2.70E-10
regulation of cell cycle 83 3.00E-10
cell cycle 55 2.30E-09
cell cycle 108 7.30E-09
negative regulation of progression through cell cycle 38 1.20E-08
anti-oncogene 20 2.80E-06
Cluster 7, Enrichment Score: 7.51 Count P_Value
macromolecule metabolism 545 1.10E-17
primary metabolism 785 1.40E-13
biopolymer metabolism 345 4.80E-12
protein metabolism 371 4.10E-06
cellular macromolecule metabolism 344 3.50E-05
cellular protein metabolism 338 5.20E-05
biopolymer modification 181 3.60E-03
protein modification 176 4.00E-03
Cluster 8. Enrichment Score: 7.1 Count P Value
negative regulation of progression through cell cycle 38 1.20E-08
negative regulation of cellular physiological process 97 4.90E-08
negative regulation of physiological process 99 7.80E-08
negative regulation of biological process 108 2.60E-07
negative regulation of cellular process 102 2.70E-07
Cluster 9. Enrichment Score: 6.9 Count P_Value
RNA binding 96 5.50E-12
RNA processing 69 8.30E-10
mrna processing 35 1.80E-09
RNA metabolism 79 3.80E-09
mrna splicing 27 2.30E-07
RNA splicing 35 2.90E-07
mRNA processing 39 6.60E-06
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 28 9.40E-06
nuclear mRNA splicing, via spliceosome 28 9.40E-06
RNA splicing, via transesterification reactions 28 9.40E-06
mRNA metabolism 42 1.00E-05
Cluster 10. Enrichment Score: 5.95 Count P_Value
golgi stack 58 5.30E-09
Golgi stack 59 7.70E-06
Golgi apparatus 69 3.40E-05




RNA-binding region RNP-1 (RNA recognition motif) 35 1.40E-03
Nucleotide-binding, alpha-beta plait 37 2.40E-03
Cluster 12. Enrichment Score: 4.79 Count P_Value
unfolded protein binding 34 1.40E-05
protein folding 47 1.40E-05
chaperone 25 2.10E-05
Cluster 13. Enrichment Score: 4.73 Count P Value
nucleotide-binding 169 1.00E-11
nucleotide binding 240 9.00E-08
atp-binding 118 5.60E-06
purine nucleotide binding 200 1.10E-05
adenyl nucleotide binding 156 2.40E-04
ATP binding 147 1.00E-03
nucleotide phosphate-binding region:ATP 87 6.20E-03
phosphotransferase activity, alcohol group as acceptor 74 1.60E-01
Cluster 14. Enrichment Score: 4.56 Count P_Value
cell death 88 1.80E-07
death 88 2.50E-07
apoptosis 85 2.60E-07
programmed cell death 85 3.10E-07
apoptosis 40 1.10E-06
regulation of apoptosis 56 1.20E-05
regulation of programmed cell death 56 1.40E-05
positive regulation of cellular process 76 1.90E-05
positive regulation of apoptosis 30 1 30E-04
positive regulation of programmed cell death 30 1.50E-04
positive regulation of biological process 81 2.40E-04
induction of programmed cell death 26 5.70E-04
induction of apoptosis 26 5.70E-04
positive regulation of cellular physiological process 60 8.30E-04
positive regulation of physiological process 61 1.30E-03
induction of apoptosis by extracellular signals 9 4.40E-03
Cluster 15. Enrichment Score: 4.32 Count P_Value
electron transporter activity 51 4.90E-07
electron transport 63 1.50E-04
generation of precursor metabolites and energy 86 1.40E-03
Cluster 16. Enrichment Score: 4.26 Count P Value
transport 147 1.50E-09
localization 316 1 30E-04
establishment of localization 313 2.00E 04
transport 290 2.80E-04
transporter activity 158 4.70E-02
Cluster 17. Enrichment Score: 4.17 Count P_Value
ribonucleoprotein 53 8.40E-13
ribosomal protein 44 1.00E-09
ribonucleoprotein complex 86 3.00E-06
protein biosynthesis 29 6.40E-05
ribosome 15 3.00E-04
structural constituent of ribosome 47 1.90E-02
ribosome 44 9.90E-02
structural molecule activity 87 3.10E-01
RIBOSOME 18 9.70E-01
Cluster 18. Enrichment Score: 4.02 Count P_Value
er-golgi transport 16 2.30E-06
ER to Golgi vesicle-mediated transport 19 5.00E-06
Golgi vesicle transport 23 1.60E-05
secretory pathway 33 1.60E-04
secretion 34 4.40E-03
vesicle-mediated transport 47 5.40E-03
Cluster 19. Enrichment Score: 4 Count P_Value
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 80 2.50E-05
pyrophosphatase activity 79 3.50E-05
nucleoside-triphosphatase activity 76 3.80E-05
hydrolase activity, acting on acid anhydrides 80 4.20E-05
ATPase activity 49 4.10E-04
ATPase activity, coupled 41 1.80E-03
Cluster 20. Enrichment Score: 3.81 Count P_Value
DNA-dependent DNA replication 21 8 80E-05
regulation of DNA replication 8 1.10E-04
regulation of DNA metabolism 11 3.80E-04
Cluster 21. Enrichment Score: 3.56 Count P_Value
mrna splicing 27 2.30E-07
spliceosome complex 14 3.70E-03
spliceosome 9 2.50E-02
Cluster 22. Enrichment Score: 3.45 Count P_Value
l-kappaB kinase/NF-kappaB cascade 26 1.40E-05
protein kinase cascade 45 7.80E-05
regulation of l-kappaB kinase/NF-kappaB cascade 19 2.80E-04
positive regulation of l-kappaB kinase/NF-kappaB cascade 18 3.40E-04
positive regulation of signal transduction 18 3.50E-03
regulation of signal transduction 32 5.80E-03
Cluster 23. Enrichment Score: 3.4 Count P_Value
DNA-dependent DNA replication 21 8.80E-05
dna replication 15 1.30E-04
DNA replication 34 2.70E-04
DNA replication initiation 8 7.60E-03
Cluster 24. Enrichment Score: 3.4 Count P_Value
magnesium ion binding 43 1.50E-04
magnesium 39 2.80E-04
metal ion-binding site:Magnesium 17 1.50E-03
Cluster 25. Enrichment Score: 3.32 Count P_Value
organelle membrane 77 2.50E-07
organelle envelope 49 3.40E-05
mitochondrial envelope 30 3.70E-03
mitochondrial membrane 27 7.50E-03
organelle inner membrane 24 1.90E-02
mitochondrial inner membrane 22 2.00E-02
